<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1 20151215//EN"  "JATS-archivearticle1.dtd"><article article-type="research-article" dtd-version="1.1" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn pub-type="epub" publication-format="electronic">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">54812</article-id><article-id pub-id-type="doi">10.7554/eLife.54812</article-id><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Neuroscience</subject></subj-group></article-categories><title-group><article-title>CB<sub>1</sub>-receptor-mediated inhibitory LTD triggers presynaptic remodeling via protein synthesis and ubiquitination</article-title></title-group><contrib-group><contrib contrib-type="author" id="author-170076"><name><surname>Monday</surname><given-names>Hannah R</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0003-3969-492X</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="other" rid="fund1"/><xref ref-type="fn" rid="con1"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-170077"><name><surname>Bourdenx</surname><given-names>Mathieu</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="other" rid="fund6"/><xref ref-type="fn" rid="con2"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-170078"><name><surname>Jordan</surname><given-names>Bryen A</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="other" rid="fund5"/><xref ref-type="fn" rid="con3"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes" id="author-169799"><name><surname>Castillo</surname><given-names>Pablo E</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-9834-1801</contrib-id><email>pablo.castillo@einsteinmed.org</email><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="other" rid="fund2"/><xref ref-type="other" rid="fund3"/><xref ref-type="other" rid="fund4"/><xref ref-type="fn" rid="con4"/><xref ref-type="fn" rid="conf1"/></contrib><aff id="aff1"><label>1</label><institution>Dominick P. Purpura Department of Neuroscience, Albert Einstein College of Medicine</institution><addr-line><named-content content-type="city">Bronx</named-content></addr-line><country>United States</country></aff><aff id="aff2"><label>2</label><institution>Department of Developmental and Molecular Biology, Albert Einstein College of Medicine</institution><addr-line><named-content content-type="city">Bronx</named-content></addr-line><country>United States</country></aff><aff id="aff3"><label>3</label><institution>Institute for Aging Studies, Albert Einstein College of Medicine</institution><addr-line><named-content content-type="city">Bronx</named-content></addr-line><country>United States</country></aff><aff id="aff4"><label>4</label><institution>Department of Psychiatry and Behavioral Sciences, Albert Einstein College of Medicine</institution><addr-line><named-content content-type="city">Bronx</named-content></addr-line><country>United States</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Westbrook</surname><given-names>Gary L</given-names></name><role>Reviewing Editor</role><aff><institution>Oregon Health and Science University</institution><country>United States</country></aff></contrib><contrib contrib-type="senior_editor"><name><surname>Westbrook</surname><given-names>Gary L</given-names></name><role>Senior Editor</role><aff><institution>Oregon Health and Science University</institution><country>United States</country></aff></contrib></contrib-group><pub-date date-type="publication" publication-format="electronic"><day>09</day><month>09</month><year>2020</year></pub-date><pub-date pub-type="collection"><year>2020</year></pub-date><volume>9</volume><elocation-id>e54812</elocation-id><history><date date-type="received" iso-8601-date="2019-12-30"><day>30</day><month>12</month><year>2019</year></date><date date-type="accepted" iso-8601-date="2020-09-08"><day>08</day><month>09</month><year>2020</year></date></history><permissions><copyright-statement>© 2020, Monday et al</copyright-statement><copyright-year>2020</copyright-year><copyright-holder>Monday et al</copyright-holder><ali:free_to_read/><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><ali:license_ref>http://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-54812-v2.pdf"/><abstract><p>Long-lasting forms of postsynaptic plasticity commonly involve protein synthesis-dependent structural changes of dendritic spines. However, the relationship between protein synthesis and presynaptic structural plasticity remains unclear. Here, we investigated structural changes in cannabinoid-receptor 1 (CB<sub>1</sub>)-mediated long-term depression of inhibitory transmission (iLTD), a form of presynaptic plasticity that involves a protein-synthesis-dependent long-lasting reduction in GABA release. We found that CB<sub>1</sub>-iLTD in acute rat hippocampal slices was associated with protein synthesis-dependent presynaptic structural changes. Using proteomics, we determined that CB<sub>1</sub> activation in hippocampal neurons resulted in increased ribosomal proteins and initiation factors, but decreased levels of proteins involved in regulation of the actin cytoskeleton, such as ARPC2 and WASF1/WAVE1, and presynaptic release. Moreover, while CB<sub>1</sub>-iLTD increased ubiquitin/proteasome activity, ubiquitination but not proteasomal degradation was critical for structural and functional presynaptic CB<sub>1</sub>-iLTD. Thus, CB<sub>1</sub>-iLTD relies on both protein synthesis and ubiquitination to elicit structural changes that underlie long-term reduction of GABA release.</p></abstract><kwd-group kwd-group-type="author-keywords"><kwd>structural plasticity</kwd><kwd>presynaptic</kwd><kwd>protein synthesis</kwd><kwd>ubiquitination</kwd><kwd>cannabinoid</kwd></kwd-group><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Rat</kwd></kwd-group><funding-group><award-group id="fund1"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000025</institution-id><institution>National Institute of Mental Health</institution></institution-wrap></funding-source><award-id>F31MH114431</award-id><principal-award-recipient><name><surname>Monday</surname><given-names>Hannah R</given-names></name></principal-award-recipient></award-group><award-group id="fund2"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000025</institution-id><institution>National Institute of Mental Health</institution></institution-wrap></funding-source><award-id>R01-MH081935</award-id><principal-award-recipient><name><surname>Castillo</surname><given-names>Pablo E</given-names></name></principal-award-recipient></award-group><award-group id="fund3"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000026</institution-id><institution>National Institute on Drug Abuse</institution></institution-wrap></funding-source><award-id>R01-DA17392</award-id><principal-award-recipient><name><surname>Castillo</surname><given-names>Pablo E</given-names></name></principal-award-recipient></award-group><award-group id="fund4"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000065</institution-id><institution>National Institute of Neurological Disorders and Stroke</institution></institution-wrap></funding-source><award-id>R01-NS113600</award-id><principal-award-recipient><name><surname>Castillo</surname><given-names>Pablo E</given-names></name></principal-award-recipient></award-group><award-group id="fund5"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000049</institution-id><institution>National Institute on Aging</institution></institution-wrap></funding-source><award-id>R01-AG039521</award-id><principal-award-recipient><name><surname>Jordan</surname><given-names>Bryen A</given-names></name></principal-award-recipient></award-group><award-group id="fund6"><funding-source><institution-wrap><institution>Rainwater Charitable Foundation</institution></institution-wrap></funding-source><principal-award-recipient><name><surname>Bourdenx</surname><given-names>Mathieu</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.</funding-statement></funding-group><custom-meta-group><custom-meta specific-use="meta-only"><meta-name>Author impact statement</meta-name><meta-value>CB<sub>1</sub>-receptor-mediated inhibitory long-term depression (LTD) relies on both protein synthesis and ubiquitination to elicit structural changes that underlie long-term reduction of GABA release.</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="s1" sec-type="intro"><title>Introduction</title><p>Synaptic plasticity, the ability of synapses to change their strength in response to activity or experience, underlies information storage in the brain. While presynaptic forms of plasticity, that is long-term synaptic strengthening (long-term potentiation or LTP) and weakening (long-term depression or LTD) due to long-lasting increase and decrease in neurotransmitter release, respectively, are widely expressed in the brain, their mechanism remains poorly understood (<xref ref-type="bibr" rid="bib20">Castillo, 2012</xref>; <xref ref-type="bibr" rid="bib87">Monday and Castillo, 2017</xref>; <xref ref-type="bibr" rid="bib86">Monday et al., 2018</xref>; <xref ref-type="bibr" rid="bib120">Yang and Calakos, 2013</xref>). A good example of a ubiquitous form of long-lasting reduction of transmitter release is type-1 cannabinoid receptor (CB<sub>1</sub>)-mediated LTD (<xref ref-type="bibr" rid="bib2">Araque et al., 2017</xref>; <xref ref-type="bibr" rid="bib21">Castillo et al., 2012</xref>; <xref ref-type="bibr" rid="bib53">Heifets and Castillo, 2009</xref>). Here, endogenous cannabinoids (eCBs) are released upon activity and travel in a retrograde manner to bind presynaptic CB<sub>1</sub>, a G<sub>i/o</sub>-coupled receptor, resulting in CB<sub>1</sub>-LTD at both excitatory and inhibitory synapses. Induction of long-term eCB-mediated plasticity requires extended (minutes) CB<sub>1</sub> activation (<xref ref-type="bibr" rid="bib27">Chevaleyre and Castillo, 2003</xref>; <xref ref-type="bibr" rid="bib26">Chevaleyre et al., 2007</xref>; <xref ref-type="bibr" rid="bib101">Ronesi, 2004</xref>). Although the presynaptic changes downstream CB<sub>1</sub> that suppress transmitter release in a long-term manner remain unclear, there is evidence that presynaptic protein synthesis is required (<xref ref-type="bibr" rid="bib122">Yin et al., 2006</xref>; <xref ref-type="bibr" rid="bib124">Younts et al., 2016</xref>), but what proteins are synthesized and the precise role of these proteins in CB<sub>1</sub>-LTD is unclear.</p><p>Proteostatic mechanisms, the cellular processes that balance protein synthesis and degradation, are vital for neuronal function and synaptic plasticity (<xref ref-type="bibr" rid="bib12">Biever et al., 2019</xref>; <xref ref-type="bibr" rid="bib14">Birdsall and Waites, 2019</xref>; <xref ref-type="bibr" rid="bib30">Cohen and Ziv, 2019</xref>; <xref ref-type="bibr" rid="bib75">Liang and Sigrist, 2018</xref>; <xref ref-type="bibr" rid="bib115">Wang et al., 2017</xref>). In postsynaptic forms of plasticity, such as NMDA receptor-dependent LTP, local protein synthesis has been tightly correlated with both consolidation of LTP and structural changes (<xref ref-type="bibr" rid="bib15">Bosch et al., 2014</xref>; <xref ref-type="bibr" rid="bib94">Ostroff et al., 2002</xref>; <xref ref-type="bibr" rid="bib109">Tanaka et al., 2008</xref>; <xref ref-type="bibr" rid="bib112">Tominaga-Yoshino et al., 2008</xref>; <xref ref-type="bibr" rid="bib119">Yang et al., 2008</xref>). In particular, synthesis of β-actin, AMPA receptors, and CaMKII proteins may be critical for the increase in dendritic spine volume and synapse strength associated with LTP (<xref ref-type="bibr" rid="bib17">Bramham, 2008</xref>; <xref ref-type="bibr" rid="bib88">Nakahata and Yasuda, 2018</xref>; <xref ref-type="bibr" rid="bib98">Rangaraju et al., 2017</xref>). Concurrent regulation of protein degradation through the proteasome and lysosome is also required for activity-dependent pre- and postsynaptic changes in synapse strength (<xref ref-type="bibr" rid="bib12">Biever et al., 2019</xref>; <xref ref-type="bibr" rid="bib29">Cohen and Ziv, 2017</xref>; <xref ref-type="bibr" rid="bib51">Hegde, 2017</xref>; <xref ref-type="bibr" rid="bib86">Monday et al., 2018</xref>). We and others have recently provided evidence for rapid (&lt;30 min) presynaptic protein synthesis under basal conditions and during plasticity (<xref ref-type="bibr" rid="bib45">Hafner et al., 2019</xref>; <xref ref-type="bibr" rid="bib124">Younts et al., 2016</xref>), but whether these newly synthesized proteins participate in CB<sub>1</sub>-LTD by regulating presynaptic structural changes is unknown.</p><p>Presynaptic structure and function are controlled by actin polymerization and depolymerization (<xref ref-type="bibr" rid="bib28">Cingolani and Goda, 2008</xref>; <xref ref-type="bibr" rid="bib90">Nelson et al., 2013</xref>). Branched actin filaments in the presynaptic compartment provide a scaffold for synaptic vesicles and the active zone (<xref ref-type="bibr" rid="bib85">Michel et al., 2015</xref>; <xref ref-type="bibr" rid="bib102">Rust and Maritzen, 2015</xref>). Moreover, structural changes of the presynaptic terminal are associated with altered synapse strength (<xref ref-type="bibr" rid="bib44">Gundelfinger and Fejtova, 2012</xref>; <xref ref-type="bibr" rid="bib81">Matz et al., 2010</xref>; <xref ref-type="bibr" rid="bib84">Meyer et al., 2014</xref>; <xref ref-type="bibr" rid="bib87">Monday and Castillo, 2017</xref>), and the size of the presynaptic terminal and active zone has been correlated with the postsynaptic response (<xref ref-type="bibr" rid="bib8">Bartol et al., 2015</xref>; <xref ref-type="bibr" rid="bib16">Bourne et al., 2013</xref>; <xref ref-type="bibr" rid="bib84">Meyer et al., 2014</xref>). There is evidence that CB<sub>1</sub> activation alters the ultrastructural vesicle distribution in CB<sub>1</sub>-expressing (CB<sub>1</sub><sup>+</sup>) boutons on short time scales (<xref ref-type="bibr" rid="bib41">García-Morales et al., 2015</xref>; <xref ref-type="bibr" rid="bib97">Ramírez-Franco et al., 2014</xref>) and leads to retraction of growth cones in developing axons (<xref ref-type="bibr" rid="bib100">Roland et al., 2014</xref>). However, it is not known whether CB<sub>1</sub>-LTD is associated with morphological changes in presynaptic structure in the mature mammalian brain.</p><p>Here, to gain insights into the expression mechanisms of CB<sub>1</sub>-LTD, we examined potential structural changes in CB<sub>1</sub>-mediated LTD of inhibitory transmission (CB<sub>1-</sub>iLTD) in the hippocampus (<xref ref-type="bibr" rid="bib27">Chevaleyre and Castillo, 2003</xref>). Using high-resolution microscopy in acute rat hippocampal slices we found that this form of plasticity was associated with a reduction of presynaptic bouton volume that required protein synthesis. To test how protein synthesis could alter presynaptic structure during CB<sub>1</sub>-iLTD, we used an unbiased proteomics approach to identify CB<sub>1</sub> activation-mediated changes in the proteome of hippocampal neuron cultures. CB<sub>1</sub> activation elicited an increase in proteins involved in protein synthesis, processing and degradation, whereas presynaptic and actin cytoskeletal proteins, including ARPC2 and WASF1/WAVE1 were decreased. CB<sub>1</sub>-iLTD involved actin remodeling, Rac1 and the actin branching protein complex Arp2/3. Lastly, ubiquitination of proteins but not proteasomal degradation was necessary for both structural and functional CB<sub>1</sub>-iLTD.</p></sec><sec id="s2" sec-type="results"><title>Results</title><sec id="s2-1"><title>Induction of CB<sub>1</sub>-iLTD is associated with a reduction in CB<sub>1</sub><sup>+</sup> bouton size</title><p>Diverse forms of long-lasting synaptic plasticity require translation-dependent structural remodeling (<xref ref-type="bibr" rid="bib6">Bailey et al., 2015</xref>; <xref ref-type="bibr" rid="bib17">Bramham, 2008</xref>; <xref ref-type="bibr" rid="bib88">Nakahata and Yasuda, 2018</xref>; <xref ref-type="bibr" rid="bib98">Rangaraju et al., 2017</xref>). To test whether CB<sub>1</sub>-iLTD is associated with structural plasticity, we examined changes in the morphology of CB<sub>1</sub><sup>+</sup> boutons following induction of CB<sub>1</sub>-iLTD. To accurately measure individual bouton volume in acute hippocampal slices, we utilized high-resolution and high yield Airyscan confocal microscopy combined with 3D reconstruction (<xref ref-type="fig" rid="fig1">Figure 1A</xref>). To induce CB<sub>1</sub>-iLTD the CB<sub>1</sub> agonist WIN 55,212–2 (5 µM) was bath applied for 25 min, and induction was confirmed by monitoring extracellular field inhibitory postsynaptic potentials (fIPSPs), which allows non-invasive, stable long-term assessment of inhibitory synaptic transmission (<xref ref-type="bibr" rid="bib52">Heifets et al., 2008</xref>; <xref ref-type="bibr" rid="bib124">Younts et al., 2016</xref>; <xref ref-type="fig" rid="fig1">Figure 1B</xref>). This LTD not only mimics synaptically induced iLTD (<xref ref-type="bibr" rid="bib27">Chevaleyre and Castillo, 2003</xref>; <xref ref-type="bibr" rid="bib26">Chevaleyre et al., 2007</xref>; <xref ref-type="bibr" rid="bib52">Heifets et al., 2008</xref>), but also allows us to shortcut the synthesis and release of eCBs, thereby excluding potential effects of pharmacological inhibitors (see below) on these processes.</p><fig-group><fig id="fig1" position="float"><label>Figure 1.</label><caption><title>Induction of CB<sub>1</sub>-iLTD is associated with a reduction in CB<sub>1</sub><sup>+</sup> bouton size.</title><p>(<bold>A</bold>) <italic>Left</italic>, representative stitched widefield confocal of hippocampal CB<sub>1</sub> immunolabeling. White boxes indicate where high-magnification images were acquired (as seen in center panel). <italic>Center</italic>, High-resolution Airyscan confocal maximum projection used for 3D reconstruction of individual boutons in CA1 stratum pyramidale. <italic>Right</italic>, 3D reconstruction of Airyscan confocal image shown in center panel. (<bold>B</bold>) <italic>Top</italic>, representative extracellular field inhibitory postsynaptic potentials (fIPSPs) recorded in the CA1 pyramidal cell body layer in acute hippocampal slices before and after WIN treatment (5 µM, 25 min). <italic>Bottom</italic>, summary time-course plot showing WIN-induced depression; n = 3 slices, three animals. For all electrophysiology figures, representative traces correspond to the gray-shaded areas and in the summary time-course plots (averaged summary data expressed as normalized change from baseline ± S.E.M.). Shaded boxes in all electrophysiology figures correspond to when plasticity was analyzed with respect to baseline and when representative traces were collected and averaged. (<bold>C</bold>) Quantification of mean bouton volume per slice normalized to Control. Activation of CB<sub>1</sub> receptors with 5 µM WIN for 25 min led to decreased bouton volume that remained 1 hr after WIN treatment and was blocked by treatment with cycloheximide (CHX, 80 µM, applied throughout the experiment). Control: 1.0 ± 0.02 vs. WIN: 0.92 ± 0.02 vs. WIN + 1 hr: 0.89 ± 0.02 vs. CHX + WIN: 0.97 ± 0.02 (Mean ± S.E.M.); F[3,22]=8.682; p=0.0005, one-way ANOVA with post-hoc Tukey test for multiple comparisons. Control vs. WIN: CI[0.005,0.14], p=0.03. Control vs. WIN 1 hr: CI[0.05,0.18], p=0.0005. WIN 1 hr vs. WIN + CHX: CI[−0.11,0.03], p=0.012. n = number of slices (three images/slice, 1–2 slices/rat, six rats/condition). For all structural plasticity figures, data are presented as points representing mean bouton volume per slice with a horizontal black line representing the mean per condition and the vertical line indicating 95% confidence interval (CI). 95% CIs are given as CI[lower CI, upper CI]. p-Values are exact. Refer to <xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1A</xref> for distribution of individual bouton values. (<bold>D</bold>) Representative 3D reconstruction widefield images of Bassoon labeling inside CB<sub>1</sub><sup>+</sup> boutons. (<bold>E</bold>) Representative single CB<sub>1</sub> boutons with Bassoon reconstructed in 3D. (<bold>F</bold>) Quantification of mean Bassoon volume per slice normalized to Control after 25 min WIN treatment revealed a reduction in active zone volume as measured using Bassoon immunolabeling that was blocked by treatment with cycloheximide (CHX, 80 µM, applied throughout the experiment). Control: 1.0 ± 0.01 vs. WIN: 0.89 ± 0.04 vs. CHX + WIN: 1.0 ± 0.01 vs. CHX: 0.98 ± 0.03 (Mean ± S.E.M.); F[3,12]=4.11, p=0.032, one-way ANOVA with post-hoc Tukey test for multiple comparisons. Control vs. WIN: CI[0.004,0.22], p=0.042. n = number of slices (three images/slice, 1–2 slices/rat, three rats/condition). Refer to <xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1D</xref> for distribution of individual Bassoon values.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-54812-fig1-v2.tif"/></fig><fig id="fig1s1" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 1.</label><caption><title>Individual bouton and Bassoon sizes are altered by CB<sub>1</sub>-iLTD induction in a protein synthesis-dependent manner.</title><p>(<bold>A</bold>) Quantification of bouton volume normalized to control by slice. Activation of CB<sub>1</sub> receptors with 5 µM WIN for 25 min led to decreased bouton volume that remained 1 hr after WIN treatment and was diminished by treatment with cycloheximide (CHX, 80 µM, applied throughout the experiment). Superplot shows individual bouton volume values color-coded by slice in swarmplot with solid larger dots overlaid representing mean bouton volume per slice. Overall mean of slices is indicated with the black circle, 95% CI is indicated with the vertical black line. Control: 1.0 ± 0.02 vs. WIN: 0.92 ± 0.02 vs. WIN + 1 hr: 0.87 ± 0.02 vs. WIN + CHX: 0.98 ± 0.02 (Mean ± S.E.M.); F[3,20]=8.40, p=0.00082, one-way ANOVA with post-hoc Tukey test for multiple comparisons. WIN vs. Control: CI [−0.15,–0.0015], p=0.044, WIN 1 hr vs. Control: CI [−0.19,–0.048], p=0.00077, WIN + CHX vs. WIN 1 hr: CI[0.02,0.16], p=0.0095. n = slices (three images/slice, one slice/rat, six rats/condition). 95% Confidence intervals (CI) are given as CI[lower CI, upper CI]. P-values are exact. (<bold>B</bold>) <italic>Left,</italic> Representative single CB<sub>1</sub> boutons with Bassoon reconstructed in 3D. <italic>Right,</italic> Quantification of bouton volume normalized to control. CHX had no significant effect on basal CB<sub>1</sub> bouton volume. Control 1.0 ± 0.03 v. CHX: 0.94 ± 0.02, Two sample t-test, p=0.20267. n = number of slices (three images/slice, one slices/rat, three rats/condition). Superplot shows individual bouton volume values color-coded by slice in swarmplot with solid larger dots overlaid representing mean bouton volume per slice. Overall mean of slices is indicated with the black circle, 95% CI is indicated with the vertical black line. Control: 1.0 ± 0.06 v. WIN: 1.07 ± 0.09 (Mean ± S.E.M.); Two sample t-test, p=0.49581, n = number of slices (five slices, five rats per condition). (<bold>C</bold>) CB<sub>1</sub> activation shifts distribution to smaller sizes. Plot shows boutons in each bin divided by total boutons measured in a slice. Bin [0–0.5]: Control: 0.143 ± 0.025 vs. WIN + 1 hr: 0.246 ± 0.02, Two-sample t-test, p=0.009. Bin [1.5–2.0]: Control: 0.138 ± 0.025 vs. WIN + 1 hr: 0.09 ± 0.019, Two-sample t-test, p=0.16, n.s. = non significant, n = 6 slices, six animals per group. (<bold>D</bold>) Quantification of Bassoon after 25 min WIN treatment revealed a reduction in active zone volume as measured using Bassoon immunolabeling that was impaired by treatment with cycloheximide (CHX, 80 µM, applied throughout the experiment). Superplot shows individual Bassoon volume values color-coded by slice in swarmplot with solid larger dots overlaid representing mean volume per slice. Overall mean of slices is indicated with the black circle, 95% CI is indicated with the vertical black line. Control: 1.0 ± 0.01 vs. WIN: 0.89 ± 0.04 vs. CHX + WIN: 1.0 ± 0.01 vs. CHX: 0.98 ± 0.03 (Mean ± S.E.M.); F[3,12]=4.11, p=0.032, one-way ANOVA with post-hoc Tukey test for multiple comparisons. WIN vs. Control: CI[−0.22,–0.004], p=0.042. n = number of slices (three images/slice, one slice/rat, four rats/condition). 95% Confidence intervals (CI) are given as CI[lower CI, upper CI]. p-Values are exact.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-54812-fig1-figsupp1-v2.tif"/></fig><fig id="fig1s2" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 2.</label><caption><title>WIN treatment affects CB<sub>1</sub><sup>+</sup> boutons specifically and results in reduction in VGAT volume.</title><p>(<bold>A</bold>) <italic>Left</italic>, representative widefield confocal z-stack of CA1 pyramidal layer and 3D Imaris reconstruction of CB<sub>1</sub><sup>+</sup> boutons. Dotted lines indicate location of putative pyramidal cell somas. <italic>Center</italic>, volume of individual boutons was quantified using dense PV immunolabeling of inhibitory interneuron terminals. <italic>Right,</italic> representative single boutons reconstructed in 3D. (<bold>B</bold>) Quantification of bouton volume normalized to control. Activation of CB<sub>1</sub> receptors with WIN (5 µM, 25 min) resulted in no change in PV bouton volume. Superplot indicates distribution of all PV boutons color-coded by slice. Overall mean of slices is indicated with the black circle, 95% CI is indicated with the vertical black line. Control: 1.0 ± 0.06 v. WIN: 1.07 ± 0.09 (Mean ± S.E.M.); Two sample t-test, p=0.49581, n = number of slices (five slices, five rats per condition). (<bold>C</bold>) Representative widefield confocal maximum projection of CA1 pyramidal layer showing PV and CB<sub>1</sub><sup>+</sup> boutons. (<bold>D</bold>) <italic>Left</italic>, Representative Airyscan confocal image of VGAT/CB<sub>1</sub> labeling. <italic>Center</italic>, Representative single CB<sub>1</sub> boutons with VGAT reconstructed in 3D. <italic>Right,</italic> VGAT volume in CB<sub>1</sub><sup>+</sup> boutons was significantly reduced by 25 min WIN treatment. Superplot indicates distribution of all VGAT puncta color-coded by slice. Overall mean of slices is indicated with the black circle, 95% CI is indicated with the vertical black line. Control: 1.0 ± 0.12 v. WIN: 0.57153 ± 0.10 (Mean ± S.E.M.); Two-sample t-test, p=0.0242, n = number of slices (six slices, six rats per condition).</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-54812-fig1-figsupp2-v2.tif"/></fig></fig-group><p>Using CB<sub>1</sub> immunolabeling, which accurately approximates bouton volume (<xref ref-type="bibr" rid="bib38">Dudok et al., 2015</xref>), we found that CB<sub>1</sub>-iLTD is associated with a significant decrease of CB<sub>1</sub> bouton volume (<xref ref-type="fig" rid="fig1">Figure 1C</xref>). This structural change was long-lasting as it persisted for 60 min after WIN treatment (<xref ref-type="fig" rid="fig1">Figure 1C</xref>), and it was blocked by concurrent bath application with protein synthesis inhibitor cycloheximide (CHX, 80 µM), demonstrating a requirement for protein synthesis (<xref ref-type="fig" rid="fig1">Figure 1C,E</xref>, <xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1A</xref>). CHX alone did not affect basal bouton volume (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1B</xref>). This overall shrinkage by WIN treatment was driven by an increase in the proportion of the small CB<sub>1</sub> boutons and a trend toward a decrease in large boutons (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1C</xref>). This effect was specific because volume of parvalbumin (PV<sup>+</sup>) boutons in the CA1 pyramidal layer was not altered by WIN application (<xref ref-type="fig" rid="fig1s2">Figure 1—figure supplement 2A,B</xref>), as assessed by immunolabeling for PV boutons (<xref ref-type="bibr" rid="bib124">Younts et al., 2016</xref>), which do not express CB<sub>1</sub> receptors (<xref ref-type="bibr" rid="bib43">Glickfeld and Scanziani, 2006</xref>; <xref ref-type="fig" rid="fig1s2">Figure 1—figure supplement 2C</xref>). As a complementary approach, we used Bassoon immunolabeling to assess the size of the presynaptic active zone. Similar to the total bouton volume, Bassoon size within CB<sub>1</sub><sup>+</sup> boutons was also significantly decreased following WIN application and this effect was blocked by CHX treatment (<xref ref-type="fig" rid="fig1">Figure 1D–F</xref>, <xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1D</xref>). We also found that the volume of vesicular GABA transporter (VGAT), a well-established marker of inhibitory synapses, was markedly reduced in CB<sub>1</sub><sup>+</sup> boutons by WIN treatment (<xref ref-type="fig" rid="fig1s2">Figure 1—figure supplement 2D</xref>). These results strongly suggest that CB<sub>1</sub>-iLTD is associated with a protein-synthesis-dependent shrinkage of CB<sub>1</sub><sup>+</sup> boutons, which may contribute to the long-lasting reduction in neurotransmitter release observed in this form of plasticity. Along with our previous study (<xref ref-type="bibr" rid="bib124">Younts et al., 2016</xref>), our findings indicate that protein synthesis is required for both structural and functional presynaptic changes involved in CB<sub>1</sub>-iLTD.</p></sec><sec id="s2-2"><title>CB<sub>1</sub> activation alters the abundance of proteins linked to protein synthesis, synaptic structure/function and energy metabolism</title><p>To glean insights into the mechanism(s) underlying structural and functional CB<sub>1</sub>-iLTD, we sought to identify proteins synthesized upon CB<sub>1</sub> activation. We previously showed CB<sub>1</sub>-dependent increases in protein synthesis were evident after brief CB<sub>1</sub> activation in cultured hippocampal neurons (<xref ref-type="bibr" rid="bib124">Younts et al., 2016</xref>). To identify and quantitate changes in the neuronal proteome, we used Stable Isotope Labeling of Amino Acids in Cell Culture (SILAC) coupled with tandem mass spectrometry (MS/MS) (<xref ref-type="bibr" rid="bib66">Jordan et al., 2006</xref>; <xref ref-type="bibr" rid="bib125">Zhang et al., 2011</xref>; <xref ref-type="bibr" rid="bib126">Zhang et al., 2012</xref>). Two populations of cultured rat hippocampal neurons (‘medium’ and ‘heavy’) were labeled using distinct combinations of ‘medium’ or ‘heavy’ stable-isotope weight variants of Arginine and Lysine. The two groups were treated with WIN (25 min, 5 µM) or Vehicle as before (<xref ref-type="fig" rid="fig1">Figure 1</xref>) then rapidly lysed and harvested (<xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1A,B</xref>). Samples were combined and simultaneously analyzed by tandem MS/MS to identify and quantify changes induced by CB<sub>1</sub> receptor activation. To strengthen the robustness of findings, we performed a replicate ‘reverse’ experiment where ‘heavy’ neurons were treated with WIN and observed a high degree of correlation between replicates (<xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1C</xref>).</p><p>We found significant changes across the protein landscape. Examples of these proteins grouped by their suggested function are shown in <xref ref-type="fig" rid="fig2">Figure 2A</xref> (see <xref ref-type="supplementary-material" rid="supp1">Supplementary file 1</xref> for all proteins). Consistent with previous studies of axonal mRNAs, components of the protein synthesis machinery were upregulated (<xref ref-type="bibr" rid="bib45">Hafner et al., 2019</xref>; <xref ref-type="bibr" rid="bib104">Shigeoka et al., 2016</xref>), as well as the protein degradation machinery. A number of presynaptic proteins were downregulated following CB<sub>1</sub> activation. Notably, two key regulators of the actin cytoskeleton, Actin-related protein 2/3 complex subunit 2 (ARPC2) and Wiscott-Aldrich Associated Protein family (WASF1/WAVE1) were significantly downregulated, suggesting these proteins could be implicated in the reduction of neurotransmitter release and presynaptic volume associated with CB<sub>1</sub>-iLTD. Using Gene Set Enrichment Analysis (GSEA) (<xref ref-type="bibr" rid="bib108">Subramanian et al., 2005</xref>), we identified enriched functional gene ontology (GO) terms (<xref ref-type="fig" rid="fig2">Figure 2B</xref> and <xref ref-type="supplementary-material" rid="supp2">Supplementary file 2</xref>). To reduce redundancy, we clustered closely related GO terms using network analysis (<xref ref-type="bibr" rid="bib83">Merico et al., 2010</xref>), where edge length corresponds to the number of overlapping proteins in the GO term, node size indicates the number of proteins belonging to the term, and color represents the enrichment score (<xref ref-type="fig" rid="fig2">Figure 2C</xref> and <xref ref-type="supplementary-material" rid="supp2">Supplementary file 2</xref>). In accordance with translational upregulation following CB<sub>1</sub> activation (<xref ref-type="bibr" rid="bib124">Younts et al., 2016</xref>), the top cluster represented upregulated GO terms related to ‘Protein synthesis and processing’ (<xref ref-type="fig" rid="fig2">Figure 2C</xref>). The second cluster was composed of GO terms relating to ‘Neuronal projections’, suggestive of the structural change associated with CB<sub>1</sub>-iLTD. The third cluster was GO terms associated with ‘Energy metabolism’ which may be representative of the previously reported CB<sub>1</sub>-mediated decrease in cellular respiration (<xref ref-type="bibr" rid="bib50">Hebert-Chatelain et al., 2016</xref>; <xref ref-type="bibr" rid="bib82">Mendizabal-Zubiaga et al., 2016</xref>; <xref ref-type="fig" rid="fig2">Figure 2C</xref>). Examples of GO terms identified in each cluster are provided in <xref ref-type="fig" rid="fig2s2">Figure 2—figure supplement 2</xref>. Ingenuity pathway analysis (IPA) also identified pathways related to the processes outlined above, including eIF2 signaling, mitochondrial dysfunction, and actin cytoskeleton signaling (<xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1D</xref>). Similarly, analyses using SynGO (<xref ref-type="bibr" rid="bib72">Koopmans et al., 2019</xref>), an expert-curated tool to identify GO terms associated with synaptic function, linked our results to regulation of synaptic protein synthesis (<xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1E</xref>). Among the differentially expressed proteins, we found that 43 proteins were upregulated and 56 proteins were downregulated by CB<sub>1</sub> activation (<xref ref-type="fig" rid="fig2">Figure 2D</xref>). Together, these results suggest that both protein synthesis and coincident degradation of structural and presynaptic proteins occur downstream of CB<sub>1</sub> activation, and could therefore be implicated in CB<sub>1</sub>-iLTD.</p><fig-group><fig id="fig2" position="float"><label>Figure 2.</label><caption><title>CB<sub>1</sub>activation alters the abundance of proteins linked to protein synthesis, synaptic structure/function and energy metabolism.</title><p>(<bold>A</bold>) Examples of proteins that were identified in enriched GO terms and were significantly altered by CB<sub>1</sub> activation (p&lt;0.05). Proteins are grouped by proposed biological function and average log<sub>2</sub> fold change is plotted. (<bold>B</bold>) List of enriched GO terms and normalized enrichment scores (NES) as identified by GSEA. Positive NES reflects overall upregulation of proteins associated with the GO term whereas negative values indicate the opposite. (<bold>C</bold>) Cluster analysis of enriched/depleted GO terms from GSEA revealed four distinct biological processes that were consistently up- or downregulated by CB<sub>1</sub> activation. Each node represents a single GO term. Node size represents magnitude of enrichment and edge length gives degree of overlap between 2 GO terms. Color represents up (red) or downregulation (blue) of proteins associated with that GO term. See <xref ref-type="fig" rid="fig2s2">Figure 2—figure supplement 2</xref> for examples. (<bold>D</bold>) Volcano plot of differentially expressed proteins between vehicle and CB<sub>1</sub> activation. Red dots: differentially expressed proteins showing upregulation (adj. p&lt;0.05 and log2 fold change &gt;0). Blue dots: differentially expressed proteins showing downregulation (adj. p&lt;0.05 and log2 fold change &lt;0). six select top hits are highlighted: ECHA: trifunctional enzyme subunit alpha (mitochondrial); SNX3: Sorting nexin-3; RPN2: Subunit of the oligosaccharyl transferase; SV2A: Synaptic vesicle glycoprotein 2A; ANXA1: Annexin A1; SYPH: Synaptophysin.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-54812-fig2-v2.tif"/></fig><fig id="fig2s1" position="float" specific-use="child-fig"><label>Figure 2—figure supplement 1.</label><caption><title>SILAC experiment design and additional analysis.</title><p>(<bold>A</bold>) Experimental timeline for SILAC. Neurons were grown for 15 days in isotope-labeled amino acids, before being treated for 25 min with WIN and harvested. (<bold>B</bold>) Schematic of workflow to identify proteins. Cultures were lysed and combined to give ‘forward’ and ‘reverse’ replicates. Mass spectrometry was performed for identification and quantification of proteins altered by WIN treatment. (<bold>C</bold>) Scatterplot of all proteins identified in forward and reverse experiments by log<sub>2</sub> fold change. Forward and reverse experiments are significantly correlated indicating good reproducibility (Pearson’s correlation coefficient = 0.696, p&lt;0.05). Top regulated proteins are identified. HMGB1 = high mobility group box 1, PTN = pleiotropin, ANXA1 = annexin A1, RPL35 = ribosomal protein 35, SNAP91 = synaptosome associated protein 91. WASF1/WAVE1 = Wiskott Aldrich Syndrome Family 1,SYPH = synaptophysin, RPS36 = ribosomal protein 36. (<bold>D</bold>) Top 22 selected pathways identified by Ingenuity Pathway Analysis (IPA) ranked by -log10(p-value). Blue dashed line indicates p-value=0.001, all pathways have p&lt;0.001. (<bold>E</bold>) SynGO term analysis identified significant upregulation of local synaptic translation pathways and downregulation of GO terms involved in presynaptic function, as indicated by log q-value. Size of circle represents number of genes identified per SynGO term.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-54812-fig2-figsupp1-v2.tif"/></fig><fig id="fig2s2" position="float" specific-use="child-fig"><label>Figure 2—figure supplement 2.</label><caption><title>Examples of GO terms in each cluster are provided.</title><p>Enrichment score (green line) is computed by individual protein rank (black vertical lines) in the ranked list for each GO term and direction of change (up vs. down vs. no change).</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-54812-fig2-figsupp2-v2.tif"/></fig></fig-group></sec><sec id="s2-3"><title>CB<sub>1</sub>-iLTD involves actin remodeling via Rac1 and Arp2/3</title><p>CB<sub>1</sub> directly interacts with Rac1 and members of the WAVE regulatory complex (WRC), which includes actin branching modulators WASF1/WAVE1 and Arp2/3 (<xref ref-type="bibr" rid="bib92">Njoo et al., 2015</xref>), and these proteins are downregulated in hippocampal neurons following CB<sub>1</sub> activation (<xref ref-type="fig" rid="fig2">Figure 2A</xref>). Therefore, regulation of the abundance of these proteins may represent a mechanism underlying structural and functional presynaptic changes involved in CB<sub>1</sub>-iLTD. For example, CB<sub>1</sub> activation could reduce the presynaptic terminal volume by favoring actin depolymerization. To test this possibility, we first examined whether actin cytoskeletal dynamics were required for CB<sub>1</sub>-iLTD induced structural plasticity (<xref ref-type="fig" rid="fig1">Figure 1</xref>). Using the same high-resolution microscopy and 3D reconstruction as <xref ref-type="fig" rid="fig1">Figure 1</xref>, we activated CB<sub>1</sub> in the presence of jasplakinolide (JSK, 250 nM), a reagent that promotes actin polymerization (<xref ref-type="bibr" rid="bib57">Holzinger, 2009</xref>). We found that JSK application blocked the WIN-induced decrease in presynaptic bouton volume (<xref ref-type="fig" rid="fig3">Figure 3A</xref>, <xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1A</xref>). These results indicate that actin dynamics likely underlie the structural changes following CB<sub>1</sub> activation. We next tested the functional requirement for actin remodeling in CB<sub>1</sub>-iLTD (as in <xref ref-type="fig" rid="fig1">Figure 1</xref>). Similar to the effects on structural plasticity, bath application of JSK impaired CB<sub>1</sub>-iLTD (<xref ref-type="fig" rid="fig3">Figure 3B</xref>), whereas JSK application alone had no effect on basal synaptic transmission (<xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1B</xref>). These results strongly suggest that actin remodeling is critical for structural and functional CB<sub>1</sub>-iLTD.</p><fig-group><fig id="fig3" position="float"><label>Figure 3.</label><caption><title>CB<sub>1</sub>-iLTD involves actin remodeling via Rac1 and Arp2/3.</title><p>(<bold>A</bold>) <italic>Left</italic>, representative single boutons reconstructed in 3D. <italic>Right</italic>, quantification of mean bouton volume per slice normalized to control. Activation of CB<sub>1</sub> receptors with WIN for 25 min led to decreased bouton volume that was blocked by treatment with jasplakinolide (JSK, 250 nM). Summary data expressed as normalized change from Control. WIN + 1 hr: 0.89 ± 0.02 vs. WIN + JSK: 0.97 ± 0.02 vs. JSK: 0.95 ± 0.02 (Mean ± S.E.M.); F[2,16]=5.56, p=0.015, one-way ANOVA with post-hoc Tukey test for multiple comparisons. WIN vs. WIN + JSK: CI[−0.16,–0.018], p=0.014. n = number of slices (three images/slice, 1–2 slices/rat, six rats/condition). For all structural plasticity figures, data are presented as points representing mean bouton volume per slice with a horizontal black line representing the mean per condition and the vertical line indicating 95% confidence interval (CI). 95% CIs are given as CI[lower CI, upper CI]. p-Values are exact. Refer to <xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1A</xref> for distribution of individual bouton values. (<bold>B</bold>) CB<sub>1</sub>-iLTD is impaired by bath application of actin-stabilizing drug, jasplakinolide (JSK, 250 nM). Extracellular field inhibitory postsynaptic potential (fIPSP) were recorded in the CA1 pyramidal cell body layer in acute hippocampal slices. Control: 61.4 ± 4% vs. JSK: 80.5 ± 4%; p&lt;0.05, unpaired t-test. Unless otherwise specified, n = number of slices (<bold>s</bold>), number of animals (<bold>a</bold>). (<bold>C</bold>) CB<sub>1</sub>-iLTD was blocked by acute bath application of the Rac1 inhibitor NSC (30 µM). Control: 68.8 ± 6% vs. NSC23766: 89.7 ± 4%; p&lt;0.05, unpaired t-test. (<bold>D</bold>) NSC (30 µM) bath application reversibly depressed basal transmission. NSC: 98 ± 2%, one sample t-test, p&gt;0.05. (<bold>E</bold>) CB<sub>1</sub>-iLTD is enhanced by acute bath application of the Arp2/3 inhibitor CK-666 (100 µM). Control: 63.8 ± 4% vs. CK-666: 45.2 ± 4%, p&gt;0.05, unpaired t-test. (<bold>F</bold>) <italic>Left</italic>, representative Western blots of staining for Arpc2 and Ponceau loading control in vehicle or WIN-treated hippocampal cultures. <italic>Right</italic>, Arpc2 was downregulated in hippocampal neuron cultures after CB<sub>1</sub> activation with WIN (5 µM, 25 min). Arpc2 (Fold of Veh): 0.851 ± 0.06, U = 16, Z = 2.31, * indicates p&lt;0.05, Mann-Whitney. Dots represent individual values for four independent experiments. Data in the bar plot represent mean ± S.E.M. (<bold>G</bold>) Proposed model of CB<sub>1</sub>-iLTD pathway and mechanism of action of pharmacological reagents. CB<sub>1</sub> activation triggers protein synthesis (not shown) and leads to inhibition of Rac1 which causes disassembly of the Arp2/3-WASF1 complex. Arp2/3 is degraded leading to actin remodeling. Actin dynamics are required for CB<sub>1</sub>-iLTD. NSC inhibits Rac1-GEF interaction. CK-666 stabilizes the inactive conformation of Arp2/3, preventing it from binding actin filaments. JSK stabilizes actin filaments and promotes polymerization.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-54812-fig3-v2.tif"/></fig><fig id="fig3s1" position="float" specific-use="child-fig"><label>Figure 3—figure supplement 1.</label><caption><title>Individual bouton sizes are altered by CB<sub>1</sub>-iLTD and dependent on actin dynamics but actin inhibitors have no effect on basal transmission.</title><p>(<bold>A</bold>) Quantification of bouton volume normalized to control by slice. Activation of CB<sub>1</sub> receptors with WIN for 25 min led to decreased bouton volume that was blocked by treatment with jasplakinolide (JSK, 250 nM). Superplot shows individual bouton volume values color-coded by slice in swarmplot with solid larger dots overlaid representing mean bouton volume per slice. Overall mean of each slice is given by solid black circle with 95% CI represented by the vertical black line. Control: 1.0 ± 0.02 vs. WIN 1 hr: 0.88 ± 0.02 vs. WIN + JSK: 0.97 ± 0.02 vs. JSK: 0.95 ± 0.02 (Mean ± S.E.M.); F[3,20]=7.33, p=0.0017, one-way ANOVA with post-hoc Tukey test for multiple comparisons. WIN 1 hr vs. Control: CI [−0.20,–0.04], p=0.0016, WIN 1 hr vs. WIN + JSK: CI [−0.17,–0.017], p=0.012. n = number of slices (three images/slice, one slice/rat, six rats). 95% Confidence intervals (CI) are given as CI[lower CI, upper CI]. p-Values are exact. (<bold>B</bold>) JSK (250 nM) had no effect on baseline. JSK: 97.76 ± 2.8, one-sample t-test, p&gt;0.05. For all electrophysiology figures, averaged summary data expressed as normalized change from baseline ± S.E.M. and n = number of slices (<bold>s</bold>), number of animals (<bold>a</bold>). (<bold>C</bold>) NSC application on baseline caused decreased PPR (measured at 35–45 min) suggesting a presynaptic target. Pre: 0.65 ± 0.06 vs. NSC: 0.57 ± 0.08, paired-sample t-test, p&lt;0.05, n = 5 slices (same as <xref ref-type="fig" rid="fig4">Figure 4B</xref>). (<bold>D</bold>) CK-666 (100 µM) had no effect on baseline. CK-666: 95.44 ± 5.0, one sample t-test, p&gt;0.05.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-54812-fig3-figsupp1-v2.tif"/></fig></fig-group><p>The Rac1 GTPase is one of the principal regulators of actin polymerization via WASF1/WAVE1 and Arp2/3 activity (<xref ref-type="bibr" rid="bib34">Derivery and Gautreau, 2010</xref>; <xref ref-type="bibr" rid="bib107">Stradal and Scita, 2006</xref>). To test the role of this pathway, we inhibited Rac1 activity using NSC 23766 (NSC), an inhibitor of Rac1-GEF interaction (<xref ref-type="bibr" rid="bib40">Gao et al., 2004</xref>). CB<sub>1</sub>-iLTD was impaired by application of NSC (30 µM, 25 min) during induction (<xref ref-type="fig" rid="fig3">Figure 3C</xref>). NSC alone transiently suppressed inhibitory transmission (<xref ref-type="fig" rid="fig3">Figure 3D</xref>), unlike excitatory transmission (<xref ref-type="bibr" rid="bib58">Hou et al., 2014</xref>), and this effect was associated with a decrease in PPR (<xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1C</xref>), suggesting Rac1 activity regulates GABA release. To directly test the role of Arp2/3 in CB<sub>1</sub>-iLTD we utilized CK-666 (100 µM), a compound that inhibits Arp2/3-mediated actin assembly by stabilizing the inactive conformation of Arp (see <xref ref-type="fig" rid="fig3">Figure 3G</xref>; <xref ref-type="bibr" rid="bib10">Basu et al., 2016</xref>; <xref ref-type="bibr" rid="bib54">Hetrick et al., 2013</xref>). CK-666 bath application enhanced CB<sub>1</sub>-iLTD (<xref ref-type="fig" rid="fig3">Figure 3E</xref>) suggesting that Arp2/3 participates in CB<sub>1</sub>-iLTD. Unlike NSC, CK-666 had no effect on basal inhibitory transmission (<xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1D</xref>), presumably because the inhibitor stabilizes the inactive (unbound) Arp2/3, but does not affect the Arp2/3 bound to actin filaments. ARPC2 protein, an essential component of the Arp2/3 complex, was reduced upon CB<sub>1</sub> activation in hippocampal neuron cultures (<xref ref-type="fig" rid="fig3">Figure 3F</xref>). We speculate that during normal CB<sub>1</sub>-iLTD, CB<sub>1</sub> activation-mediated Rac1 inhibition leads to removal of Arp2/3 from actin branches, and the subsequent degradation of Arp2/3 (<xref ref-type="fig" rid="fig3">Figure 3G</xref>). The enhancement of CB<sub>1</sub>-iLTD by CK-666 application probably occurs because the unbound Arp2/3 that has not been degraded following CB<sub>1</sub> activation becomes inhibited and cannot maintain actin branches, thereby resulting in further depolymerization. Together, our findings suggest that Rac1 signaling and loss of Arp2/3 likely underlie the actin remodeling required for functional and structural CB<sub>1</sub>-iLTD (<xref ref-type="fig" rid="fig3">Figure 3G</xref>).</p></sec><sec id="s2-4"><title>CB<sub>1</sub>-iLTD requires ubiquitination, but not degradation by the proteasome</title><p>The simplest interpretation of our findings is that CB<sub>1</sub>-induced degradation of ARPC2 and WASF1/WAVE1 led to impaired actin remodeling and reduced presynaptic bouton size (see <xref ref-type="fig" rid="fig2">Figure 2</xref>). Congruent with this idea, presynaptic release machinery and cytomatrix proteins were consistently downregulated (<xref ref-type="fig" rid="fig4">Figure 4A</xref>), whereas proteins involved in the ubiquitin/proteasome system (UPS) were upregulated (<xref ref-type="fig" rid="fig4">Figure 4B</xref>). We confirmed that presynaptic proteins identified in the SILAC screen, Munc18-1, Synapsin-1, and α-Synuclein, were significantly reduced by WIN (25 min, 5 µM) in hippocampal cultures (<xref ref-type="fig" rid="fig4">Figure 4C</xref>), suggesting rapid protein degradation upon CB<sub>1</sub> activation. To test whether presynaptic proteins are downregulated locally in acute hippocampal slices, we prevented anterograde and retrograde axonal transport by incubating slices in nocodazole (1 hr, 20 µM), an agent that depolymerizes axonal microtubules (<xref ref-type="bibr" rid="bib7">Barnes et al., 2010</xref>; <xref ref-type="bibr" rid="bib124">Younts et al., 2016</xref>). We found that CB<sub>1</sub> activation with WIN reduced Synapsin-1 puncta intensity in CB<sub>1</sub><sup>+</sup> boutons despite blockade of axonal transport (<xref ref-type="fig" rid="fig4">Figure 4D</xref>), as measured by immunostaining and quantitative Airyscan microscopy, consistent with local downregulation. These results suggest that CB<sub>1</sub> activation elicits rapid downregulation of presynaptic proteins in culture and in acute slices which likely contributes to the reduction in GABA release associated with CB<sub>1</sub>-iLTD and may be mediated by degradation by the UPS.</p><fig id="fig4" position="float"><label>Figure 4.</label><caption><title>Presynaptic proteins are rapidly reduced following CB<sub>1</sub> activation.</title><p>(<bold>A</bold>) Combined score plot of differentially expressed proteins between vehicle vs. CB<sub>1</sub> activation with WIN. Blue dots are manually selected presynaptic cytomatrix and release machinery proteins. SYPH: Synaptophysin; SV2A: Synaptic vesicle glycoprotein 2A; Synaptosome associated protein 91: SNAP91; WASF1: Wiskott-Aldrich syndrome protein family member 1; NSF: Vesicle-fusing ATPase; SNG1: synaptogyrin; MUNC18: mammalian homologue of UNC-18; SYUA: alpha-synuclein; SYN1: Synapsin-1; ARPC2: Arp complex subunit 2; STX1A-B: Syntaxin1A-1B; SYUB: beta-synuclein; NCKP1: Nck-associated protein 1. (<bold>B</bold>) Combined score plot of differentially expressed proteins between vehicle vs. CB<sub>1</sub> activation with WIN. Yellow dots are manually selected ubibquitin-proteasome system-related proteins. Note that the only downregulated protein is a de-ubiquitinase. UCHL1: Ubiquitin carboxyl-terminal hydrolase isozyme L1; PSB 2,3,4,5,6: Proteasome subunit beta type-2,4,5,6; PSA 1,6: Proteasome subunit alpha type 1,6; SUMO2: Small ubiquitin-related modifier 2; PSME1: Proteasome activator complex subunit 1. (<bold>C</bold>) <italic>Left</italic>, representative Western blot images of staining for presynaptic proteins Munc18-1, Synapsin-1, and α-Synuclein and Ponceau loading control in vehicle vs. WIN-treated hippocampal cultures (5 µM, 25 min). <italic>Right</italic>, quantification of three experimental replicates normalized to Vehicle revealed a decrease in all three proteins consistent with SILAC. Munc18-1: 0.78 ± 0.09, p&lt;0.05; Synapsin-1: 0.60 ± 0.11, p&lt;0.01; α-Synuclein: 0.86 ± 0.01, p&lt;0.0001, unpaired t-test, n = number of cultures. (<bold>D</bold>) <italic>Top</italic>, Airyscan confocal representative images of CB<sub>1</sub><sup>+</sup> boutons in acute hippocampal slices in CA1 pyramidal layer showing colocalization of CB<sub>1</sub><sup>+</sup> boutons (green) and Synapsin-1 (magenta). <italic>Bottom</italic>, Gardner-Altman estimation plot showing the mean difference between Control and WIN of intensity of Synapsin-1 puncta within CB<sub>1</sub><sup>+</sup> boutons per slice was significantly diminished by WIN application (5 µM, 25 min). Both groups are plotted on the left axes; the mean difference is plotted on a floating axes on the right as a bootstrap sampling distribution. The mean difference is depicted as a dot; the 95% confidence interval is indicated by the ends of the vertical error bar. Control: 1.0 ± 0.09, WIN: 0.73 ± 0.06 (Mean ± S.E.M.), n = number of slices (10 slices, four rats/condition). The unpaired mean difference between Control and WIN is −0.267 [95.0%CI −0.494, −0.0819]. Two-sided permutation t-test, p=0.0234.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-54812-fig4-v2.tif"/></fig><p>Next, we assessed the overall contribution of the UPS to CB<sub>1</sub>-iLTD. First, to dynamically assess the UPS pathway, we measured K48-linked ubiquitinated proteins, the canonical form of ubiquitin linkage (<xref ref-type="bibr" rid="bib32">Dantuma and Bott, 2014</xref>), following induction of CB<sub>1</sub>-iLTD in acute rat hippocampal slices in presence or absence of the specific proteasome inhibitor, MG-132. We found that both net flux, that is the amount of ubiquitinated proteins degraded by the proteasome (difference between UbK48 level when proteasomal degradation is blocked and UbK48 level under normal conditions), and the rate of degradation, (measured by the ratio of UbK48 levels between blocked and basal conditions), were significantly increased. These results suggest both a larger pool of protein to degrade as well as a faster turnover rate (<xref ref-type="fig" rid="fig5">Figure 5A</xref>). However, to our surprise, CB<sub>1-</sub>iLTD was unaffected by application of the proteasomal inhibitor MG-132 (5 µM) during the baseline and induction (<xref ref-type="fig" rid="fig5">Figure 5B</xref>). MG-132 alone had no lasting effect on basal transmission either (<xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1A</xref>). As a positive control, MG-132 application in interleaved slices resulted in accumulation of ubiquitinated proteins (<xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1B</xref>). Therefore, while UPS activity is increased downstream of CB<sub>1</sub> activation, proteasomal degradation is not necessary for CB<sub>1</sub>-iLTD.</p><fig-group><fig id="fig5" position="float"><label>Figure 5.</label><caption><title>CB<sub>1</sub>-iLTD requires ubiquitination, but not degradation by the proteasome.</title><p>(<bold>A</bold>) <italic>Left</italic>, representative Western blot images of K48 polyubiquitin in hippocampal slices treated with Veh v. WIN or Veh v. WIN and MG-132. <italic>Right</italic>, <italic>top</italic>: Levels of K48 polyubiquitin following CB<sub>1</sub> activation with WIN (5 µM, 25 min). <italic>Bottom left:</italic> UPS net flux [difference between basal (none) and proteasome blockade (MG-132) condition] is significantly increased upon CB<sub>1</sub> activation. Control: 1.0 ± 0.04 vs. WIN: 1.74 ± 0.04, unpaired t-test, ****=p &lt; 0.0001, n = 5 animals. <italic>Bottom right</italic>: UPS rate [ratio between MG-132 and basal condition] of K48 polyubiquitinated protein degradation is significantly increased after WIN. Control: 1.65 ± 0.08 vs. WIN: 2.31 ± 0.12, unpaired t-test, **=p &lt; 0.01, n = 5 animals. (<bold>B</bold>) Blockade of the proteasome by bath application of MG-132 (5 µM) had no effect on iLTD. Control: 77.6 ± 4% vs. MG-132: 73.3 ± 5%; p&gt;0.05, unpaired t-test. For all electrophysiology figures, averaged summary data expressed as normalized change from baseline ± S.E.M. and n = number of slices (s), number of animals (a). (<bold>C</bold>) Inhibiting ubiquitination with ziram (25 µM) or PYR-41 (50 µM) fully blocked iLTD. Control: 66 ± 5 vs. ziram: 99 ± 4 vs. PYR-41: 93 ± 6; F[2,19]=10.22; p&lt;0.05, one-way ANOVA. (<bold>D</bold>) Blockade of E1 ubiquitin ligase function with ziram (25 µM, 25 min) rescued the volumetric decrease associated with CB<sub>1</sub> activation by WIN (5 µM, 25 min). <italic>Top</italic>, representative inhibitory boutons immunolabeled with CB<sub>1</sub> and reconstructed in 3D. <italic>Bottom</italic>, quantification of normalized mean CB<sub>1</sub> bouton volume per slice. Control: 1.0 ± 0.04 vs. WIN: 0.81 ± 0.03 vs. WIN + ziram: 0.95 ± 0.03 vs. ziram: 1.0 ± 0.03 (mean ± S.E.M.); F[3,30]=8.11, p=0.0004, one-way ANOVA with post-hoc Tukey test for multiple comparisons. Control vs. WIN: CI[0.07,0.32], p=0.0008; WIN vs. WIN + ziram: CI[−0.27,–0.025], p=0.014; WIN vs. ziram: CI[−0.32,–0.063], p=0.0018. n = number of slices (three images/slice, one slices/rat, nine rats/condition for Control, WIN, WIN + ziram, seven rats/condition for ziram). For all structural plasticity figures, data are presented as points representing mean bouton volume per slice with a horizontal black line representing the mean per condition and the vertical line indicating 95% confidence interval (CI). 95% CIs are given as CI[lower CI, upper CI]. p-Values are exact. Refer to <xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1E</xref> for distribution of individual bouton values. (<bold>E</bold>) Schematic summary of proposed mechanism of CB<sub>1</sub>–iLTD 1. CB<sub>1</sub> activation rapidly engages presynaptic protein synthesis (<xref ref-type="bibr" rid="bib124">Younts et al., 2016</xref>). 2. CB<sub>1</sub>–iLTD increases components of the ubiquitin/proteasome system and leads to enhanced proteasomal activity (<xref ref-type="fig" rid="fig4">Figure 4A,B</xref> and (<bold>A</bold>)) 3. Ubiquitination is required for concomitant decrease in the volume of the bouton (<bold>D</bold>) and reduction in neurotransmitter release (<bold>C</bold>). 4. CB<sub>1</sub>–iLTD involves signaling via Rac1 and Arp2/3 and actin dynamics.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-54812-fig5-v2.tif"/></fig><fig id="fig5s1" position="float" specific-use="child-fig"><label>Figure 5—figure supplement 1.</label><caption><title>CB1-iLTD results in changes in proteins with ubiquitination sites in functional domains.</title><p>(<bold>A</bold>) MG-132 (5 µM) did not cause a change in baseline transmission upon washout. MG-132: 99.66 ± 2.43%; p&gt;0.05, one sample t-test. For all electrophysiology figures, averaged summary data expressed as normalized change from baseline ± S.E.M. and n = number of slices (s), number of animals (a). (<bold>B</bold>) Western blot of accumulated K48 ubiquitinated proteins when proteasome is blocked with 5 µM MG-132 demonstrated the efficacy of the drug. (<bold>C</bold>) Predicted ubiquitination sites based on protein sequence plotted with UbiSite. Percentage represents # of predicted Ub sites in functional domains of protein divided by total predicted sites. Note: no protein structure data was available for Arpc2. NAC: non-amyloid component region of α-synuclein. SNARE: SNARE protein interaction site. TM: transmembrane domain. (<bold>D</bold>) Ziram (25 µM) or PYR-41 (50 µM) did not cause a significant change in baseline transmission. ziram: 91.56 ± 6.49%; p&gt;0.05, one sample t-test. PYR-41: 91.49 ± 4.0; p&gt;0.05, one sample t-test. (<bold>E</bold>) Quantification of normalized CB<sub>1</sub> bouton volume by slice. Superplot shows individual bouton volume values color-coded by slice in swarmplot with solid larger dots overlaid representing mean bouton volume per slice. Overall mean of each slice is given by solid black circle with 95% CI represented by the vertical black line. Control: 1.00 ± 0.05 vs. WIN: 0.83 ± 0.03 vs. WIN + ziram: 0.95 ± 0.04 vs. ziram: 1.00 ± 0.03 (Mean ± S.E.M.); F[3,24]=4.87, p=0.009, one-way ANOVA with post-hoc Tukey test for multiple comparisons. WIN vs. Control: CI [−0.32,–0.032], p=0.013, WIN vs. Control: CI[−0.32,–0.032], p=0.013, ziram vs. WIN: CI[0.03, 0.31], p=0.02. n = number of slices (three images/slice, one slice/rat, seven rats/condition). 95% Confidence intervals (CI) are given as CI[lower CI, upper CI]. p-Values are exact.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-54812-fig5-figsupp1-v2.tif"/></fig></fig-group><p>Ubiquitination not only targets proteins for degradation, but can also affect their localization and function (<xref ref-type="bibr" rid="bib47">Hamilton and Zito, 2013</xref>). We analyzed ubiquitination sites on a subset of proteins that were decreased by CB<sub>1</sub> activation and found that most ubiquitination sites (~60%) were located in protein-protein or protein-membrane interaction domains (<xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1C</xref>; <xref ref-type="bibr" rid="bib1">Akimov et al., 2018</xref>), indicating that ubiquitination of these proteins could impact their function. We hypothesized that perhaps protein ubiquitination itself, independent of degradation, may play a role in CB<sub>1</sub>-iLTD. Using two structurally and mechanistically distinct E1 Ubiquitin ligase inhibitors, ziram and PYR-41 (<xref ref-type="bibr" rid="bib99">Rinetti and Schweizer, 2010</xref>), we directly tested whether ubiquitination was required for CB<sub>1-</sub>iLTD and found that bath application of ziram or PYR-41 blocked CB<sub>1</sub>-iLTD (<xref ref-type="fig" rid="fig5">Figure 5C</xref>) but had no significant effect on basal transmission (<xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1D</xref>). Moreover, inhibition of ubiquitination also blocked the CB<sub>1</sub>-mediated decrease in CB<sub>1</sub><sup>+</sup> bouton volume (<xref ref-type="fig" rid="fig5">Figure 5D</xref>, <xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1E</xref>). In summary, CB<sub>1</sub>-iLTD leads to increases in UPS proteins and is associated with functional increases in proteasomal activity (<xref ref-type="fig" rid="fig5">Figure 5E</xref>). Ubiquitination is required for protein synthesis-dependent structural and functional changes of CB<sub>1</sub><sup>+</sup> boutons. CB<sub>1</sub>-iLTD is associated with decreases in presynaptic and cytomatrix proteins, including ARPC2 and WASF1/WAVE1, and relies on actin dynamics. However, while proteasomal activity increases by CB<sub>1</sub> activation, only protein ubiquitination is required for structural and functional CB<sub>1-</sub>iLTD.</p></sec></sec><sec id="s3" sec-type="discussion"><title>Discussion</title><p>We discovered that CB<sub>1</sub>-iLTD involves structural changes of the presynaptic bouton that require protein synthesis. We identified the proteins that are up- and downregulated following CB<sub>1</sub> activation. Increased proteins are implicated in protein synthesis, processing and degradation, whereas decreased proteins are implicated in presynaptic structure, including ARPC2 and WASF1/WAVE, and function. CB<sub>1</sub>-iLTD involved actin remodeling, Rac1 and Arp2/3 signaling. Unexpectedly, we found that protein ubiquitination, but not proteasomal degradation, is responsible for structural and functional CB<sub>1</sub>-iLTD. Together, these findings point to a mechanism by which inhibitory presynapses can control their strength in response to CB<sub>1</sub> activation via rapid proteostatic regulation of presynaptic structural change.</p><sec id="s3-1"><title>Presynaptic structural changes in CB<sub>1</sub>-iLTD</title><p>While structural changes are part and parcel of postsynaptic forms of plasticity (<xref ref-type="bibr" rid="bib17">Bramham, 2008</xref>; <xref ref-type="bibr" rid="bib88">Nakahata and Yasuda, 2018</xref>), and changes associated with plasticity are thought to be coordinated across the synaptic cleft, the involvement of structural changes of the presynaptic terminal in forms of long-term presynaptic plasticity are less clear. Here, we provide evidence for long-term structural changes at mature CB<sub>1</sub><sup>+</sup> terminals associated with CB<sub>1</sub>-iLTD. Previous work showed CB<sub>1</sub> receptor activation can trigger ultrastructural changes in vesicle distribution associated with short-term CB<sub>1</sub>-mediated plasticity (<xref ref-type="bibr" rid="bib41">García-Morales et al., 2015</xref>; <xref ref-type="bibr" rid="bib97">Ramírez-Franco et al., 2014</xref>), collapse of axonal growth cones (<xref ref-type="bibr" rid="bib11">Berghuis et al., 2007</xref>), and inhibitory bouton formation in response to strong postsynaptic excitation (<xref ref-type="bibr" rid="bib60">Hu et al., 2019</xref>). Our data show that transient activation of CB<sub>1</sub> receptors leads to a long-term reduction of the presynaptic CB<sub>1</sub><sup>+</sup> compartment volume in somatic synapses onto CA1 pyramidal cells. Our findings (<xref ref-type="fig" rid="fig3">Figure 3</xref>) are consistent with a previous study showing that CB<sub>1</sub> receptors regulate actin dynamics in growth cones by directly interacting with Rac1 (<xref ref-type="bibr" rid="bib92">Njoo et al., 2015</xref>), a Rho GTPase (<xref ref-type="bibr" rid="bib80">Mattheus et al., 2016</xref>). By directly binding CB<sub>1</sub>, Rac1 can localize the WRC which consists of WASF1/WAVE1, Cyfip1, Nap1, Abi and HSP300, at the plasma membrane (<xref ref-type="bibr" rid="bib24">Chen et al., 2010</xref>; <xref ref-type="bibr" rid="bib39">Eden et al., 2002</xref>). The WRC is intrinsically inactive at rest (<xref ref-type="bibr" rid="bib33">Derivery et al., 2009</xref>), but upon recruitment to the membrane by Rac1 the cytoplasmic side is opened for binding to Arp2/3 and actin (<xref ref-type="bibr" rid="bib24">Chen et al., 2010</xref>; <xref ref-type="bibr" rid="bib39">Eden et al., 2002</xref>), leading to dissociation of WASF1. Although the exact mechanism of degradation has not been shown for Arp2/3 or WASF1/WAVE1, the non-neuronal, structurally homologous isoform WAVE2 was demonstrated to undergo activation-dependent dissociation from the WRC ubiquitination and proteasomal degradation (<xref ref-type="bibr" rid="bib67">Joseph et al., 2017</xref>). Therefore, Rac1 could be required for the degradation of WASF1/WAVE1, but its direct involvement in presynaptic degradation of Arp2/3 is not as clear. Our strategy of bath application of pharmacological inhibitors does not allow us to rule out an extra-presynaptic effect.</p><p>Other studies have suggested alternative signaling pathways by which structural changes occur downstream of CB<sub>1</sub> activation. For instance, atypical coupling of CB<sub>1</sub> to G<sub>12/13</sub> proteins reportedly engages Rho-associated kinase (ROCK) signaling to the actomyosin cytoskeleton (<xref ref-type="bibr" rid="bib100">Roland et al., 2014</xref>), whereas in another example, β-integrin signaling to ROCK has been implicated in a cannabinoid-mediated form of LTP (<xref ref-type="bibr" rid="bib116">Wang et al., 2018a</xref>). Therefore, the signaling pathways and structural changes involved downstream of CB<sub>1</sub> receptors seem to be synapse and cell-type-dependent (<xref ref-type="bibr" rid="bib106">Steindel et al., 2013</xref>). Whether CB-LTD at other synapses shares similar mechanisms remains unclear.</p><p>We showed that CB<sub>1</sub>-iLTD involves a rapid reduction in the size of CB<sub>1</sub> boutons and the volume of active zones that requires both actin dynamics and protein synthesis (<xref ref-type="fig" rid="fig1">Figure 1</xref>). CB<sub>1</sub> bouton size was measured by immunolabeling the CB<sub>1</sub> receptor, which, due to the extremely high density and of CB<sub>1</sub> receptors expressed on presynaptic boutons in the CA1 region of the hippocampus, has been shown to be a reliable approximation of bouton volume (<xref ref-type="bibr" rid="bib38">Dudok et al., 2015</xref>). Although studies in cultured neurons suggest CB<sub>1</sub> internalization occurs (<xref ref-type="bibr" rid="bib31">Coutts et al., 2001</xref>; <xref ref-type="bibr" rid="bib59">Hsieh et al., 1999</xref>; <xref ref-type="bibr" rid="bib64">Jin et al., 1999</xref>; <xref ref-type="bibr" rid="bib110">Tappe-Theodor et al., 2007</xref>), little is known about the internalization of CB<sub>1</sub> receptor in the intact brain, which may require longer timescales than the brief CB<sub>1</sub> activation (25 min) we have used here (<xref ref-type="bibr" rid="bib38">Dudok et al., 2015</xref>; <xref ref-type="bibr" rid="bib111">Thibault et al., 2013</xref>). It is unlikely that CB<sub>1</sub> internalization can account for the volumetric change since the high density of CB<sub>1</sub> means that a large proportion of receptors would have to be internalized to affect measurement of the bouton size (<xref ref-type="bibr" rid="bib111">Thibault et al., 2013</xref>). Moreover, the CB<sub>1</sub>-mediated presynaptic shrinkage is blocked by protein synthesis inhibition whereas internalization is not protein synthesis-dependent (<xref ref-type="bibr" rid="bib59">Hsieh et al., 1999</xref>) and is also detectable at the sub-presynaptic compartment level with Bassoon and VGAT labeling (<xref ref-type="fig" rid="fig1">Figure 1</xref>; <xref ref-type="fig" rid="fig1s1">Figure 1—figure supplements 1</xref> and <xref ref-type="fig" rid="fig1s2">2</xref>), two well-established markers of presynaptic structure. Intriguingly, VGAT size showed a marked reduction in CB<sub>1+</sub> boutons, which could reflect synaptic vesicle redistribution, consistent with previous reports showing short-term CB<sub>1</sub> activation-induced vesicle redistribution and changes in numbers of docked/primed vesicles (<xref ref-type="bibr" rid="bib41">García-Morales et al., 2015</xref>; <xref ref-type="bibr" rid="bib97">Ramírez-Franco et al., 2014</xref>). While the exact functional implications of presynaptic bouton and active zone shrinkage are yet unclear, associated changes in neurotransmitter release may result from altered Ca<sup>2+</sup> channel coupling distance with the active zone (<xref ref-type="bibr" rid="bib89">Nakamura et al., 2015</xref>), less area for vesicular release, shift from multi- to univesicular release mode (<xref ref-type="bibr" rid="bib3">Aubrey et al., 2017</xref>), or reorganization of transsynaptic nanocolumns (<xref ref-type="bibr" rid="bib25">Chen et al., 2018</xref>; <xref ref-type="bibr" rid="bib42">Glebov et al., 2017</xref>).</p></sec><sec id="s3-2"><title>Protein synthesis in presynaptic CB<sub>1</sub>-iLTD likely regulates diverse cellular processes</title><p>We have recently reported that protein synthesis is required for CB<sub>1</sub>-iLTD (<xref ref-type="bibr" rid="bib124">Younts et al., 2016</xref>). Using a well-established unbiased proteomics approach in primary hippocampal neuron cultures (<xref ref-type="fig" rid="fig2">Figure 2</xref>; <xref ref-type="bibr" rid="bib66">Jordan et al., 2006</xref>; <xref ref-type="bibr" rid="bib125">Zhang et al., 2011</xref>; <xref ref-type="bibr" rid="bib126">Zhang et al., 2012</xref>), we identified what proteins are synthesized upon CB<sub>1</sub> activation and thus can mediate CB<sub>1</sub>-iLTD. Despite the fact that we used whole neuron lysates, our data revealed results highly consistent with other studies that isolated presynaptic mRNAs (<xref ref-type="bibr" rid="bib13">Bigler et al., 2017</xref>; <xref ref-type="bibr" rid="bib45">Hafner et al., 2019</xref>; <xref ref-type="bibr" rid="bib95">Ostroff et al., 2019</xref>; <xref ref-type="bibr" rid="bib104">Shigeoka et al., 2016</xref>), specifically, an enrichment of mRNAs encoding for initiation factors and ribosomal proteins. We found that CB<sub>1</sub> activation significantly upregulated proteins involved in protein synthesis and processing pathways (<xref ref-type="fig" rid="fig2">Figure 2</xref>). This increase in initiation factors and ribosomal proteins suggests that plasticity likely triggers an enhanced translational capacity which is consistent with our previous findings using Fluorescent Noncanonical Amino acid Tagging (FUNCAT) (<xref ref-type="bibr" rid="bib124">Younts et al., 2016</xref>). mRNAs for Arp2/3, WAVE1, and β-actin have been detected in axonal preparations and their synthesis may be important for axon formation (<xref ref-type="bibr" rid="bib36">Donnelly et al., 2013</xref>; <xref ref-type="bibr" rid="bib105">Spillane et al., 2012</xref>; <xref ref-type="bibr" rid="bib118">Wong et al., 2017</xref>). However, in CB<sub>1</sub>-iLTD, protein synthesis seems to mediate the change in presynaptic structure via the UPS, rather than direct synthesis of actin regulators. What then is being synthesized to mediate the change in structure and function? Our finding of downregulation of many presynaptic proteins and upregulation of components of the UPS suggested to us that perhaps this upregulation represents an activity-dependent synthesis of regulatory elements in the ubiquitination and proteasomal degradation pathway.</p><p>Although such a mechanism requires greater coordination, it would also reduce energy expenditure over time, that is if a presynaptic terminal will not be releasing neurotransmitter for an extended period of time (hours to days) it makes sense to degrade and recycle the release machinery, to reduce energy production, and to shrink the terminal to make space for new growth. Protein synthesis is likely necessary for the coordination and engagement of these structural, metabolic, and degradative processes. We measured changes in the protein landscape that occur fairly rapidly after CB<sub>1</sub>-iLTD induction (25 min) given that CB<sub>1</sub>-iLTD was dependent on protein synthesis during this time window (<xref ref-type="bibr" rid="bib124">Younts et al., 2016</xref>). It is likely that additional ‘plasticity-related’ proteins are synthesized or degraded in the hours that follow iLTD induction.</p></sec><sec id="s3-3"><title>Protein degradation and presynaptic function</title><p>Proteomic analysis revealed a population of downregulated proteins involved in presynaptic function and structure, as well as energy metabolism (<xref ref-type="fig" rid="fig1">Figures 1</xref> and <xref ref-type="fig" rid="fig4">4</xref>). In contrast, components of the protein degradation pathway, including proteasomal subunits, E2 ubiquitin ligases, and degradative enzymes, were upregulated perhaps reflecting on-demand synthesis which could regulate fast, local presynaptic protein degradation. While activity-dependent local presynaptic synthesis of UPS machinery has never been demonstrated, there is strong evidence that presynaptic function can be regulated by expression of specific E3 ubiquitin ligases and degradation of select presynaptic proteins. For example, SCRAPPER an E3 ligase has been shown to target presynaptic proteins like RIM1, synaptophysin, and Munc18 (<xref ref-type="bibr" rid="bib121">Yao et al., 2007</xref>), amongst other proteins with high similarity to those identified in our SILAC dataset. Moreover, SCRAPPER KO has been shown to impair neurotransmitter release, short-term plasticity and presynaptic LTP (<xref ref-type="bibr" rid="bib71">Koga et al., 2017</xref>; <xref ref-type="bibr" rid="bib121">Yao et al., 2007</xref>). The tight coupling of translation and degradation in the context of synaptic plasticity was described previously (<xref ref-type="bibr" rid="bib70">Klein et al., 2015</xref>) and is presumed to occur widely in the brain as a means of maintaining proteostasis over the course of plastic changes (<xref ref-type="bibr" rid="bib12">Biever et al., 2019</xref>; <xref ref-type="bibr" rid="bib35">Dong et al., 2008</xref>; <xref ref-type="bibr" rid="bib48">Hanus and Schuman, 2013</xref>; <xref ref-type="bibr" rid="bib115">Wang et al., 2017</xref>). This rapid activity-dependent degradation could be mediated by the recently discovered neuron-specific proteasome complex (NMP) (<xref ref-type="bibr" rid="bib96">Ramachandran et al., 2018</xref>), although this complex is believed to target non-ubiquitinated substrates. Protein degradation has also been shown to regulate presynaptic silencing, specifically by degradation of presynaptic proteins such as RIM1 and Munc13 (<xref ref-type="bibr" rid="bib63">Jiang et al., 2010</xref>) and CB<sub>1</sub>-mediated suppression of transmission at excitatory synapses via degradation of Munc18 (<xref ref-type="bibr" rid="bib103">Schmitz et al., 2016</xref>; <xref ref-type="bibr" rid="bib117">Wang et al., 2018b</xref>). Homeostatic plasticity in response to neuron silencing has also been associated with degradation of select presynaptic proteins (<xref ref-type="bibr" rid="bib74">Lazarevic et al., 2011</xref>). However, our data strongly support the idea that protein degradation by the UPS is not directly required for CB<sub>1-</sub>iLTD, but likely does occur quickly after CB<sub>1</sub> activation, as indicated by rapid loss of presynaptic proteins measured with both SILAC and western blot (<xref ref-type="fig" rid="fig4">Figure 4</xref>). This rapid reduction in protein levels presumably occurs as a consequence of enhanced UPS activity (<xref ref-type="fig" rid="fig5">Figure 5</xref>), but we cannot exclude that a different mechanism could be involved including reduced synthesis (<xref ref-type="bibr" rid="bib37">Dörrbaum et al., 2020</xref>) or other protein degradation pathways, such as autophagy (<xref ref-type="bibr" rid="bib75">Liang and Sigrist, 2018</xref>).</p><p>We demonstrated that ubiquitination is required for CB<sub>1</sub>-iLTD, likely by controlling the trafficking, interactions, or the activity of its substrates, upstream of degradation (<xref ref-type="bibr" rid="bib47">Hamilton and Zito, 2013</xref>). A previous study showed that inhibition of protein ubiquitination and degradation increased miniature EPSCs/IPSCs in cultured neurons, suggesting an important role for these processes in maintaining normal neurotransmitter release (<xref ref-type="bibr" rid="bib99">Rinetti and Schweizer, 2010</xref>). However, in our hands, proteasomal inhibitor MG-132 had no significant effects on basal synaptic transmission and neither did E1 ubiquitin ligase inhibitors, ziram and PYR-41. To our knowledge, our study is the first to describe a mechanism of long-term presynaptic structural and functional plasticity that relies on ubiquitination. The regulation of presynaptic ubiquitination is likely achieved through the targeted expression of different E2 and E3 ubiquitin ligases (<xref ref-type="bibr" rid="bib46">Hallengren et al., 2013</xref>; <xref ref-type="bibr" rid="bib71">Koga et al., 2017</xref>; <xref ref-type="bibr" rid="bib121">Yao et al., 2007</xref>) or via presynaptic cytomatrix proteins themselves (<xref ref-type="bibr" rid="bib23">Chen et al., 2003</xref>; <xref ref-type="bibr" rid="bib62">Ivanova et al., 2016</xref>; <xref ref-type="bibr" rid="bib114">Waites et al., 2013</xref>). This raises the possibility that presynaptic structural dynamics and UPS activity are tightly linked.</p></sec><sec id="s3-4"><title>Potential relevance in the normal and diseased brain</title><p>CB<sub>1</sub> activation via eCBs, as well as exogenous cannabinoids like Δ<sup>9</sup>- tetrahydrocannabinol (THC), the primary psychoactive ingredient in marijuana, can influence cognition, goal-directed behaviors, sensory processing and other critical brain functions (<xref ref-type="bibr" rid="bib2">Araque et al., 2017</xref>; <xref ref-type="bibr" rid="bib4">Augustin and Lovinger, 2018</xref>; <xref ref-type="bibr" rid="bib49">Häring et al., 2012</xref>; <xref ref-type="bibr" rid="bib53">Heifets and Castillo, 2009</xref>; <xref ref-type="bibr" rid="bib56">Hoffman and Lupica, 2013</xref>; <xref ref-type="bibr" rid="bib128">Zlebnik and Cheer, 2016</xref>). Cannabinoid signaling has also been implicated in several brain disorders (<xref ref-type="bibr" rid="bib129">Zou and Kumar, 2018</xref>). Autism is broadly associated with changes in synaptic protein levels, but also disruption of CB<sub>1</sub>-LTD (<xref ref-type="bibr" rid="bib19">Busquets-Garcia et al., 2014</xref>; <xref ref-type="bibr" rid="bib22">Chakrabarti et al., 2015</xref>). In particular, in a mouse model of Fragile X Syndrome (FXS), the most common monogenic cause of autism, where RNA-binding protein, Fragile X mental retardation protein (FMRP) is deleted (<xref ref-type="bibr" rid="bib5">Bagni and Zukin, 2019</xref>), eCB-mediated plasticity in the hippocampus, striatum, prefrontal cortex is impaired (<xref ref-type="bibr" rid="bib68">Jung et al., 2012</xref>; <xref ref-type="bibr" rid="bib78">Maccarrone et al., 2010</xref>; <xref ref-type="bibr" rid="bib79">Martin et al., 2017</xref>; <xref ref-type="bibr" rid="bib117">Wang et al., 2018b</xref>; <xref ref-type="bibr" rid="bib127">Zhang and Alger, 2010</xref>). Although changes in the eCB mobilization in FXS may explain some of the impairment (<xref ref-type="bibr" rid="bib68">Jung et al., 2012</xref>; <xref ref-type="bibr" rid="bib78">Maccarrone et al., 2010</xref>; <xref ref-type="bibr" rid="bib127">Zhang and Alger, 2010</xref>), the role of FMRP in the regulation of local presynaptic protein synthesis may also play a role (but see <xref ref-type="bibr" rid="bib68">Jung et al., 2012</xref>), although this remains to be tested (<xref ref-type="bibr" rid="bib18">Busquets-Garcia et al., 2013</xref>). Many neurodegenerative diseases are characterized by imbalanced proteostasis, including Alzheimer’s disease (AD) and Parkinson’s disease (PD), resulting in pathological accumulations of misfolded proteins (<xref ref-type="bibr" rid="bib69">Klaips et al., 2018</xref>). WIN treatment in animal models of AD and PD has been shown to be neuroprotective and to alleviate cognitive and motor symptoms (<xref ref-type="bibr" rid="bib9">Basavarajappa et al., 2017</xref>), potentially through the ability of the CB<sub>1</sub> receptor to regulate synaptic proteostasis.</p></sec></sec><sec id="s4" sec-type="materials|methods"><title>Materials and methods</title><table-wrap id="keyresource" position="anchor"><label>Key resources table</label><table frame="hsides" rules="groups"><thead><tr><th>Reagent type <break/>(species) or resource</th><th>Designation</th><th>Source or reference</th><th>Identifiers</th><th>Additional <break/>information</th></tr></thead><tbody><tr><td>Biological sample wildtype, Sprague Dawley, <italic>Rattus norvegicus,</italic> male and female</td><td>Primary hippocampal neuron cultures</td><td>Charles River</td><td/><td>Isolated from DIV 20–21 pups</td></tr><tr><td>Biological sample wildtype, Sprague Dawley, <italic>Rattus norvegicus,</italic> male and female</td><td>Acute hippocampal slices</td><td>Charles River</td><td/><td>Isolated DOB 18–25 rats</td></tr><tr><td>Antibody</td><td>CB1 (rabbit polyclonal)</td><td>ImmunoGenes</td><td>Cat# CB1, RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/AB_2813823">AB_2813823</ext-link></td><td>1:1000</td></tr><tr><td>Antibody</td><td>Synapsin 1 (mouse monoclonal)</td><td>Synaptic Systems</td><td>Cat# 106 011C2, RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/AB_10805139">AB_10805139</ext-link></td><td>1:1000</td></tr><tr><td>Antibody</td><td>vGAT (mouse monoclonal)</td><td>Synaptic Systems</td><td>Cat# 131 011C3, RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/AB_887868">AB_887868</ext-link></td><td>1:500</td></tr><tr><td>Antibody</td><td>Bassoon (mouse <break/>monoclonal)</td><td>Enzo Life Sciences</td><td>Cat# ADI-VAM-PS003, RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/AB_10618753">AB_10618753</ext-link></td><td>1:1000</td></tr><tr><td>Antibody</td><td>Paravalbumin</td><td>Sigma-Aldrich</td><td>Cat# P3171, RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/AB_2313804">AB_2313804</ext-link></td><td>1:1000</td></tr><tr><td>Antibody</td><td>α-Synuclein</td><td>BD Biosciences</td><td>Cat# 610787, RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/AB_398108">AB_398108</ext-link></td><td>1:1000</td></tr><tr><td>Antibody</td><td>Munc-18–1</td><td>Synaptic Systems</td><td>Cat# 116 002, RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/AB_887736">AB_887736</ext-link></td><td>1:1000</td></tr><tr><td>Antibody</td><td>Arp2/3</td><td>Novus</td><td>Cat# NBP1-88852, RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/AB_11040464">AB_11040464</ext-link></td><td>1:1000</td></tr><tr><td>Antibody</td><td>Ubiquitin K48</td><td>Millipore</td><td>Cat# 05–1307, RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/AB_1587578">AB_1587578</ext-link></td><td>1:1000</td></tr><tr><td>Software</td><td>Igor Pro</td><td>IGOR Pro</td><td>RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/SCR_000325">SCR_000325</ext-link></td><td/></tr></tbody></table></table-wrap><sec id="s4-1"><title>Immunohistochemistry and microscopy</title><p>Acute rat hippocampal slices were made as described below for electrophysiological recordings and allowed to recover for at least 1 hr after slicing. Slices were incubated in beakers containing ACSF and drug treatments described in Results and underwent constant oxygenation. Slices were fixed immediately after treatments in 4% PFA in PBS overnight at RT. Slices were washed twice in PBS then incubated in blocking buffer (4% BSA in PBS + 0.1% Tx-100) for 1 hr at RT. Primary antibodies (CB<sub>1,</sub> 1:1000, Immunogenes (Budapest, Hungary)); Synapsin-1 1:1000 Synaptic Systems (Goettingen, Germany); Bassoon, 1:1000, Enzo Life Sciences (Farmingdale, NY); Paravalbumin, 1:1000, Sigma Aldrich; VGAT, 1:500, Synaptic Systems were diluted directly into the blocking buffer and floating slices were incubated overnight at 4C. After four washes with PBS, slices were incubated in secondary antibodies (Invitrogen) diluted in blocking buffer overnight at 4°C. Slices were washed 5X with PBS, then mounted. Images were acquired on a Zeiss LSM 880 with Airyscan using a Plan-Apochromat 63x/1.4 Oil DIC M27 and 1.8X zoom. Images were Airyscan processed prior to analysis. Pixel width and height was 0.049 µm and voxel depth was 0.187 µm. Imaris 9.2 software was used to reconstruct boutons in 3D using the Surface function. Threshold, laser power, and gain were kept constant for each experiment. CB<sub>1</sub> boutons were screened after 3D reconstruction to ensure correct identification. Only boutons that fell between 0.05–5 µm<sup>3</sup>, did not touch the image border, and had a sphericity value above 0.3 were considered. For Bassoon (<xref ref-type="fig" rid="fig1">Figure 1F</xref>) and VGAT (<xref ref-type="fig" rid="fig1s2">Figure 1—figure supplement 2D</xref>), FIJI was used to remove all Bassoon signal that did not overlap with CB<sub>1</sub> labeling by creating a dilated binary mask of CB<sub>1</sub> labeling then using the Image Calculator ‘AND’ function to create a mask for the non-CB<sub>1</sub> channel, then this mask was used to isolate signal in the non-CB<sub>1</sub> channel, then Imaris was used to measure the volume of the non-CB<sub>1</sub> channel. FIJI was used to analyze synapsin puncta (<xref ref-type="fig" rid="fig4">Figure 4D</xref>) inside CB<sub>1</sub> boutons by creating a dilated binary mask of CB<sub>1</sub> labeling then using the Image Calculator ‘AND’ function to create a mask for the non-CB<sub>1</sub> channel, followed by the ‘Analyze Particles’ function to determine the intensity or percent overlap of the two channels. All imaging and analysis were performed blind to treatment group.</p></sec><sec id="s4-2"><title>SILAC</title><p>Primary hippocampal neurons were prepared from E18-19 rat brains and grown on poly-D-lysine coated 15 cm plates at a density of 3.5 million cells/ 15 cm plate in DMEM media without l-arginine or l-lysine (Cambridge Isotope Laboratories, Tewksbury, MA, USA, Cat# DMEM-500), with pen/strep and B-27 supplement (Invitrogen, Carlsbad, CA, USA). 84 mg/L of l-arginine 13 <sub>C6</sub> (Sigma Aldrich, St. Louis, MO) and 146mg/L of l-lysine D<sub>4</sub> (Thermofisher, Waltham, MA) was supplemented for ‘medium’ labeled media and 84 mg/L of l-arginine 13 <sub>C</sub>615<sub>N4</sub> and 146 mg/L of l-lysine 13 <sub>C</sub>615<sub>N4</sub> was added to ‘heavy’ labeled media. Neurons were grown in this media for 15 days, which results in &gt;90% incorporation of labeled amino acids into the cellular proteomes (<xref ref-type="bibr" rid="bib125">Zhang et al., 2011</xref>; <xref ref-type="bibr" rid="bib126">Zhang et al., 2012</xref>). For treatment, neuron cultures DIV 16 received 15 ml fresh media containing either vehicle or WIN (5 µM) for 25 min. Neurons were washed 3X with ice-cold PBS without Mg<sup>2+</sup> or Ca<sup>2+</sup> (0.01 M, pH = 7.4). After three washes, cells were harvested and lysed in SDS lysis buffer containing: (50 mM Tris, 2% SDS, 2 mM EDTA) for 30 min at RT. Lysates were then sonicated briefly, allowed to incubate for another 30 min at RT, and centrifuged for 5 min at 15,000 g to remove insoluble debris. 10 µg of lysate from ‘medium’ cells treated with vehicle were mixed with 10 µg ‘heavy’ WIN-treated cells (Forward sample). Separately, 10 µg of lysate from ‘medium’ cells treated with WIN were mixed with 10 µg ‘heavy’ vehicle-treated cells (Reverse sample). These mixtures (20 µg total protein) were loaded onto a 10% Bis-Tris gel and subjected to SDS-PAGE. The gel was stained with Coomasie for 1 hr and protein lanes were cut up into 12 equal sized portion in order to improve protein coverage (<xref ref-type="bibr" rid="bib65">Jordan et al., 2004</xref>). Mass spectrometry was performed in collaboration with the Einstein Proteomic Facility using the Orbitrap Velos. In Mascot the Quantitation Method (SILAC K+4 K+8 R+6 R+10) was used with each SILAC modification in exclusive mode. Those listed as variable were for determining incomplete protein labeling: 2H(4) (K); 13C(6) (R); 13C(6)15N(2) (K); and 13C(6)15N(4) (R). The raw data files were first processed using precursor ion quantitation of the Quantitation toolbox of Mascot Distiller (Matrix Science Ltd; version 2.7). Mascot was then used to search the rat databases (SwissProt and NCBInr along with a decoy database to obtain FDRs) using the following parameters: trypsin; product ion mass tolerance of 0.40 Da; precursor ion tolerance of 50 PPM; carbamidomethyl Cys - fixed modification and variable modifications of: deamidated Asn and Gln; label:2H(4) of Lys; label:13C(6) of Arg; label:13C(6)15N(2) of Lys; label:13C(6)15N(4) of Arg and oxidation of Met. The result files obtained from Distiller and the Mascot searches were then uploaded to Scaffold Q+S (Proteome Software Inc; version 4.9) using between-subjects, log<sub>2</sub> ratio-based analysis of unique peptides against a reference to obtain the protein’s mean quantitative values and t-test p-values with Benjamini-Hochberg correction. Peptide identifications were accepted if they could be established at greater than 95.0% probability by the Scaffold Local FDR algorithm. Protein identifications were accepted if they could be established at greater than 99.0% probability and contained at least two identified peptides. Protein probabilities were assigned by the Protein Prophet algorithm (<xref ref-type="bibr" rid="bib91">Nesvizhskii et al., 2003</xref>). Proteins that contained similar peptides and could not be differentiated based on MS/MS analysis alone were grouped to satisfy the principles of parsimony. Proteins sharing significant peptide evidence were grouped into clusters. The mass spectrometry proteomics data have been deposited to the ProteomeX change with identifier Consortium via the PRIDE [1] partner repository with the dataset identifier PXD020008 and 10.6019/PXD020008.</p></sec><sec id="s4-3"><title>Gene ontology analysis</title><p>SILAC results were ranked according based on fold change and submitted to a GSEA Preranked analysis in GSEA (v. 4.0.2) with 1000 permutations. Terms smaller than 15 genes or bigger than 500 were discarded as previously reported (<xref ref-type="bibr" rid="bib83">Merico et al., 2010</xref>). The enrichment map was generated in Cytoscape (3.7.1) (<xref ref-type="bibr" rid="bib73">Kucera et al., 2016</xref>) using Enrichment map plugin (3.2.0) (<xref ref-type="bibr" rid="bib83">Merico et al., 2010</xref>) using the following thresholds: p value &lt; 0.05, FDR &lt; 0.001. The overlap coefficient was set to 0.5. For confirmation, we also performed Gene Ontology analysis using two other tools. First, filtered lists (|log<sub>2</sub> fold change| &gt; 0.5) were analyzed through the use of IPA (QIAGEN Inc, Hilden, Germany, <ext-link ext-link-type="uri" xlink:href="https://www.qiagenbioinformatics.com/products/ingenuitypathway-analysis">https://www.qiagenbioinformatics.com/products/ingenuitypathway-analysis</ext-link>). Then, we performed ontology enrichment using a recently published expert-curated knowledge database for synapses (<xref ref-type="bibr" rid="bib72">Koopmans et al., 2019</xref>). Terms were selected with a FDR &lt; 0.01. The parental term ‘Synapse’ was discarded as not being informative (e.g. to general).</p></sec><sec id="s4-4"><title>Electrophysiology slice preparation and recording</title><p>Experimental procedures adhered to NIH and Albert Einstein College of Medicine Institutional Animal Care and Use Committee guidelines. Acute transverse slices were prepared from young adult male and female Sprague Dawley rats (P18-27). The cutting solution contained (in mM): 215 sucrose, 20 glucose, 26 NaHCO<sub>3</sub>, 4 MgCl<sub>2</sub>, 4 MgSO<sub>4</sub>, 1.6 NaH<sub>2</sub>PO<sub>4</sub>, 2.5 KCl, and 1 CaCl<sub>2</sub>. The artificial cerebral spinal fluid (ACSF) recording solution contained (in mM): 124 NaCl, 26 NaHCO<sub>3</sub>, 10 glucose, 2.5 KCl, 1 NaH<sub>2</sub>PO<sub>4</sub>, 2.5 CaCl<sub>2</sub>, and 1.3 MgSO<sub>4</sub>. After ice-cold cutting, slices recovered at RT (in 50% cutting solution, 50% ACSF) for &lt;30 min and then at room temperature (RT) for 1 hr in ACSF. All solutions were bubbled with 95% O<sub>2</sub> and 5% CO<sub>2</sub> for at least 30 min. Although the form of long-term inhibitory synaptic plasticity studied here (i.e. iLTD) is present under physiological recording conditions at 37°C (<xref ref-type="bibr" rid="bib123">Younts et al., 2013</xref>), inhibitory synaptic transmission is less stable at this temperature, and therefore we conducted our experiments at 25.5 ± 0.1°C.</p><p>For extracellular field recordings, a single borosilicate glass stimulating pipette filled with ACSF and a glass recording pipette filled with 1M NaCl were placed approximately 100 µm apart in <italic>stratum pyramidale</italic>. To elicit synaptic responses, paired, monopolar square-wave voltage or current pulses (100–200 μs pulse width) were delivered through a stimulus isolator (Isoflex, AMPI) connected to a broken tip (∼10–20 μm) stimulating patch-type micropipette filled with ACSF. Typically, stimulating pipettes were placed in CA1 stratum pyramidale (150–300 μm from the putative apical dendrite of the recorded pyramidal cell, 150–200 μm slice depth). Stimulus intensity was adjusted to give comparable magnitude synaptic responses across experiments less than ∼0.6 mV. Inhibitory synaptic transmission was monitored in the continuous presence of the NMDA receptor antagonist d-(-)−2-amino-5-phosphonopentanoic acid (d-APV; 25 μM), the AMPA/kainate receptor antagonist 2,3-dihydroxy-6-nitro-7-sulfonyl-benzo[f]quinoxaline (NBQX; 5 μM), and the μ-opioid receptor agonist, [D-Ala<sup>2</sup>, N-MePhe<sup>4</sup>, Gly-ol]-enkephalin (DAMGO, 50 nM). To elicit chemical-iLTD (<xref ref-type="bibr" rid="bib52">Heifets et al., 2008</xref>) the CB<sub>1</sub> agonist WIN 55,212–2 (WIN; 5 µM) was bath applied for 25 min, and 5 stimuli at 10 Hz were delivered at 0.1 Hz during the last 10 min of WIN. WIN was chased with the CB<sub>1</sub> inverse agonist/antagonist SR 141716 (5 µM) or AM251 (5 µM) to halt CB<sub>1</sub> signaling. Baseline and post-induction synaptic responses were monitored at 0.05 Hz during iLTD. Stimulation and acquisition were controlled with IgorPro 7 (Wavemetrics). Shaded boxes in figures correspond to when plasticity was analyzed with respect to baseline and when representative traces were collected and averaged. Summary data (i.e. time-course plots and bar graphs) are presented as mean ± standard error of mean (S.E.M.). PPR was defined as the ratio of the amplitude of the second EPSC (baseline taken 1–2 ms before the stimulus artifact) to the amplitude of the first EPSC. The magnitude of LTD was determined by comparing 20 min baseline responses with responses 80–100 min post-LTD induction.</p></sec><sec id="s4-5"><title>Western blotting</title><p>Protein concentration was determined using the Lowry method with bovine serum albumin as a standard (<xref ref-type="bibr" rid="bib77">Lowry et al., 1951</xref>). Primary hippocampal neurons or hippocampal slices were solubilized on ice with RIPA buffer (1% Triton X-100, 1% sodiumdeoxycholate, 0.1% SDS, 0.15MNaCl, 0.01Msodium phosphate, pH7.2) followed by sonication. Immunoblotting was performed after transferring SDS-PAGE gels to nitrocellulose membrane and blocking with 5% low-fat milk for 1 hr at room temperature. The proteins of interest were visualized after incubation with primary antibodies (α-synuclein 1:1000 BD Biosciences (San Jose, CA) #610787; Synapsin-1 1:1000 Synaptic System (Goettingen, Germany) #106001; Munc18–1 1:1000 Synaptic System #116 002; Arp2/3 1:1000 Novus Biologicals (Centennial, CO) # NBP188852; Ubiquitin K48 1:1000 EMD Millipore (Burlington, MA) #05–1307) by chemiluminescence using peroxidase-conjugated secondary antibodies in LAS-3000 Imaging System (Fujifilm, Tokyo, Japan). Densitometric quantification of the immunoblotted membranes was performed using ImageJ (NIH). All protein quantifications were done upon normalization of protein levels to Ponceau staining. Ponceau normalization was chosen over comparison to actin as our work and others showed that CB<sub>1</sub>-iLTD induces modification of actin cytoskeleton.</p></sec><sec id="s4-6"><title>Ubiquitination sites analysis</title><p>Ubiquitination sites were identified using Ubisite, a publicly available resource for ubiquitination site prediction (<xref ref-type="bibr" rid="bib1">Akimov et al., 2018</xref>). To minimize false positive rate, confidence level was set on high. When available, functional domains were annotated using the <ext-link ext-link-type="uri" xlink:href="https://www.uniprot.org/">uniport.org</ext-link> database (<xref ref-type="bibr" rid="bib113">UniProt Consortium, 2019</xref>).</p></sec><sec id="s4-7"><title>Data analysis, statistics and graphing</title><p>Analysis and statistics were carried out in OriginPro 2015 (OriginLab) and Graphpad Prism 7.02. Significance (p&lt;0.05) was assessed with one-way ANOVA (means comparison with <italic>post hoc</italic> Tukey test), Student’s paired and unpaired t-tests, Wilcoxon matched-pairs signed rank test, Mann Whitney U test, or Pearson’s correlation coefficient, as indicated. All electrophysiology experiments were performed in an interleaved fashion –that is control experiments were performed every test experiment. Unless stated otherwise, ‘n’ represents number of field recordings in slices. All experiments include at three animals. Plotting of SynGO results was made using matplotlib (3.0.3)(<xref ref-type="bibr" rid="bib61">Hunter, 2007</xref>) in Python (3.7. 3)(<xref ref-type="bibr" rid="bib93">Oliphant, 2007</xref>) environment. <xref ref-type="fig" rid="fig4">Figure 4D</xref> used Garder-Altman estimation plots to represent effect size. Statistics and graphing were performed using <ext-link ext-link-type="uri" xlink:href="http://estimationstats.com/">estimationstats.com</ext-link> (<xref ref-type="bibr" rid="bib55">Ho et al., 2019</xref>). Supplementary figures include Superplots to represent individual bouton values color-coded by slice that were created using Python (3.7.3) (<xref ref-type="bibr" rid="bib76">Lord et al., 2020</xref>) and informed by plot design from the Superplots app (<ext-link ext-link-type="uri" xlink:href="https://huygens.science.uva.nl/SuperPlotsOfData/">https://huygens.science.uva.nl/SuperPlotsOfData/</ext-link>). Slice numbers were balanced across conditions in some Superplots (in <xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1A</xref>, <xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1A</xref>, and <xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1E</xref>) to make statistical comparison across similar sized groups (<xref ref-type="bibr" rid="bib76">Lord et al., 2020</xref>), and to make it easier for the reader to compare the distribution of individual bouton values across conditions. To balance the conditions in an unbiased manner, if a condition had an unequal number of slices, the slice that had the most different number of ‘n’ was removed. Importantly, balancing the conditions did not change the interpretation of the data as plotted in the main figures and all key observations were reproduced.</p></sec><sec id="s4-8"><title>Reagents</title><p>Stock reagents were prepared according to the manufacturer’s recommendation in water, DMSO (&lt;0.01% final volume during experiments), or phosphate buffered saline (PBS), stored at −20°C, and diluted into ACSF or intracellular recording solutions as needed. CNQX, D-APV, SR 141716, and WIN 55,212–2 were acquired from the NIMH Chemical Synthesis and Drug Supply Program; salts for making cutting, ACSF, ziram, and intracellular recording solutions from Sigma Aldrich (St. Louis, MO); AM251, NSC-23766, MG-132, DAMGO, cycloheximide from Tocris Bioscience (Bristol UK); jasplakinolide, anisomycin, PYR41 from Cayman Chemical (Ann Arbor, MI); CK-666 from EMD Millipore. Reagents were either acutely bath applied, diluted into the intracellular recording solution, or preincubated with slices/cultures, as indicated in Results.</p></sec></sec></body><back><ack id="ack"><title>Acknowledgements</title><p>We thank Dr. Thomas Younts, Dr. Matthew Klein, and Dr. Ana Maria Cuervo for helpful discussions. We thank Dr. Kostantin Dobrenis, Kevin Fisher, and Vladimir Mudragel of the Einstein Neural Cell Engineering and Imaging Core (supported by The Rose F Kennedy Intellectual Disabilities Research Center) for their advice and assistance with Airyscan confocal microscopy acquisition and analysis. We thank Edward Nieves of the Einstein Proteomics Facility for assistance performing and analyzing proteomic data. This research was supported by the National Institutes of Health: F31MH114431 to HRM, R01-MH081935, R01-DA17392, R01-NS113600 and a pilot grant through NICHD U54 HD090260 to PEC, a shared instrument grant (1S10OD25295) to KD, R01-AG039521 to BAJ. MB was supported by the Rainwater Charitable Foundation. HM and MB also received Junior Investigator Neuroscience Research Award (JINRA) from Dominick P Purpura Department of Neuroscience at Albert Einstein College of Medicine for this project.</p></ack><sec id="s5" sec-type="additional-information"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interests</title><fn fn-type="COI-statement" id="conf1"><p>No competing interests declared</p></fn></fn-group><fn-group content-type="author-contribution"><title>Author contributions</title><fn fn-type="con" id="con1"><p>Conceptualization, Resources, Data curation, Software, Formal analysis, Supervision, Funding acquisition, Validation, Investigation, Methodology, Writing - original draft, Writing - review and editing</p></fn><fn fn-type="con" id="con2"><p>Conceptualization, Resources, Data curation, Software, Formal analysis, Funding acquisition, Visualization, Writing - review and editing</p></fn><fn fn-type="con" id="con3"><p>Supervision, Methodology, Writing - review and editing</p></fn><fn fn-type="con" id="con4"><p>Conceptualization, Resources, Supervision, Funding acquisition, Writing - original draft, Writing - review and editing</p></fn></fn-group><fn-group content-type="ethics-information"><title>Ethics</title><fn fn-type="other"><p>Animal experimentation: Experimental procedures adhered to NIH and Albert Einstein College of Medicine Institutional Animal Care and Use Committee guidelines as approved by protocol #00001047.</p></fn></fn-group></sec><sec id="s6" sec-type="supplementary-material"><title>Additional files</title><supplementary-material id="supp1"><label>Supplementary file 1.</label><caption><title>Full protein list and Ingenuity Pathway Analysis.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-54812-supp1-v2.xlsx"/></supplementary-material><supplementary-material id="supp2"><label>Supplementary file 2.</label><caption><title>Raw data for GSEA and enrichment map analysis.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-54812-supp2-v2.xlsx"/></supplementary-material><supplementary-material id="transrepform"><label>Transparent reporting form</label><media mime-subtype="pdf" mimetype="application" xlink:href="elife-54812-transrepform-v2.pdf"/></supplementary-material></sec><sec id="s7" sec-type="data-availability"><title>Data availability</title><p>All data generated in this study are included in the manuscript and supporting files. Source data files are provided for Figure 2. The mass spectrometry proteomics data have been deposited to the ProteomeX change with identifier Consortium via the PRIDE [1] partner repository with the dataset identifier PXD020008 and <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.6019/PXD020008">https://doi.org/10.6019/PXD020008</ext-link>.</p><p>The following dataset was generated:</p><p><element-citation id="dataset1" publication-type="data" specific-use="isSupplementedBy"><person-group person-group-type="author"><name><surname>Monday</surname><given-names>HR</given-names></name><name><surname>Bourdenx</surname><given-names>M</given-names></name><name><surname>Jordan</surname><given-names>BA</given-names></name><name><surname>Castillo</surname><given-names>PE</given-names></name></person-group><year iso-8601-date="2020">2020</year><data-title>CB1 receptor-mediated inhibitory LTD triggers presynaptic remodeling via protein synthesis and ubiquitination</data-title><source>PRIDE</source><pub-id assigning-authority="EBI" pub-id-type="accession" xlink:href="https://www.ebi.ac.uk/pride/archive/projects/PXD020008">PXD020008</pub-id></element-citation></p></sec><ref-list><title>References</title><ref id="bib1"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Akimov</surname> <given-names>V</given-names></name><name><surname>Barrio-Hernandez</surname> <given-names>I</given-names></name><name><surname>Hansen</surname> <given-names>SVF</given-names></name><name><surname>Hallenborg</surname> <given-names>P</given-names></name><name><surname>Pedersen</surname> <given-names>AK</given-names></name><name><surname>Bekker-Jensen</surname> <given-names>DB</given-names></name><name><surname>Puglia</surname> <given-names>M</given-names></name><name><surname>Christensen</surname> <given-names>SDK</given-names></name><name><surname>Vanselow</surname> <given-names>JT</given-names></name><name><surname>Nielsen</surname> <given-names>MM</given-names></name><name><surname>Kratchmarova</surname> <given-names>I</given-names></name><name><surname>Kelstrup</surname> <given-names>CD</given-names></name><name><surname>Olsen</surname> <given-names>JV</given-names></name><name><surname>Blagoev</surname> <given-names>B</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>UbiSite approach for comprehensive mapping of lysine and N-terminal ubiquitination sites</article-title><source>Nature Structural &amp; Molecular Biology</source><volume>25</volume><fpage>631</fpage><lpage>640</lpage><pub-id pub-id-type="doi">10.1038/s41594-018-0084-y</pub-id><pub-id pub-id-type="pmid">29967540</pub-id></element-citation></ref><ref id="bib2"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Araque</surname> <given-names>A</given-names></name><name><surname>Castillo</surname> <given-names>PE</given-names></name><name><surname>Manzoni</surname> <given-names>OJ</given-names></name><name><surname>Tonini</surname> <given-names>R</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Synaptic functions of endocannabinoid signaling in health and disease</article-title><source>Neuropharmacology</source><volume>124</volume><fpage>13</fpage><lpage>24</lpage><pub-id pub-id-type="doi">10.1016/j.neuropharm.2017.06.017</pub-id></element-citation></ref><ref id="bib3"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aubrey</surname> <given-names>KR</given-names></name><name><surname>Drew</surname> <given-names>GM</given-names></name><name><surname>Jeong</surname> <given-names>HJ</given-names></name><name><surname>Lau</surname> <given-names>BK</given-names></name><name><surname>Vaughan</surname> <given-names>CW</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Endocannabinoids control vesicle release mode at Midbrain periaqueductal grey inhibitory synapses</article-title><source>The Journal of Physiology</source><volume>595</volume><fpage>165</fpage><lpage>178</lpage><pub-id pub-id-type="doi">10.1113/JP272292</pub-id><pub-id pub-id-type="pmid">27461371</pub-id></element-citation></ref><ref id="bib4"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Augustin</surname> <given-names>SM</given-names></name><name><surname>Lovinger</surname> <given-names>DM</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Functional Relevance of Endocannabinoid-Dependent Synaptic Plasticity in the Central Nervous System</article-title><source>ACS Chemical Neuroscience</source><volume>9</volume><fpage>2146</fpage><lpage>2161</lpage><pub-id pub-id-type="doi">10.1021/acschemneuro.7b00508</pub-id></element-citation></ref><ref id="bib5"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bagni</surname> <given-names>C</given-names></name><name><surname>Zukin</surname> <given-names>RS</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>A Synaptic Perspective of Fragile X Syndrome and Autism Spectrum Disorders</article-title><source>Neuron</source><volume>101</volume><fpage>1070</fpage><lpage>1088</lpage><pub-id pub-id-type="doi">10.1016/j.neuron.2019.02.041</pub-id></element-citation></ref><ref id="bib6"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bailey</surname> <given-names>CH</given-names></name><name><surname>Kandel</surname> <given-names>ER</given-names></name><name><surname>Harris</surname> <given-names>KM</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Structural components of synaptic plasticity and memory consolidation</article-title><source>Cold Spring Harbor Perspectives in Biology</source><volume>7</volume><elocation-id>a021758</elocation-id><pub-id pub-id-type="doi">10.1101/cshperspect.a021758</pub-id><pub-id pub-id-type="pmid">26134321</pub-id></element-citation></ref><ref id="bib7"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Barnes</surname> <given-names>SJ</given-names></name><name><surname>Opitz</surname> <given-names>T</given-names></name><name><surname>Merkens</surname> <given-names>M</given-names></name><name><surname>Kelly</surname> <given-names>T</given-names></name><name><surname>von der Brelie</surname> <given-names>C</given-names></name><name><surname>Krueppel</surname> <given-names>R</given-names></name><name><surname>Beck</surname> <given-names>H</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Stable mossy fiber long-term potentiation requires calcium influx at the granule cell soma, protein synthesis, and microtubule-dependent axonal transport</article-title><source>Journal of Neuroscience</source><volume>30</volume><fpage>12996</fpage><lpage>13004</lpage><pub-id pub-id-type="doi">10.1523/JNEUROSCI.1847-10.2010</pub-id><pub-id pub-id-type="pmid">20881117</pub-id></element-citation></ref><ref id="bib8"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bartol</surname> <given-names>TM</given-names></name><name><surname>Bromer</surname> <given-names>C</given-names></name><name><surname>Kinney</surname> <given-names>J</given-names></name><name><surname>Chirillo</surname> <given-names>MA</given-names></name><name><surname>Bourne</surname> <given-names>JN</given-names></name><name><surname>Harris</surname> <given-names>KM</given-names></name><name><surname>Sejnowski</surname> <given-names>TJ</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Nanoconnectomic upper bound on the variability of synaptic plasticity</article-title><source>eLife</source><volume>4</volume><elocation-id>e10778</elocation-id><pub-id pub-id-type="doi">10.7554/eLife.10778</pub-id><pub-id pub-id-type="pmid">26618907</pub-id></element-citation></ref><ref id="bib9"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Basavarajappa</surname> <given-names>BS</given-names></name><name><surname>Shivakumar</surname> <given-names>M</given-names></name><name><surname>Joshi</surname> <given-names>V</given-names></name><name><surname>Subbanna</surname> <given-names>S</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Endocannabinoid system in neurodegenerative disorders</article-title><source>Journal of Neurochemistry</source><volume>142</volume><fpage>624</fpage><lpage>648</lpage><pub-id pub-id-type="doi">10.1111/jnc.14098</pub-id><pub-id pub-id-type="pmid">28608560</pub-id></element-citation></ref><ref id="bib10"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Basu</surname> <given-names>S</given-names></name><name><surname>Kustanovich</surname> <given-names>I</given-names></name><name><surname>Lamprecht</surname> <given-names>R</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Arp2/3 and VASP are essential for fear memory formation in lateral amygdala</article-title><source>Eneuro</source><volume>3</volume><elocation-id>ENEURO.0302-16.2016</elocation-id><pub-id pub-id-type="doi">10.1523/ENEURO.0302-16.2016</pub-id><pub-id pub-id-type="pmid">27957528</pub-id></element-citation></ref><ref id="bib11"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Berghuis</surname> <given-names>P</given-names></name><name><surname>Rajnicek</surname> <given-names>AM</given-names></name><name><surname>Morozov</surname> <given-names>YM</given-names></name><name><surname>Ross</surname> <given-names>RA</given-names></name><name><surname>Mulder</surname> <given-names>J</given-names></name><name><surname>Urbán</surname> <given-names>GM</given-names></name><name><surname>Monory</surname> <given-names>K</given-names></name><name><surname>Marsicano</surname> <given-names>G</given-names></name><name><surname>Matteoli</surname> <given-names>M</given-names></name><name><surname>Canty</surname> <given-names>A</given-names></name><name><surname>Irving</surname> <given-names>AJ</given-names></name><name><surname>Katona</surname> <given-names>I</given-names></name><name><surname>Yanagawa</surname> <given-names>Y</given-names></name><name><surname>Rakic</surname> <given-names>P</given-names></name><name><surname>Lutz</surname> <given-names>B</given-names></name><name><surname>Mackie</surname> <given-names>K</given-names></name><name><surname>Harkany</surname> <given-names>T</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Hardwiring the brain: endocannabinoids shape neuronal connectivity</article-title><source>Science</source><volume>316</volume><fpage>1212</fpage><lpage>1216</lpage><pub-id pub-id-type="doi">10.1126/science.1137406</pub-id><pub-id pub-id-type="pmid">17525344</pub-id></element-citation></ref><ref id="bib12"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Biever</surname> <given-names>A</given-names></name><name><surname>Donlin-Asp</surname> <given-names>PG</given-names></name><name><surname>Schuman</surname> <given-names>EM</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Local translation in neuronal processes</article-title><source>Current Opinion in Neurobiology</source><volume>57</volume><fpage>141</fpage><lpage>148</lpage><pub-id pub-id-type="doi">10.1016/j.conb.2019.02.008</pub-id><pub-id pub-id-type="pmid">30861464</pub-id></element-citation></ref><ref id="bib13"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bigler</surname> <given-names>RL</given-names></name><name><surname>Kamande</surname> <given-names>JW</given-names></name><name><surname>Dumitru</surname> <given-names>R</given-names></name><name><surname>Niedringhaus</surname> <given-names>M</given-names></name><name><surname>Taylor</surname> <given-names>AM</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Messenger RNAs localized to distal projections of human stem cell derived neurons</article-title><source>Scientific Reports</source><volume>7</volume><elocation-id>611</elocation-id><pub-id pub-id-type="doi">10.1038/s41598-017-00676-w</pub-id><pub-id pub-id-type="pmid">28377585</pub-id></element-citation></ref><ref id="bib14"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Birdsall</surname> <given-names>V</given-names></name><name><surname>Waites</surname> <given-names>CL</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Autophagy at the synapse</article-title><source>Neuroscience Letters</source><volume>697</volume><fpage>24</fpage><lpage>28</lpage><pub-id pub-id-type="doi">10.1016/j.neulet.2018.05.033</pub-id><pub-id pub-id-type="pmid">29802916</pub-id></element-citation></ref><ref id="bib15"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bosch</surname> <given-names>M</given-names></name><name><surname>Castro</surname> <given-names>J</given-names></name><name><surname>Saneyoshi</surname> <given-names>T</given-names></name><name><surname>Matsuno</surname> <given-names>H</given-names></name><name><surname>Sur</surname> <given-names>M</given-names></name><name><surname>Hayashi</surname> <given-names>Y</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Structural and molecular remodeling of dendritic spine substructures during long-term potentiation</article-title><source>Neuron</source><volume>82</volume><fpage>444</fpage><lpage>459</lpage><pub-id pub-id-type="doi">10.1016/j.neuron.2014.03.021</pub-id><pub-id pub-id-type="pmid">24742465</pub-id></element-citation></ref><ref id="bib16"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bourne</surname> <given-names>JN</given-names></name><name><surname>Chirillo</surname> <given-names>MA</given-names></name><name><surname>Harris</surname> <given-names>KM</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Presynaptic ultrastructural plasticity along CA3-&gt;CA1 axons during long-term potentiation in mature Hippocampus</article-title><source>The Journal of Comparative Neurology</source><volume>521</volume><fpage>3898</fpage><lpage>3912</lpage><pub-id pub-id-type="doi">10.1002/cne.23384</pub-id><pub-id pub-id-type="pmid">23784793</pub-id></element-citation></ref><ref id="bib17"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bramham</surname> <given-names>CR</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Local protein synthesis, actin dynamics, and LTP consolidation</article-title><source>Current Opinion in Neurobiology</source><volume>18</volume><fpage>524</fpage><lpage>531</lpage><pub-id pub-id-type="doi">10.1016/j.conb.2008.09.013</pub-id><pub-id pub-id-type="pmid">18834940</pub-id></element-citation></ref><ref id="bib18"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Busquets-Garcia</surname> <given-names>A</given-names></name><name><surname>Gomis-González</surname> <given-names>M</given-names></name><name><surname>Guegan</surname> <given-names>T</given-names></name><name><surname>Agustín-Pavón</surname> <given-names>C</given-names></name><name><surname>Pastor</surname> <given-names>A</given-names></name><name><surname>Mato</surname> <given-names>S</given-names></name><name><surname>Pérez-Samartín</surname> <given-names>A</given-names></name><name><surname>Matute</surname> <given-names>C</given-names></name><name><surname>de la Torre</surname> <given-names>R</given-names></name><name><surname>Dierssen</surname> <given-names>M</given-names></name><name><surname>Maldonado</surname> <given-names>R</given-names></name><name><surname>Ozaita</surname> <given-names>A</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Targeting the endocannabinoid system in the treatment of fragile X syndrome</article-title><source>Nature Medicine</source><volume>19</volume><fpage>603</fpage><lpage>607</lpage><pub-id pub-id-type="doi">10.1038/nm.3127</pub-id><pub-id pub-id-type="pmid">23542787</pub-id></element-citation></ref><ref id="bib19"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Busquets-Garcia</surname> <given-names>A</given-names></name><name><surname>Maldonado</surname> <given-names>R</given-names></name><name><surname>Ozaita</surname> <given-names>A</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>New insights into the molecular pathophysiology of fragile X syndrome and therapeutic perspectives from the animal model</article-title><source>The International Journal of Biochemistry &amp; Cell Biology</source><volume>53</volume><fpage>121</fpage><lpage>126</lpage><pub-id pub-id-type="doi">10.1016/j.biocel.2014.05.004</pub-id><pub-id pub-id-type="pmid">24831882</pub-id></element-citation></ref><ref id="bib20"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Castillo</surname> <given-names>PE</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Presynaptic LTP and LTD of excitatory and inhibitory synapses</article-title><source>Cold Spring Harbor Perspectives in Biology</source><volume>4</volume><elocation-id>a005728</elocation-id><pub-id pub-id-type="doi">10.1101/cshperspect.a005728</pub-id><pub-id pub-id-type="pmid">22147943</pub-id></element-citation></ref><ref id="bib21"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Castillo</surname> <given-names>PE</given-names></name><name><surname>Younts</surname> <given-names>TJ</given-names></name><name><surname>Chávez</surname> <given-names>AE</given-names></name><name><surname>Hashimotodani</surname> <given-names>Y</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Endocannabinoid signaling and synaptic function</article-title><source>Neuron</source><volume>76</volume><fpage>70</fpage><lpage>81</lpage><pub-id pub-id-type="doi">10.1016/j.neuron.2012.09.020</pub-id><pub-id pub-id-type="pmid">23040807</pub-id></element-citation></ref><ref id="bib22"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chakrabarti</surname> <given-names>B</given-names></name><name><surname>Persico</surname> <given-names>A</given-names></name><name><surname>Battista</surname> <given-names>N</given-names></name><name><surname>Maccarrone</surname> <given-names>M</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Endocannabinoid signaling in autism</article-title><source>Neurotherapeutics</source><volume>12</volume><fpage>837</fpage><lpage>847</lpage><pub-id pub-id-type="doi">10.1007/s13311-015-0371-9</pub-id><pub-id pub-id-type="pmid">26216231</pub-id></element-citation></ref><ref id="bib23"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname> <given-names>H</given-names></name><name><surname>Polo</surname> <given-names>S</given-names></name><name><surname>Di Fiore</surname> <given-names>PP</given-names></name><name><surname>De Camilli</surname> <given-names>PV</given-names></name></person-group><year iso-8601-date="2003">2003</year><article-title>Rapid Ca2+-dependent decrease of protein ubiquitination at synapses</article-title><source>PNAS</source><volume>100</volume><fpage>14908</fpage><lpage>14913</lpage><pub-id pub-id-type="doi">10.1073/pnas.2136625100</pub-id><pub-id pub-id-type="pmid">14657369</pub-id></element-citation></ref><ref id="bib24"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname> <given-names>Z</given-names></name><name><surname>Borek</surname> <given-names>D</given-names></name><name><surname>Padrick</surname> <given-names>SB</given-names></name><name><surname>Gomez</surname> <given-names>TS</given-names></name><name><surname>Metlagel</surname> <given-names>Z</given-names></name><name><surname>Ismail</surname> <given-names>AM</given-names></name><name><surname>Umetani</surname> <given-names>J</given-names></name><name><surname>Billadeau</surname> <given-names>DD</given-names></name><name><surname>Otwinowski</surname> <given-names>Z</given-names></name><name><surname>Rosen</surname> <given-names>MK</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Structure and control of the actin regulatory WAVE complex</article-title><source>Nature</source><volume>468</volume><fpage>533</fpage><lpage>538</lpage><pub-id pub-id-type="doi">10.1038/nature09623</pub-id><pub-id pub-id-type="pmid">21107423</pub-id></element-citation></ref><ref id="bib25"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname> <given-names>H</given-names></name><name><surname>Tang</surname> <given-names>AH</given-names></name><name><surname>Blanpied</surname> <given-names>TA</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Subsynaptic spatial organization as a regulator of synaptic strength and plasticity</article-title><source>Current Opinion in Neurobiology</source><volume>51</volume><fpage>147</fpage><lpage>153</lpage><pub-id pub-id-type="doi">10.1016/j.conb.2018.05.004</pub-id><pub-id pub-id-type="pmid">29902592</pub-id></element-citation></ref><ref id="bib26"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chevaleyre</surname> <given-names>V</given-names></name><name><surname>Heifets</surname> <given-names>BD</given-names></name><name><surname>Kaeser</surname> <given-names>PS</given-names></name><name><surname>Südhof</surname> <given-names>TC</given-names></name><name><surname>Purpura</surname> <given-names>DP</given-names></name><name><surname>Castillo</surname> <given-names>PE</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Endocannabinoid-mediated long-term plasticity requires cAMP/PKA signaling and RIM1alpha</article-title><source>Neuron</source><volume>54</volume><fpage>801</fpage><lpage>812</lpage><pub-id pub-id-type="doi">10.1016/j.neuron.2007.05.020</pub-id><pub-id pub-id-type="pmid">17553427</pub-id></element-citation></ref><ref id="bib27"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chevaleyre</surname> <given-names>V</given-names></name><name><surname>Castillo</surname> <given-names>PE</given-names></name></person-group><year iso-8601-date="2003">2003</year><article-title>Heterosynaptic LTD of hippocampal GABAergic synapses: a novel role of endocannabinoids in regulating excitability</article-title><source>Neuron</source><volume>38</volume><fpage>461</fpage><lpage>472</lpage><pub-id pub-id-type="doi">10.1016/s0896-6273(03)00235-6</pub-id><pub-id pub-id-type="pmid">12741992</pub-id></element-citation></ref><ref id="bib28"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cingolani</surname> <given-names>LA</given-names></name><name><surname>Goda</surname> <given-names>Y</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Actin in action: the interplay between the actin cytoskeleton and synaptic efficacy</article-title><source>Nature Reviews Neuroscience</source><volume>9</volume><fpage>344</fpage><lpage>356</lpage><pub-id pub-id-type="doi">10.1038/nrn2373</pub-id><pub-id pub-id-type="pmid">18425089</pub-id></element-citation></ref><ref id="bib29"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cohen</surname> <given-names>LD</given-names></name><name><surname>Ziv</surname> <given-names>NE</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Recent insights on principles of synaptic protein degradation</article-title><source>F1000Research</source><volume>6</volume><elocation-id>675</elocation-id><pub-id pub-id-type="doi">10.12688/f1000research.10599.1</pub-id><pub-id pub-id-type="pmid">28620464</pub-id></element-citation></ref><ref id="bib30"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cohen</surname> <given-names>LD</given-names></name><name><surname>Ziv</surname> <given-names>NE</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Neuronal and synaptic protein lifetimes</article-title><source>Current Opinion in Neurobiology</source><volume>57</volume><fpage>9</fpage><lpage>16</lpage><pub-id pub-id-type="doi">10.1016/j.conb.2018.12.007</pub-id><pub-id pub-id-type="pmid">30677713</pub-id></element-citation></ref><ref id="bib31"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Coutts</surname> <given-names>AA</given-names></name><name><surname>Anavi-Goffer</surname> <given-names>S</given-names></name><name><surname>Ross</surname> <given-names>RA</given-names></name><name><surname>MacEwan</surname> <given-names>DJ</given-names></name><name><surname>Mackie</surname> <given-names>K</given-names></name><name><surname>Pertwee</surname> <given-names>RG</given-names></name><name><surname>Irving</surname> <given-names>AJ</given-names></name></person-group><year iso-8601-date="2001">2001</year><article-title>Agonist-induced internalization and trafficking of cannabinoid CB1 receptors in hippocampal neurons</article-title><source>The Journal of Neuroscience</source><volume>21</volume><fpage>2425</fpage><lpage>2433</lpage><pub-id pub-id-type="doi">10.1523/JNEUROSCI.21-07-02425.2001</pub-id><pub-id pub-id-type="pmid">11264316</pub-id></element-citation></ref><ref id="bib32"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dantuma</surname> <given-names>NP</given-names></name><name><surname>Bott</surname> <given-names>LC</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>The ubiquitin-proteasome system in neurodegenerative diseases: precipitating factor, yet part of the solution</article-title><source>Frontiers in Molecular Neuroscience</source><volume>7</volume><elocation-id>70</elocation-id><pub-id pub-id-type="doi">10.3389/fnmol.2014.00070</pub-id><pub-id pub-id-type="pmid">25132814</pub-id></element-citation></ref><ref id="bib33"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Derivery</surname> <given-names>E</given-names></name><name><surname>Lombard</surname> <given-names>B</given-names></name><name><surname>Loew</surname> <given-names>D</given-names></name><name><surname>Gautreau</surname> <given-names>A</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>The wave complex is intrinsically inactive</article-title><source>Cell Motility and the Cytoskeleton</source><volume>66</volume><fpage>777</fpage><lpage>790</lpage><pub-id pub-id-type="doi">10.1002/cm.20342</pub-id><pub-id pub-id-type="pmid">19206172</pub-id></element-citation></ref><ref id="bib34"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Derivery</surname> <given-names>E</given-names></name><name><surname>Gautreau</surname> <given-names>A</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Generation of branched actin networks: assembly and regulation of the N-WASP and WAVE molecular machines</article-title><source>BioEssays</source><volume>32</volume><fpage>119</fpage><lpage>131</lpage><pub-id pub-id-type="doi">10.1002/bies.200900123</pub-id><pub-id pub-id-type="pmid">20091750</pub-id></element-citation></ref><ref id="bib35"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dong</surname> <given-names>C</given-names></name><name><surname>Upadhya</surname> <given-names>SC</given-names></name><name><surname>Ding</surname> <given-names>L</given-names></name><name><surname>Smith</surname> <given-names>TK</given-names></name><name><surname>Hegde</surname> <given-names>AN</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Proteasome inhibition enhances the induction and impairs the maintenance of late-phase long-term potentiation</article-title><source>Learning &amp; Memory</source><volume>15</volume><fpage>335</fpage><lpage>347</lpage><pub-id pub-id-type="doi">10.1101/lm.984508</pub-id><pub-id pub-id-type="pmid">18441292</pub-id></element-citation></ref><ref id="bib36"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Donnelly</surname> <given-names>CJ</given-names></name><name><surname>Park</surname> <given-names>M</given-names></name><name><surname>Spillane</surname> <given-names>M</given-names></name><name><surname>Yoo</surname> <given-names>S</given-names></name><name><surname>Pacheco</surname> <given-names>A</given-names></name><name><surname>Gomes</surname> <given-names>C</given-names></name><name><surname>Vuppalanchi</surname> <given-names>D</given-names></name><name><surname>McDonald</surname> <given-names>M</given-names></name><name><surname>Kim</surname> <given-names>HH</given-names></name><name><surname>Kim</surname> <given-names>HK</given-names></name><name><surname>Merianda</surname> <given-names>TT</given-names></name><name><surname>Gallo</surname> <given-names>G</given-names></name><name><surname>Twiss</surname> <given-names>JL</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Axonally synthesized β-actin and GAP-43 proteins support distinct modes of axonal growth</article-title><source>Journal of Neuroscience</source><volume>33</volume><fpage>3311</fpage><lpage>3322</lpage><pub-id pub-id-type="doi">10.1523/JNEUROSCI.1722-12.2013</pub-id><pub-id pub-id-type="pmid">23426659</pub-id></element-citation></ref><ref id="bib37"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dörrbaum</surname> <given-names>AR</given-names></name><name><surname>Alvarez-Castelao</surname> <given-names>B</given-names></name><name><surname>Nassim-Assir</surname> <given-names>B</given-names></name><name><surname>Langer</surname> <given-names>JD</given-names></name><name><surname>Schuman</surname> <given-names>EM</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Proteome dynamics during homeostatic scaling in cultured neurons</article-title><source>eLife</source><volume>9</volume><elocation-id>e52939</elocation-id><pub-id pub-id-type="doi">10.7554/eLife.52939</pub-id><pub-id pub-id-type="pmid">32238265</pub-id></element-citation></ref><ref id="bib38"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dudok</surname> <given-names>B</given-names></name><name><surname>Barna</surname> <given-names>L</given-names></name><name><surname>Ledri</surname> <given-names>M</given-names></name><name><surname>Szabó</surname> <given-names>SI</given-names></name><name><surname>Szabadits</surname> <given-names>E</given-names></name><name><surname>Pintér</surname> <given-names>B</given-names></name><name><surname>Woodhams</surname> <given-names>SG</given-names></name><name><surname>Henstridge</surname> <given-names>CM</given-names></name><name><surname>Balla</surname> <given-names>GY</given-names></name><name><surname>Nyilas</surname> <given-names>R</given-names></name><name><surname>Varga</surname> <given-names>C</given-names></name><name><surname>Lee</surname> <given-names>SH</given-names></name><name><surname>Matolcsi</surname> <given-names>M</given-names></name><name><surname>Cervenak</surname> <given-names>J</given-names></name><name><surname>Kacskovics</surname> <given-names>I</given-names></name><name><surname>Watanabe</surname> <given-names>M</given-names></name><name><surname>Sagheddu</surname> <given-names>C</given-names></name><name><surname>Melis</surname> <given-names>M</given-names></name><name><surname>Pistis</surname> <given-names>M</given-names></name><name><surname>Soltesz</surname> <given-names>I</given-names></name><name><surname>Katona</surname> <given-names>I</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Cell-specific STORM super-resolution imaging reveals nanoscale organization of cannabinoid signaling</article-title><source>Nature Neuroscience</source><volume>18</volume><fpage>75</fpage><lpage>86</lpage><pub-id pub-id-type="doi">10.1038/nn.3892</pub-id><pub-id pub-id-type="pmid">25485758</pub-id></element-citation></ref><ref id="bib39"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Eden</surname> <given-names>S</given-names></name><name><surname>Rohatgi</surname> <given-names>R</given-names></name><name><surname>Podtelejnikov</surname> <given-names>AV</given-names></name><name><surname>Mann</surname> <given-names>M</given-names></name><name><surname>Kirschner</surname> <given-names>MW</given-names></name></person-group><year iso-8601-date="2002">2002</year><article-title>Mechanism of regulation of WAVE1-induced actin nucleation by Rac1 and nck</article-title><source>Nature</source><volume>418</volume><fpage>790</fpage><lpage>793</lpage><pub-id pub-id-type="doi">10.1038/nature00859</pub-id><pub-id pub-id-type="pmid">12181570</pub-id></element-citation></ref><ref id="bib40"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gao</surname> <given-names>Y</given-names></name><name><surname>Dickerson</surname> <given-names>JB</given-names></name><name><surname>Guo</surname> <given-names>F</given-names></name><name><surname>Zheng</surname> <given-names>J</given-names></name><name><surname>Zheng</surname> <given-names>Y</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>Rational design and characterization of a rac GTPase-specific small molecule inhibitor</article-title><source>PNAS</source><volume>101</volume><fpage>7618</fpage><lpage>7623</lpage><pub-id pub-id-type="doi">10.1073/pnas.0307512101</pub-id><pub-id pub-id-type="pmid">15128949</pub-id></element-citation></ref><ref id="bib41"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>García-Morales</surname> <given-names>V</given-names></name><name><surname>Montero</surname> <given-names>F</given-names></name><name><surname>Moreno-López</surname> <given-names>B</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Cannabinoid agonists rearrange synaptic vesicles at excitatory synapses and depress motoneuron activity in vivo</article-title><source>Neuropharmacology</source><volume>92</volume><fpage>69</fpage><lpage>79</lpage><pub-id pub-id-type="doi">10.1016/j.neuropharm.2014.12.036</pub-id><pub-id pub-id-type="pmid">25595101</pub-id></element-citation></ref><ref id="bib42"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Glebov</surname> <given-names>OO</given-names></name><name><surname>Jackson</surname> <given-names>RE</given-names></name><name><surname>Winterflood</surname> <given-names>CM</given-names></name><name><surname>Owen</surname> <given-names>DM</given-names></name><name><surname>Barker</surname> <given-names>EA</given-names></name><name><surname>Doherty</surname> <given-names>P</given-names></name><name><surname>Ewers</surname> <given-names>H</given-names></name><name><surname>Burrone</surname> <given-names>J</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Nanoscale structural plasticity of the active zone matrix modulates presynaptic function</article-title><source>Cell Reports</source><volume>18</volume><fpage>2715</fpage><lpage>2728</lpage><pub-id pub-id-type="doi">10.1016/j.celrep.2017.02.064</pub-id><pub-id pub-id-type="pmid">28297674</pub-id></element-citation></ref><ref id="bib43"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Glickfeld</surname> <given-names>LL</given-names></name><name><surname>Scanziani</surname> <given-names>M</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>Distinct timing in the activity of cannabinoid-sensitive and cannabinoid-insensitive basket cells</article-title><source>Nature Neuroscience</source><volume>9</volume><fpage>807</fpage><lpage>815</lpage><pub-id pub-id-type="doi">10.1038/nn1688</pub-id><pub-id pub-id-type="pmid">16648849</pub-id></element-citation></ref><ref id="bib44"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gundelfinger</surname> <given-names>ED</given-names></name><name><surname>Fejtova</surname> <given-names>A</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Molecular organization and plasticity of the cytomatrix at the active zone</article-title><source>Current Opinion in Neurobiology</source><volume>22</volume><fpage>423</fpage><lpage>430</lpage><pub-id pub-id-type="doi">10.1016/j.conb.2011.10.005</pub-id><pub-id pub-id-type="pmid">22030346</pub-id></element-citation></ref><ref id="bib45"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hafner</surname> <given-names>AS</given-names></name><name><surname>Donlin-Asp</surname> <given-names>PG</given-names></name><name><surname>Leitch</surname> <given-names>B</given-names></name><name><surname>Herzog</surname> <given-names>E</given-names></name><name><surname>Schuman</surname> <given-names>EM</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Local protein synthesis is a ubiquitous feature of neuronal pre- and postsynaptic compartments</article-title><source>Science</source><volume>364</volume><elocation-id>eaau3644</elocation-id><pub-id pub-id-type="doi">10.1126/science.aau3644</pub-id><pub-id pub-id-type="pmid">31097639</pub-id></element-citation></ref><ref id="bib46"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hallengren</surname> <given-names>J</given-names></name><name><surname>Chen</surname> <given-names>PC</given-names></name><name><surname>Wilson</surname> <given-names>SM</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Neuronal ubiquitin homeostasis</article-title><source>Cell Biochemistry and Biophysics</source><volume>67</volume><fpage>67</fpage><lpage>73</lpage><pub-id pub-id-type="doi">10.1007/s12013-013-9634-4</pub-id><pub-id pub-id-type="pmid">23686613</pub-id></element-citation></ref><ref id="bib47"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hamilton</surname> <given-names>AM</given-names></name><name><surname>Zito</surname> <given-names>K</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Breaking it down: the ubiquitin proteasome system in neuronal morphogenesis</article-title><source>Neural Plasticity</source><volume>2013</volume><fpage>1</fpage><lpage>10</lpage><pub-id pub-id-type="doi">10.1155/2013/196848</pub-id></element-citation></ref><ref id="bib48"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hanus</surname> <given-names>C</given-names></name><name><surname>Schuman</surname> <given-names>EM</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Proteostasis in complex dendrites</article-title><source>Nature Reviews Neuroscience</source><volume>14</volume><fpage>638</fpage><lpage>648</lpage><pub-id pub-id-type="doi">10.1038/nrn3546</pub-id><pub-id pub-id-type="pmid">23900412</pub-id></element-citation></ref><ref id="bib49"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Häring</surname> <given-names>M</given-names></name><name><surname>Guggenhuber</surname> <given-names>S</given-names></name><name><surname>Lutz</surname> <given-names>B</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Neuronal populations mediating the effects of endocannabinoids on stress and emotionality</article-title><source>Neuroscience</source><volume>204</volume><fpage>145</fpage><lpage>158</lpage><pub-id pub-id-type="doi">10.1016/j.neuroscience.2011.12.035</pub-id><pub-id pub-id-type="pmid">22233782</pub-id></element-citation></ref><ref id="bib50"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hebert-Chatelain</surname> <given-names>E</given-names></name><name><surname>Desprez</surname> <given-names>T</given-names></name><name><surname>Serrat</surname> <given-names>R</given-names></name><name><surname>Bellocchio</surname> <given-names>L</given-names></name><name><surname>Soria-Gomez</surname> <given-names>E</given-names></name><name><surname>Busquets-Garcia</surname> <given-names>A</given-names></name><name><surname>Pagano Zottola</surname> <given-names>AC</given-names></name><name><surname>Delamarre</surname> <given-names>A</given-names></name><name><surname>Cannich</surname> <given-names>A</given-names></name><name><surname>Vincent</surname> <given-names>P</given-names></name><name><surname>Varilh</surname> <given-names>M</given-names></name><name><surname>Robin</surname> <given-names>LM</given-names></name><name><surname>Terral</surname> <given-names>G</given-names></name><name><surname>García-Fernández</surname> <given-names>MD</given-names></name><name><surname>Colavita</surname> <given-names>M</given-names></name><name><surname>Mazier</surname> <given-names>W</given-names></name><name><surname>Drago</surname> <given-names>F</given-names></name><name><surname>Puente</surname> <given-names>N</given-names></name><name><surname>Reguero</surname> <given-names>L</given-names></name><name><surname>Elezgarai</surname> <given-names>I</given-names></name><name><surname>Dupuy</surname> <given-names>JW</given-names></name><name><surname>Cota</surname> <given-names>D</given-names></name><name><surname>Lopez-Rodriguez</surname> <given-names>ML</given-names></name><name><surname>Barreda-Gómez</surname> <given-names>G</given-names></name><name><surname>Massa</surname> <given-names>F</given-names></name><name><surname>Grandes</surname> <given-names>P</given-names></name><name><surname>Bénard</surname> <given-names>G</given-names></name><name><surname>Marsicano</surname> <given-names>G</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>A cannabinoid link between mitochondria and memory</article-title><source>Nature</source><volume>539</volume><fpage>555</fpage><lpage>559</lpage><pub-id pub-id-type="doi">10.1038/nature20127</pub-id><pub-id pub-id-type="pmid">27828947</pub-id></element-citation></ref><ref id="bib51"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hegde</surname> <given-names>AN</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Proteolysis, synaptic plasticity and memory</article-title><source>Neurobiology of Learning and Memory</source><volume>138</volume><fpage>98</fpage><lpage>110</lpage><pub-id pub-id-type="doi">10.1016/j.nlm.2016.09.003</pub-id><pub-id pub-id-type="pmid">27614141</pub-id></element-citation></ref><ref id="bib52"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Heifets</surname> <given-names>BD</given-names></name><name><surname>Chevaleyre</surname> <given-names>V</given-names></name><name><surname>Castillo</surname> <given-names>PE</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Interneuron activity controls endocannabinoid-mediated presynaptic plasticity through calcineurin</article-title><source>PNAS</source><volume>105</volume><fpage>10250</fpage><lpage>10255</lpage><pub-id pub-id-type="doi">10.1073/pnas.0711880105</pub-id><pub-id pub-id-type="pmid">18632563</pub-id></element-citation></ref><ref id="bib53"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Heifets</surname> <given-names>BD</given-names></name><name><surname>Castillo</surname> <given-names>PE</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Endocannabinoid signaling and long-term synaptic plasticity</article-title><source>Annual Review of Physiology</source><volume>71</volume><fpage>283</fpage><lpage>306</lpage><pub-id pub-id-type="doi">10.1146/annurev.physiol.010908.163149</pub-id><pub-id pub-id-type="pmid">19575681</pub-id></element-citation></ref><ref id="bib54"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hetrick</surname> <given-names>B</given-names></name><name><surname>Han</surname> <given-names>MS</given-names></name><name><surname>Helgeson</surname> <given-names>LA</given-names></name><name><surname>Nolen</surname> <given-names>BJ</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Small molecules CK-666 and CK-869 inhibit actin-related protein 2/3 complex by blocking an activating conformational change</article-title><source>Chemistry &amp; Biology</source><volume>20</volume><fpage>701</fpage><lpage>712</lpage><pub-id pub-id-type="doi">10.1016/j.chembiol.2013.03.019</pub-id><pub-id pub-id-type="pmid">23623350</pub-id></element-citation></ref><ref id="bib55"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ho</surname> <given-names>J</given-names></name><name><surname>Tumkaya</surname> <given-names>T</given-names></name><name><surname>Aryal</surname> <given-names>S</given-names></name><name><surname>Choi</surname> <given-names>H</given-names></name><name><surname>Claridge-Chang</surname> <given-names>A</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Moving beyond P values: data analysis with estimation graphics</article-title><source>Nature Methods</source><volume>16</volume><fpage>565</fpage><lpage>566</lpage><pub-id pub-id-type="doi">10.1038/s41592-019-0470-3</pub-id><pub-id pub-id-type="pmid">31217592</pub-id></element-citation></ref><ref id="bib56"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hoffman</surname> <given-names>AF</given-names></name><name><surname>Lupica</surname> <given-names>CR</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Synaptic targets of Δ9-tetrahydrocannabinol in the central nervous system</article-title><source>Cold Spring Harbor Perspectives in Medicine</source><volume>3</volume><elocation-id>a012237</elocation-id><pub-id pub-id-type="doi">10.1101/cshperspect.a012237</pub-id><pub-id pub-id-type="pmid">23209160</pub-id></element-citation></ref><ref id="bib57"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Holzinger</surname> <given-names>A</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Jasplakinolide: an actin-specific reagent that promotes actin polymerization</article-title><source>Methods in Molecular Biology</source><volume>586</volume><fpage>71</fpage><lpage>87</lpage><pub-id pub-id-type="doi">10.1007/978-1-60761-376-3_4</pub-id><pub-id pub-id-type="pmid">19768425</pub-id></element-citation></ref><ref id="bib58"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hou</surname> <given-names>H</given-names></name><name><surname>Chávez</surname> <given-names>AE</given-names></name><name><surname>Wang</surname> <given-names>CC</given-names></name><name><surname>Yang</surname> <given-names>H</given-names></name><name><surname>Gu</surname> <given-names>H</given-names></name><name><surname>Siddoway</surname> <given-names>BA</given-names></name><name><surname>Hall</surname> <given-names>BJ</given-names></name><name><surname>Castillo</surname> <given-names>PE</given-names></name><name><surname>Xia</surname> <given-names>H</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>The Rac1 inhibitor NSC23766 suppresses CREB signaling by targeting NMDA receptor function</article-title><source>Journal of Neuroscience</source><volume>34</volume><fpage>14006</fpage><lpage>14012</lpage><pub-id pub-id-type="doi">10.1523/JNEUROSCI.1659-14.2014</pub-id><pub-id pub-id-type="pmid">25319697</pub-id></element-citation></ref><ref id="bib59"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hsieh</surname> <given-names>C</given-names></name><name><surname>Brown</surname> <given-names>S</given-names></name><name><surname>Derleth</surname> <given-names>C</given-names></name><name><surname>Mackie</surname> <given-names>K</given-names></name></person-group><year iso-8601-date="1999">1999</year><article-title>Internalization and recycling of the CB1 cannabinoid receptor</article-title><source>Journal of Neurochemistry</source><volume>73</volume><fpage>493</fpage><lpage>501</lpage><pub-id pub-id-type="doi">10.1046/j.1471-4159.1999.0730493.x</pub-id><pub-id pub-id-type="pmid">10428044</pub-id></element-citation></ref><ref id="bib60"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hu</surname> <given-names>HY</given-names></name><name><surname>Kruijssen</surname> <given-names>DLH</given-names></name><name><surname>Frias</surname> <given-names>CP</given-names></name><name><surname>Rozsa</surname> <given-names>B</given-names></name><name><surname>Hoogenraad</surname> <given-names>CC</given-names></name><name><surname>Wierenga</surname> <given-names>CJ</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Endocannabinoid signaling mediates local dendritic coordination between excitatory and inhibitory synapses</article-title><source>Cell Reports</source><volume>675</volume><elocation-id>78</elocation-id><pub-id pub-id-type="doi">10.1016/j.celrep.2019.03.078</pub-id></element-citation></ref><ref id="bib61"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hunter</surname> <given-names>JD</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Matplotlib: a 2D graphics environment</article-title><source>Computing in Science &amp; Engineering</source><volume>9</volume><fpage>90</fpage><lpage>95</lpage><pub-id pub-id-type="doi">10.1109/MCSE.2007.55</pub-id></element-citation></ref><ref id="bib62"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ivanova</surname> <given-names>D</given-names></name><name><surname>Dirks</surname> <given-names>A</given-names></name><name><surname>Fejtova</surname> <given-names>A</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Bassoon and piccolo regulate ubiquitination and link presynaptic molecular dynamics with activity-regulated gene expression</article-title><source>The Journal of Physiology</source><volume>594</volume><fpage>5441</fpage><lpage>5448</lpage><pub-id pub-id-type="doi">10.1113/JP271826</pub-id><pub-id pub-id-type="pmid">26915533</pub-id></element-citation></ref><ref id="bib63"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jiang</surname> <given-names>X</given-names></name><name><surname>Litkowski</surname> <given-names>PE</given-names></name><name><surname>Taylor</surname> <given-names>AA</given-names></name><name><surname>Lin</surname> <given-names>Y</given-names></name><name><surname>Snider</surname> <given-names>BJ</given-names></name><name><surname>Moulder</surname> <given-names>KL</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>A role for the ubiquitin-proteasome system in activity-dependent presynaptic silencing</article-title><source>Journal of Neuroscience</source><volume>30</volume><fpage>1798</fpage><lpage>1809</lpage><pub-id pub-id-type="doi">10.1523/JNEUROSCI.4965-09.2010</pub-id><pub-id pub-id-type="pmid">20130189</pub-id></element-citation></ref><ref id="bib64"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jin</surname> <given-names>W</given-names></name><name><surname>Brown</surname> <given-names>S</given-names></name><name><surname>Roche</surname> <given-names>JP</given-names></name><name><surname>Hsieh</surname> <given-names>C</given-names></name><name><surname>Celver</surname> <given-names>JP</given-names></name><name><surname>Kovoor</surname> <given-names>A</given-names></name><name><surname>Chavkin</surname> <given-names>C</given-names></name><name><surname>Mackie</surname> <given-names>K</given-names></name></person-group><year iso-8601-date="1999">1999</year><article-title>Distinct domains of the CB1 cannabinoid receptor mediate desensitization and internalization</article-title><source>The Journal of Neuroscience</source><volume>19</volume><fpage>3773</fpage><lpage>3780</lpage><pub-id pub-id-type="doi">10.1523/JNEUROSCI.19-10-03773.1999</pub-id><pub-id pub-id-type="pmid">10234009</pub-id></element-citation></ref><ref id="bib65"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jordan</surname> <given-names>BA</given-names></name><name><surname>Fernholz</surname> <given-names>BD</given-names></name><name><surname>Boussac</surname> <given-names>M</given-names></name><name><surname>Xu</surname> <given-names>C</given-names></name><name><surname>Grigorean</surname> <given-names>G</given-names></name><name><surname>Ziff</surname> <given-names>EB</given-names></name><name><surname>Neubert</surname> <given-names>TA</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>Identification and verification of novel rodent postsynaptic density proteins</article-title><source>Molecular &amp; Cellular Proteomics</source><volume>3</volume><fpage>857</fpage><lpage>871</lpage><pub-id pub-id-type="doi">10.1074/mcp.M400045-MCP200</pub-id></element-citation></ref><ref id="bib66"><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Jordan</surname> <given-names>BA</given-names></name><name><surname>Fernholz</surname> <given-names>BD</given-names></name><name><surname>Neubert</surname> <given-names>TA</given-names></name><name><surname>Ziff</surname> <given-names>EB</given-names></name></person-group><year iso-8601-date="2006">2006</year><chapter-title>New Tricks for an Old Dog: Proteomics of the PSD</chapter-title><person-group person-group-type="editor"><name><surname>Kittler</surname> <given-names>J. T</given-names></name><name><surname>Moss</surname> <given-names>S. J</given-names></name></person-group><source>The Dynamic Synapse: Molecular Methods in Ionotropic Receptor Biology</source><publisher-name> CRC Press/Taylor &amp; Francis</publisher-name><fpage>37</fpage><lpage>50</lpage></element-citation></ref><ref id="bib67"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Joseph</surname> <given-names>N</given-names></name><name><surname>Biber</surname> <given-names>G</given-names></name><name><surname>Fried</surname> <given-names>S</given-names></name><name><surname>Reicher</surname> <given-names>B</given-names></name><name><surname>Levy</surname> <given-names>O</given-names></name><name><surname>Sabag</surname> <given-names>B</given-names></name><name><surname>Noy</surname> <given-names>E</given-names></name><name><surname>Barda-Saad</surname> <given-names>M</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>A conformational change within the WAVE2 complex regulates its degradation following cellular activation</article-title><source>Scientific Reports</source><volume>7</volume><elocation-id>44863</elocation-id><pub-id pub-id-type="doi">10.1038/srep44863</pub-id><pub-id pub-id-type="pmid">28332566</pub-id></element-citation></ref><ref id="bib68"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jung</surname> <given-names>KM</given-names></name><name><surname>Sepers</surname> <given-names>M</given-names></name><name><surname>Henstridge</surname> <given-names>CM</given-names></name><name><surname>Lassalle</surname> <given-names>O</given-names></name><name><surname>Neuhofer</surname> <given-names>D</given-names></name><name><surname>Martin</surname> <given-names>H</given-names></name><name><surname>Ginger</surname> <given-names>M</given-names></name><name><surname>Frick</surname> <given-names>A</given-names></name><name><surname>DiPatrizio</surname> <given-names>NV</given-names></name><name><surname>Mackie</surname> <given-names>K</given-names></name><name><surname>Katona</surname> <given-names>I</given-names></name><name><surname>Piomelli</surname> <given-names>D</given-names></name><name><surname>Manzoni</surname> <given-names>OJ</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Uncoupling of the endocannabinoid signalling complex in a mouse model of fragile X syndrome</article-title><source>Nature Communications</source><volume>3</volume><elocation-id>1080</elocation-id><pub-id pub-id-type="doi">10.1038/ncomms2045</pub-id><pub-id pub-id-type="pmid">23011134</pub-id></element-citation></ref><ref id="bib69"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Klaips</surname> <given-names>CL</given-names></name><name><surname>Jayaraj</surname> <given-names>GG</given-names></name><name><surname>Hartl</surname> <given-names>FU</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Pathways of cellular proteostasis in aging and disease</article-title><source>Journal of Cell Biology</source><volume>217</volume><fpage>51</fpage><lpage>63</lpage><pub-id pub-id-type="doi">10.1083/jcb.201709072</pub-id><pub-id pub-id-type="pmid">29127110</pub-id></element-citation></ref><ref id="bib70"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Klein</surname> <given-names>ME</given-names></name><name><surname>Castillo</surname> <given-names>PE</given-names></name><name><surname>Jordan</surname> <given-names>BA</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Coordination between translation and degradation regulates inducibility of mGluR-LTD</article-title><source>Cell Reports</source><volume>10</volume><fpage>1459</fpage><lpage>1466</lpage><pub-id pub-id-type="doi">10.1016/j.celrep.2015.02.020</pub-id><pub-id pub-id-type="pmid">25753412</pub-id></element-citation></ref><ref id="bib71"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Koga</surname> <given-names>K</given-names></name><name><surname>Yao</surname> <given-names>I</given-names></name><name><surname>Setou</surname> <given-names>M</given-names></name><name><surname>Zhuo</surname> <given-names>M</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>SCRAPPER selectively contributes to spontaneous release and presynaptic Long-Term potentiation in the anterior cingulate cortex</article-title><source>The Journal of Neuroscience</source><volume>37</volume><fpage>3887</fpage><lpage>3895</lpage><pub-id pub-id-type="doi">10.1523/JNEUROSCI.0023-16.2017</pub-id><pub-id pub-id-type="pmid">28292828</pub-id></element-citation></ref><ref id="bib72"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Koopmans</surname> <given-names>F</given-names></name><name><surname>van Nierop</surname> <given-names>P</given-names></name><name><surname>Andres-Alonso</surname> <given-names>M</given-names></name><name><surname>Byrnes</surname> <given-names>A</given-names></name><name><surname>Cijsouw</surname> <given-names>T</given-names></name><name><surname>Coba</surname> <given-names>MP</given-names></name><name><surname>Cornelisse</surname> <given-names>LN</given-names></name><name><surname>Farrell</surname> <given-names>RJ</given-names></name><name><surname>Goldschmidt</surname> <given-names>HL</given-names></name><name><surname>Howrigan</surname> <given-names>DP</given-names></name><name><surname>Hussain</surname> <given-names>NK</given-names></name><name><surname>Imig</surname> <given-names>C</given-names></name><name><surname>de Jong</surname> <given-names>APH</given-names></name><name><surname>Jung</surname> <given-names>H</given-names></name><name><surname>Kohansalnodehi</surname> <given-names>M</given-names></name><name><surname>Kramarz</surname> <given-names>B</given-names></name><name><surname>Lipstein</surname> <given-names>N</given-names></name><name><surname>Lovering</surname> <given-names>RC</given-names></name><name><surname>MacGillavry</surname> <given-names>H</given-names></name><name><surname>Mariano</surname> <given-names>V</given-names></name><name><surname>Mi</surname> <given-names>H</given-names></name><name><surname>Ninov</surname> <given-names>M</given-names></name><name><surname>Osumi-Sutherland</surname> <given-names>D</given-names></name><name><surname>Pielot</surname> <given-names>R</given-names></name><name><surname>Smalla</surname> <given-names>KH</given-names></name><name><surname>Tang</surname> <given-names>H</given-names></name><name><surname>Tashman</surname> <given-names>K</given-names></name><name><surname>Toonen</surname> <given-names>RFG</given-names></name><name><surname>Verpelli</surname> <given-names>C</given-names></name><name><surname>Reig-Viader</surname> <given-names>R</given-names></name><name><surname>Watanabe</surname> <given-names>K</given-names></name><name><surname>van Weering</surname> <given-names>J</given-names></name><name><surname>Achsel</surname> <given-names>T</given-names></name><name><surname>Ashrafi</surname> <given-names>G</given-names></name><name><surname>Asi</surname> <given-names>N</given-names></name><name><surname>Brown</surname> <given-names>TC</given-names></name><name><surname>De Camilli</surname> <given-names>P</given-names></name><name><surname>Feuermann</surname> <given-names>M</given-names></name><name><surname>Foulger</surname> <given-names>RE</given-names></name><name><surname>Gaudet</surname> <given-names>P</given-names></name><name><surname>Joglekar</surname> <given-names>A</given-names></name><name><surname>Kanellopoulos</surname> <given-names>A</given-names></name><name><surname>Malenka</surname> <given-names>R</given-names></name><name><surname>Nicoll</surname> <given-names>RA</given-names></name><name><surname>Pulido</surname> <given-names>C</given-names></name><name><surname>de Juan-Sanz</surname> <given-names>J</given-names></name><name><surname>Sheng</surname> <given-names>M</given-names></name><name><surname>Südhof</surname> <given-names>TC</given-names></name><name><surname>Tilgner</surname> <given-names>HU</given-names></name><name><surname>Bagni</surname> <given-names>C</given-names></name><name><surname>Bayés</surname> <given-names>À</given-names></name><name><surname>Biederer</surname> <given-names>T</given-names></name><name><surname>Brose</surname> <given-names>N</given-names></name><name><surname>Chua</surname> <given-names>JJE</given-names></name><name><surname>Dieterich</surname> <given-names>DC</given-names></name><name><surname>Gundelfinger</surname> <given-names>ED</given-names></name><name><surname>Hoogenraad</surname> <given-names>C</given-names></name><name><surname>Huganir</surname> <given-names>RL</given-names></name><name><surname>Jahn</surname> <given-names>R</given-names></name><name><surname>Kaeser</surname> <given-names>PS</given-names></name><name><surname>Kim</surname> <given-names>E</given-names></name><name><surname>Kreutz</surname> <given-names>MR</given-names></name><name><surname>McPherson</surname> <given-names>PS</given-names></name><name><surname>Neale</surname> <given-names>BM</given-names></name><name><surname>O'Connor</surname> <given-names>V</given-names></name><name><surname>Posthuma</surname> <given-names>D</given-names></name><name><surname>Ryan</surname> <given-names>TA</given-names></name><name><surname>Sala</surname> <given-names>C</given-names></name><name><surname>Feng</surname> <given-names>G</given-names></name><name><surname>Hyman</surname> <given-names>SE</given-names></name><name><surname>Thomas</surname> <given-names>PD</given-names></name><name><surname>Smit</surname> <given-names>AB</given-names></name><name><surname>Verhage</surname> <given-names>M</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>SynGO: an Evidence-Based, Expert-Curated knowledge base for the synapse</article-title><source>Neuron</source><volume>103</volume><fpage>217</fpage><lpage>234</lpage><pub-id pub-id-type="doi">10.1016/j.neuron.2019.05.002</pub-id><pub-id pub-id-type="pmid">31171447</pub-id></element-citation></ref><ref id="bib73"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kucera</surname> <given-names>M</given-names></name><name><surname>Isserlin</surname> <given-names>R</given-names></name><name><surname>Arkhangorodsky</surname> <given-names>A</given-names></name><name><surname>Bader</surname> <given-names>GD</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>AutoAnnotate: a cytoscape app for summarizing networks with semantic annotations</article-title><source>F1000Research</source><volume>5</volume><elocation-id>1717</elocation-id><pub-id pub-id-type="doi">10.12688/f1000research.9090.1</pub-id><pub-id pub-id-type="pmid">27830058</pub-id></element-citation></ref><ref id="bib74"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lazarevic</surname> <given-names>V</given-names></name><name><surname>Schöne</surname> <given-names>C</given-names></name><name><surname>Heine</surname> <given-names>M</given-names></name><name><surname>Gundelfinger</surname> <given-names>ED</given-names></name><name><surname>Fejtova</surname> <given-names>A</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Extensive remodeling of the presynaptic cytomatrix upon homeostatic adaptation to network activity silencing</article-title><source>Journal of Neuroscience</source><volume>31</volume><fpage>10189</fpage><lpage>10200</lpage><pub-id pub-id-type="doi">10.1523/JNEUROSCI.2088-11.2011</pub-id><pub-id pub-id-type="pmid">21752995</pub-id></element-citation></ref><ref id="bib75"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liang</surname> <given-names>Y</given-names></name><name><surname>Sigrist</surname> <given-names>S</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Autophagy and proteostasis in the control of synapse aging and disease</article-title><source>Current Opinion in Neurobiology</source><volume>48</volume><fpage>113</fpage><lpage>121</lpage><pub-id pub-id-type="doi">10.1016/j.conb.2017.12.006</pub-id><pub-id pub-id-type="pmid">29274917</pub-id></element-citation></ref><ref id="bib76"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lord</surname> <given-names>SJ</given-names></name><name><surname>Velle</surname> <given-names>KB</given-names></name><name><surname>Mullins</surname> <given-names>RD</given-names></name><name><surname>Fritz-Laylin</surname> <given-names>LK</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>SuperPlots: communicating reproducibility and variability in cell biology</article-title><source>Journal of Cell Biology</source><volume>219</volume><elocation-id>1064</elocation-id><pub-id pub-id-type="doi">10.1083/jcb.202001064</pub-id></element-citation></ref><ref id="bib77"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lowry</surname> <given-names>OH</given-names></name><name><surname>Rosebrough</surname> <given-names>NJ</given-names></name><name><surname>Farr</surname> <given-names>AL</given-names></name><name><surname>Randall</surname> <given-names>RJ</given-names></name></person-group><year iso-8601-date="1951">1951</year><article-title>Protein measurement with the folin phenol reagent</article-title><source>The Journal of Biological Chemistry</source><volume>193</volume><fpage>265</fpage><lpage>275</lpage><pub-id pub-id-type="pmid">14907713</pub-id></element-citation></ref><ref id="bib78"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Maccarrone</surname> <given-names>M</given-names></name><name><surname>Rossi</surname> <given-names>S</given-names></name><name><surname>Bari</surname> <given-names>M</given-names></name><name><surname>De Chiara</surname> <given-names>V</given-names></name><name><surname>Rapino</surname> <given-names>C</given-names></name><name><surname>Musella</surname> <given-names>A</given-names></name><name><surname>Bernardi</surname> <given-names>G</given-names></name><name><surname>Bagni</surname> <given-names>C</given-names></name><name><surname>Centonze</surname> <given-names>D</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Abnormal mGlu 5 receptor/endocannabinoid coupling in mice lacking FMRP and BC1 RNA</article-title><source>Neuropsychopharmacology</source><volume>35</volume><fpage>1500</fpage><lpage>1509</lpage><pub-id pub-id-type="doi">10.1038/npp.2010.19</pub-id><pub-id pub-id-type="pmid">20393458</pub-id></element-citation></ref><ref id="bib79"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Martin</surname> <given-names>HGS</given-names></name><name><surname>Lassalle</surname> <given-names>O</given-names></name><name><surname>Manzoni</surname> <given-names>OJ</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Differential adulthood onset mGlu5 signaling saves prefrontal function in the fragile X mouse</article-title><source>Cerebral Cortex</source><volume>27</volume><fpage>5592</fpage><lpage>5602</lpage><pub-id pub-id-type="doi">10.1093/cercor/bhw328</pub-id><pub-id pub-id-type="pmid">27797833</pub-id></element-citation></ref><ref id="bib80"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mattheus</surname> <given-names>T</given-names></name><name><surname>Kukla</surname> <given-names>K</given-names></name><name><surname>Zimmermann</surname> <given-names>T</given-names></name><name><surname>Tenzer</surname> <given-names>S</given-names></name><name><surname>Lutz</surname> <given-names>B</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Cell Type-Specific Tandem Affinity Purification of the Mouse Hippocampal CB1 Receptor-Associated Proteome</article-title><source>Journal of Proteome Research</source><volume>15</volume><fpage>3585</fpage><lpage>3601</lpage><pub-id pub-id-type="doi">10.1021/acs.jproteome.6b00339</pub-id></element-citation></ref><ref id="bib81"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Matz</surname> <given-names>J</given-names></name><name><surname>Gilyan</surname> <given-names>A</given-names></name><name><surname>Kolar</surname> <given-names>A</given-names></name><name><surname>McCarvill</surname> <given-names>T</given-names></name><name><surname>Krueger</surname> <given-names>SR</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Rapid structural alterations of the active zone lead to sustained changes in neurotransmitter release</article-title><source>PNAS</source><volume>107</volume><fpage>8836</fpage><lpage>8841</lpage><pub-id pub-id-type="doi">10.1073/pnas.0906087107</pub-id><pub-id pub-id-type="pmid">20421490</pub-id></element-citation></ref><ref id="bib82"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mendizabal-Zubiaga</surname> <given-names>J</given-names></name><name><surname>Melser</surname> <given-names>S</given-names></name><name><surname>Bénard</surname> <given-names>G</given-names></name><name><surname>Ramos</surname> <given-names>A</given-names></name><name><surname>Reguero</surname> <given-names>L</given-names></name><name><surname>Arrabal</surname> <given-names>S</given-names></name><name><surname>Elezgarai</surname> <given-names>I</given-names></name><name><surname>Gerrikagoitia</surname> <given-names>I</given-names></name><name><surname>Suarez</surname> <given-names>J</given-names></name><name><surname>Rodríguez De Fonseca</surname> <given-names>F</given-names></name><name><surname>Puente</surname> <given-names>N</given-names></name><name><surname>Marsicano</surname> <given-names>G</given-names></name><name><surname>Grandes</surname> <given-names>P</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Cannabinoid CB<sub>1</sub>receptors are localized in striated muscle mitochondria and regulate mitochondrial respiration</article-title><source>Frontiers in Physiology</source><volume>7</volume><elocation-id>476</elocation-id><pub-id pub-id-type="doi">10.3389/fphys.2016.00476</pub-id><pub-id pub-id-type="pmid">27826249</pub-id></element-citation></ref><ref id="bib83"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Merico</surname> <given-names>D</given-names></name><name><surname>Isserlin</surname> <given-names>R</given-names></name><name><surname>Stueker</surname> <given-names>O</given-names></name><name><surname>Emili</surname> <given-names>A</given-names></name><name><surname>Bader</surname> <given-names>GD</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Enrichment map: a network-based method for gene-set enrichment visualization and interpretation</article-title><source>PLOS ONE</source><volume>5</volume><elocation-id>e13984</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0013984</pub-id><pub-id pub-id-type="pmid">21085593</pub-id></element-citation></ref><ref id="bib84"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Meyer</surname> <given-names>D</given-names></name><name><surname>Bonhoeffer</surname> <given-names>T</given-names></name><name><surname>Scheuss</surname> <given-names>V</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Balance and stability of synaptic structures during synaptic plasticity</article-title><source>Neuron</source><volume>82</volume><fpage>430</fpage><lpage>443</lpage><pub-id pub-id-type="doi">10.1016/j.neuron.2014.02.031</pub-id><pub-id pub-id-type="pmid">24742464</pub-id></element-citation></ref><ref id="bib85"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Michel</surname> <given-names>K</given-names></name><name><surname>Müller</surname> <given-names>JA</given-names></name><name><surname>Oprişoreanu</surname> <given-names>AM</given-names></name><name><surname>Schoch</surname> <given-names>S</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>The presynaptic active zone: a dynamic scaffold that regulates synaptic efficacy</article-title><source>Experimental Cell Research</source><volume>335</volume><fpage>157</fpage><lpage>164</lpage><pub-id pub-id-type="doi">10.1016/j.yexcr.2015.02.011</pub-id><pub-id pub-id-type="pmid">25720549</pub-id></element-citation></ref><ref id="bib86"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Monday</surname> <given-names>HR</given-names></name><name><surname>Younts</surname> <given-names>TJ</given-names></name><name><surname>Castillo</surname> <given-names>PE</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Long-Term plasticity of neurotransmitter release: emerging mechanisms and contributions to brain function and disease</article-title><source>Annual Review of Neuroscience</source><volume>41</volume><fpage>299</fpage><lpage>322</lpage><pub-id pub-id-type="doi">10.1146/annurev-neuro-080317-062155</pub-id><pub-id pub-id-type="pmid">29709205</pub-id></element-citation></ref><ref id="bib87"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Monday</surname> <given-names>HR</given-names></name><name><surname>Castillo</surname> <given-names>PE</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Closing the gap: long-term presynaptic plasticity in brain function and disease</article-title><source>Current Opinion in Neurobiology</source><volume>45</volume><fpage>106</fpage><lpage>112</lpage><pub-id pub-id-type="doi">10.1016/j.conb.2017.05.011</pub-id><pub-id pub-id-type="pmid">28570863</pub-id></element-citation></ref><ref id="bib88"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nakahata</surname> <given-names>Y</given-names></name><name><surname>Yasuda</surname> <given-names>R</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Plasticity of spine structure: local signaling, translation and cytoskeletal reorganization</article-title><source>Frontiers in Synaptic Neuroscience</source><volume>10</volume><elocation-id>29</elocation-id><pub-id pub-id-type="doi">10.3389/fnsyn.2018.00029</pub-id><pub-id pub-id-type="pmid">30210329</pub-id></element-citation></ref><ref id="bib89"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nakamura</surname> <given-names>Y</given-names></name><name><surname>Harada</surname> <given-names>H</given-names></name><name><surname>Kamasawa</surname> <given-names>N</given-names></name><name><surname>Matsui</surname> <given-names>K</given-names></name><name><surname>Rothman</surname> <given-names>JS</given-names></name><name><surname>Shigemoto</surname> <given-names>R</given-names></name><name><surname>Silver</surname> <given-names>RA</given-names></name><name><surname>DiGregorio</surname> <given-names>DA</given-names></name><name><surname>Takahashi</surname> <given-names>T</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Nanoscale distribution of presynaptic ca(2+) channels and its impact on vesicular release during development</article-title><source>Neuron</source><volume>85</volume><fpage>145</fpage><lpage>158</lpage><pub-id pub-id-type="doi">10.1016/j.neuron.2014.11.019</pub-id><pub-id pub-id-type="pmid">25533484</pub-id></element-citation></ref><ref id="bib90"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nelson</surname> <given-names>JC</given-names></name><name><surname>Stavoe</surname> <given-names>AK</given-names></name><name><surname>Colón-Ramos</surname> <given-names>DA</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>The actin cytoskeleton in presynaptic assembly</article-title><source>Cell Adhesion &amp; Migration</source><volume>7</volume><fpage>379</fpage><lpage>387</lpage><pub-id pub-id-type="doi">10.4161/cam.24803</pub-id><pub-id pub-id-type="pmid">23628914</pub-id></element-citation></ref><ref id="bib91"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nesvizhskii</surname> <given-names>AI</given-names></name><name><surname>Keller</surname> <given-names>A</given-names></name><name><surname>Kolker</surname> <given-names>E</given-names></name><name><surname>Aebersold</surname> <given-names>R</given-names></name></person-group><year iso-8601-date="2003">2003</year><article-title>A statistical model for identifying proteins by tandem mass spectrometry</article-title><source>Analytical Chemistry</source><volume>75</volume><fpage>4646</fpage><lpage>4658</lpage><pub-id pub-id-type="doi">10.1021/ac0341261</pub-id><pub-id pub-id-type="pmid">14632076</pub-id></element-citation></ref><ref id="bib92"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Njoo</surname> <given-names>C</given-names></name><name><surname>Agarwal</surname> <given-names>N</given-names></name><name><surname>Lutz</surname> <given-names>B</given-names></name><name><surname>Kuner</surname> <given-names>R</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>The cannabinoid receptor CB1 interacts with the WAVE1 complex and plays a role in actin dynamics and structural plasticity in neurons</article-title><source>PLOS Biology</source><volume>13</volume><elocation-id>e1002286</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pbio.1002286</pub-id><pub-id pub-id-type="pmid">26496209</pub-id></element-citation></ref><ref id="bib93"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Oliphant</surname> <given-names>TE</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Python for scientific computing</article-title><source>Computing in Science &amp; Engineering</source><volume>9</volume><fpage>10</fpage><lpage>20</lpage><pub-id pub-id-type="doi">10.1109/MCSE.2007.58</pub-id></element-citation></ref><ref id="bib94"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ostroff</surname> <given-names>LE</given-names></name><name><surname>Fiala</surname> <given-names>JC</given-names></name><name><surname>Allwardt</surname> <given-names>B</given-names></name><name><surname>Harris</surname> <given-names>KM</given-names></name></person-group><year iso-8601-date="2002">2002</year><article-title>Polyribosomes redistribute from dendritic shafts into spines with enlarged synapses during LTP in developing rat hippocampal slices</article-title><source>Neuron</source><volume>35</volume><fpage>535</fpage><lpage>545</lpage><pub-id pub-id-type="doi">10.1016/S0896-6273(02)00785-7</pub-id><pub-id pub-id-type="pmid">12165474</pub-id></element-citation></ref><ref id="bib95"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ostroff</surname> <given-names>LE</given-names></name><name><surname>Santini</surname> <given-names>E</given-names></name><name><surname>Sears</surname> <given-names>R</given-names></name><name><surname>Deane</surname> <given-names>Z</given-names></name><name><surname>Kanadia</surname> <given-names>RN</given-names></name><name><surname>LeDoux</surname> <given-names>JE</given-names></name><name><surname>Lhakhang</surname> <given-names>T</given-names></name><name><surname>Tsirigos</surname> <given-names>A</given-names></name><name><surname>Heguy</surname> <given-names>A</given-names></name><name><surname>Klann</surname> <given-names>E</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Axon TRAP reveals learning-associated alterations in cortical axonal mRNAs in the lateral amgydala</article-title><source>eLife</source><volume>8</volume><elocation-id>e51607</elocation-id><pub-id pub-id-type="doi">10.7554/eLife.51607</pub-id><pub-id pub-id-type="pmid">31825308</pub-id></element-citation></ref><ref id="bib96"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ramachandran</surname> <given-names>KV</given-names></name><name><surname>Fu</surname> <given-names>JM</given-names></name><name><surname>Schaffer</surname> <given-names>TB</given-names></name><name><surname>Na</surname> <given-names>CH</given-names></name><name><surname>Delannoy</surname> <given-names>M</given-names></name><name><surname>Margolis</surname> <given-names>SS</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Activity-Dependent degradation of the nascentome by the neuronal membrane proteasome</article-title><source>Molecular Cell</source><volume>71</volume><fpage>169</fpage><lpage>177</lpage><pub-id pub-id-type="doi">10.1016/j.molcel.2018.06.013</pub-id></element-citation></ref><ref id="bib97"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ramírez-Franco</surname> <given-names>J</given-names></name><name><surname>Bartolomé-Martín</surname> <given-names>D</given-names></name><name><surname>Alonso</surname> <given-names>B</given-names></name><name><surname>Torres</surname> <given-names>M</given-names></name><name><surname>Sánchez-Prieto</surname> <given-names>J</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Cannabinoid type 1 receptors transiently silence glutamatergic nerve terminals of cultured cerebellar granule cells</article-title><source>PLOS ONE</source><volume>9</volume><elocation-id>e88594</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0088594</pub-id><pub-id pub-id-type="pmid">24533119</pub-id></element-citation></ref><ref id="bib98"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rangaraju</surname> <given-names>V</given-names></name><name><surname>Tom Dieck</surname> <given-names>S</given-names></name><name><surname>Schuman</surname> <given-names>EM</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Local translation in neuronal compartments: how local is local?</article-title><source>EMBO Reports</source><volume>18</volume><fpage>693</fpage><lpage>711</lpage><pub-id pub-id-type="doi">10.15252/embr.201744045</pub-id><pub-id pub-id-type="pmid">28404606</pub-id></element-citation></ref><ref id="bib99"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rinetti</surname> <given-names>GV</given-names></name><name><surname>Schweizer</surname> <given-names>FE</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Ubiquitination acutely regulates presynaptic neurotransmitter release in mammalian neurons</article-title><source>Journal of Neuroscience</source><volume>30</volume><fpage>3157</fpage><lpage>3166</lpage><pub-id pub-id-type="doi">10.1523/JNEUROSCI.3712-09.2010</pub-id><pub-id pub-id-type="pmid">20203175</pub-id></element-citation></ref><ref id="bib100"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Roland</surname> <given-names>AB</given-names></name><name><surname>Ricobaraza</surname> <given-names>A</given-names></name><name><surname>Carrel</surname> <given-names>D</given-names></name><name><surname>Jordan</surname> <given-names>BM</given-names></name><name><surname>Rico</surname> <given-names>F</given-names></name><name><surname>Simon</surname> <given-names>A</given-names></name><name><surname>Humbert-Claude</surname> <given-names>M</given-names></name><name><surname>Ferrier</surname> <given-names>J</given-names></name><name><surname>McFadden</surname> <given-names>MH</given-names></name><name><surname>Scheuring</surname> <given-names>S</given-names></name><name><surname>Lenkei</surname> <given-names>Z</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Cannabinoid-induced actomyosin contractility shapes neuronal morphology and growth</article-title><source>eLife</source><volume>3</volume><elocation-id>e03159</elocation-id><pub-id pub-id-type="doi">10.7554/eLife.03159</pub-id><pub-id pub-id-type="pmid">25225054</pub-id></element-citation></ref><ref id="bib101"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ronesi</surname> <given-names>J</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>Disruption of endocannabinoid release and striatal Long-Term depression by postsynaptic blockade of endocannabinoid membrane transport</article-title><source>Journal of Neuroscience</source><volume>24</volume><fpage>1673</fpage><lpage>1679</lpage><pub-id pub-id-type="doi">10.1523/JNEUROSCI.5214-03.2004</pub-id></element-citation></ref><ref id="bib102"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rust</surname> <given-names>MB</given-names></name><name><surname>Maritzen</surname> <given-names>T</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Relevance of presynaptic actin dynamics for synapse function and mouse behavior</article-title><source>Experimental Cell Research</source><volume>335</volume><fpage>165</fpage><lpage>171</lpage><pub-id pub-id-type="doi">10.1016/j.yexcr.2014.12.020</pub-id><pub-id pub-id-type="pmid">25579398</pub-id></element-citation></ref><ref id="bib103"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schmitz</surname> <given-names>SK</given-names></name><name><surname>King</surname> <given-names>C</given-names></name><name><surname>Kortleven</surname> <given-names>C</given-names></name><name><surname>Huson</surname> <given-names>V</given-names></name><name><surname>Kroon</surname> <given-names>T</given-names></name><name><surname>Kevenaar</surname> <given-names>JT</given-names></name><name><surname>Schut</surname> <given-names>D</given-names></name><name><surname>Saarloos</surname> <given-names>I</given-names></name><name><surname>Hoetjes</surname> <given-names>JP</given-names></name><name><surname>de Wit</surname> <given-names>H</given-names></name><name><surname>Stiedl</surname> <given-names>O</given-names></name><name><surname>Spijker</surname> <given-names>S</given-names></name><name><surname>Li</surname> <given-names>KW</given-names></name><name><surname>Mansvelder</surname> <given-names>HD</given-names></name><name><surname>Smit</surname> <given-names>AB</given-names></name><name><surname>Cornelisse</surname> <given-names>LN</given-names></name><name><surname>Verhage</surname> <given-names>M</given-names></name><name><surname>Toonen</surname> <given-names>RF</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Presynaptic inhibition upon CB1 or mGlu2/3 receptor activation requires ERK/MAPK phosphorylation of Munc18-1</article-title><source>The EMBO Journal</source><volume>35</volume><fpage>1236</fpage><lpage>1250</lpage><pub-id pub-id-type="doi">10.15252/embj.201592244</pub-id><pub-id pub-id-type="pmid">27056679</pub-id></element-citation></ref><ref id="bib104"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shigeoka</surname> <given-names>T</given-names></name><name><surname>Jung</surname> <given-names>H</given-names></name><name><surname>Jung</surname> <given-names>J</given-names></name><name><surname>Turner-Bridger</surname> <given-names>B</given-names></name><name><surname>Ohk</surname> <given-names>J</given-names></name><name><surname>Lin</surname> <given-names>JQ</given-names></name><name><surname>Amieux</surname> <given-names>PS</given-names></name><name><surname>Holt</surname> <given-names>CE</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Dynamic axonal translation in developing and mature visual circuits</article-title><source>Cell</source><volume>166</volume><fpage>181</fpage><lpage>192</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2016.05.029</pub-id><pub-id pub-id-type="pmid">27321671</pub-id></element-citation></ref><ref id="bib105"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Spillane</surname> <given-names>M</given-names></name><name><surname>Ketschek</surname> <given-names>A</given-names></name><name><surname>Donnelly</surname> <given-names>CJ</given-names></name><name><surname>Pacheco</surname> <given-names>A</given-names></name><name><surname>Twiss</surname> <given-names>JL</given-names></name><name><surname>Gallo</surname> <given-names>G</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Nerve growth factor-induced formation of axonal filopodia and collateral branches involves the intra-axonal synthesis of regulators of the actin-nucleating Arp2/3 complex</article-title><source>Journal of Neuroscience</source><volume>32</volume><fpage>17671</fpage><lpage>17689</lpage><pub-id pub-id-type="doi">10.1523/JNEUROSCI.1079-12.2012</pub-id><pub-id pub-id-type="pmid">23223289</pub-id></element-citation></ref><ref id="bib106"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Steindel</surname> <given-names>F</given-names></name><name><surname>Lerner</surname> <given-names>R</given-names></name><name><surname>Häring</surname> <given-names>M</given-names></name><name><surname>Ruehle</surname> <given-names>S</given-names></name><name><surname>Marsicano</surname> <given-names>G</given-names></name><name><surname>Lutz</surname> <given-names>B</given-names></name><name><surname>Monory</surname> <given-names>K</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Neuron-type specific cannabinoid-mediated G protein signalling in mouse Hippocampus</article-title><source>Journal of Neurochemistry</source><volume>124</volume><fpage>795</fpage><lpage>807</lpage><pub-id pub-id-type="doi">10.1111/jnc.12137</pub-id><pub-id pub-id-type="pmid">23289830</pub-id></element-citation></ref><ref id="bib107"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stradal</surname> <given-names>TE</given-names></name><name><surname>Scita</surname> <given-names>G</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>Protein complexes regulating Arp2/3-mediated actin assembly</article-title><source>Current Opinion in Cell Biology</source><volume>18</volume><fpage>4</fpage><lpage>10</lpage><pub-id pub-id-type="doi">10.1016/j.ceb.2005.12.003</pub-id><pub-id pub-id-type="pmid">16343889</pub-id></element-citation></ref><ref id="bib108"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Subramanian</surname> <given-names>A</given-names></name><name><surname>Tamayo</surname> <given-names>P</given-names></name><name><surname>Mootha</surname> <given-names>VK</given-names></name><name><surname>Mukherjee</surname> <given-names>S</given-names></name><name><surname>Ebert</surname> <given-names>BL</given-names></name><name><surname>Gillette</surname> <given-names>MA</given-names></name><name><surname>Paulovich</surname> <given-names>A</given-names></name><name><surname>Pomeroy</surname> <given-names>SL</given-names></name><name><surname>Golub</surname> <given-names>TR</given-names></name><name><surname>Lander</surname> <given-names>ES</given-names></name><name><surname>Mesirov</surname> <given-names>JP</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles</article-title><source>PNAS</source><volume>102</volume><fpage>15545</fpage><lpage>15550</lpage><pub-id pub-id-type="doi">10.1073/pnas.0506580102</pub-id><pub-id pub-id-type="pmid">16199517</pub-id></element-citation></ref><ref id="bib109"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tanaka</surname> <given-names>J</given-names></name><name><surname>Horiike</surname> <given-names>Y</given-names></name><name><surname>Matsuzaki</surname> <given-names>M</given-names></name><name><surname>Miyazaki</surname> <given-names>T</given-names></name><name><surname>Ellis-Davies</surname> <given-names>GC</given-names></name><name><surname>Kasai</surname> <given-names>H</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Protein synthesis and Neurotrophin-Dependent structural plasticity of single dendritic spines</article-title><source>Science</source><volume>319</volume><fpage>1683</fpage><lpage>1687</lpage><pub-id pub-id-type="doi">10.1126/science.1152864</pub-id><pub-id pub-id-type="pmid">18309046</pub-id></element-citation></ref><ref id="bib110"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tappe-Theodor</surname> <given-names>A</given-names></name><name><surname>Agarwal</surname> <given-names>N</given-names></name><name><surname>Katona</surname> <given-names>I</given-names></name><name><surname>Rubino</surname> <given-names>T</given-names></name><name><surname>Martini</surname> <given-names>L</given-names></name><name><surname>Swiercz</surname> <given-names>J</given-names></name><name><surname>Mackie</surname> <given-names>K</given-names></name><name><surname>Monyer</surname> <given-names>H</given-names></name><name><surname>Parolaro</surname> <given-names>D</given-names></name><name><surname>Whistler</surname> <given-names>J</given-names></name><name><surname>Kuner</surname> <given-names>T</given-names></name><name><surname>Kuner</surname> <given-names>R</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>A molecular basis of analgesic tolerance to cannabinoids</article-title><source>Journal of Neuroscience</source><volume>27</volume><fpage>4165</fpage><lpage>4177</lpage><pub-id pub-id-type="doi">10.1523/JNEUROSCI.5648-06.2007</pub-id><pub-id pub-id-type="pmid">17428994</pub-id></element-citation></ref><ref id="bib111"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thibault</surname> <given-names>K</given-names></name><name><surname>Carrel</surname> <given-names>D</given-names></name><name><surname>Bonnard</surname> <given-names>D</given-names></name><name><surname>Gallatz</surname> <given-names>K</given-names></name><name><surname>Simon</surname> <given-names>A</given-names></name><name><surname>Biard</surname> <given-names>M</given-names></name><name><surname>Pezet</surname> <given-names>S</given-names></name><name><surname>Palkovits</surname> <given-names>M</given-names></name><name><surname>Lenkei</surname> <given-names>Z</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Activation-dependent subcellular distribution patterns of CB1 cannabinoid receptors in the rat forebrain</article-title><source>Cerebral Cortex</source><volume>23</volume><fpage>2581</fpage><lpage>2591</lpage><pub-id pub-id-type="doi">10.1093/cercor/bhs240</pub-id><pub-id pub-id-type="pmid">22892424</pub-id></element-citation></ref><ref id="bib112"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tominaga-Yoshino</surname> <given-names>K</given-names></name><name><surname>Urakubo</surname> <given-names>T</given-names></name><name><surname>Okada</surname> <given-names>M</given-names></name><name><surname>Matsuda</surname> <given-names>H</given-names></name><name><surname>Ogura</surname> <given-names>A</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Repetitive induction of late-phase LTP produces long-lasting synaptic enhancement accompanied by synaptogenesis in cultured hippocampal slices</article-title><source>Hippocampus</source><volume>18</volume><fpage>281</fpage><lpage>293</lpage><pub-id pub-id-type="doi">10.1002/hipo.20391</pub-id><pub-id pub-id-type="pmid">18058822</pub-id></element-citation></ref><ref id="bib113"><element-citation publication-type="journal"><person-group person-group-type="author"><collab>UniProt Consortium</collab></person-group><year iso-8601-date="2019">2019</year><article-title>UniProt: a worldwide hub of protein knowledge</article-title><source>Nucleic Acids Research</source><volume>47</volume><fpage>D506</fpage><lpage>D515</lpage><pub-id pub-id-type="doi">10.1093/nar/gky1049</pub-id><pub-id pub-id-type="pmid">30395287</pub-id></element-citation></ref><ref id="bib114"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Waites</surname> <given-names>CL</given-names></name><name><surname>Leal-Ortiz</surname> <given-names>SA</given-names></name><name><surname>Okerlund</surname> <given-names>N</given-names></name><name><surname>Dalke</surname> <given-names>H</given-names></name><name><surname>Fejtova</surname> <given-names>A</given-names></name><name><surname>Altrock</surname> <given-names>WD</given-names></name><name><surname>Gundelfinger</surname> <given-names>ED</given-names></name><name><surname>Garner</surname> <given-names>CC</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Bassoon and piccolo maintain synapse integrity by regulating protein ubiquitination and degradation</article-title><source>The EMBO Journal</source><volume>32</volume><fpage>954</fpage><lpage>969</lpage><pub-id pub-id-type="doi">10.1038/emboj.2013.27</pub-id><pub-id pub-id-type="pmid">23403927</pub-id></element-citation></ref><ref id="bib115"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname> <given-names>YC</given-names></name><name><surname>Lauwers</surname> <given-names>E</given-names></name><name><surname>Verstreken</surname> <given-names>P</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Presynaptic protein homeostasis and neuronal function</article-title><source>Current Opinion in Genetics &amp; Development</source><volume>44</volume><fpage>38</fpage><lpage>46</lpage><pub-id pub-id-type="doi">10.1016/j.gde.2017.01.015</pub-id><pub-id pub-id-type="pmid">28213157</pub-id></element-citation></ref><ref id="bib116"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname> <given-names>W</given-names></name><name><surname>Cox</surname> <given-names>BM</given-names></name><name><surname>Jia</surname> <given-names>Y</given-names></name><name><surname>Le</surname> <given-names>AA</given-names></name><name><surname>Cox</surname> <given-names>CD</given-names></name><name><surname>Jung</surname> <given-names>KM</given-names></name><name><surname>Hou</surname> <given-names>B</given-names></name><name><surname>Piomelli</surname> <given-names>D</given-names></name><name><surname>Gall</surname> <given-names>CM</given-names></name><name><surname>Lynch</surname> <given-names>G</given-names></name></person-group><year iso-8601-date="2018">2018a</year><article-title>Treating a novel plasticity defect rescues episodic memory in fragile X model mice</article-title><source>Molecular Psychiatry</source><volume>23</volume><fpage>1798</fpage><lpage>1806</lpage><pub-id pub-id-type="doi">10.1038/mp.2017.221</pub-id><pub-id pub-id-type="pmid">29133950</pub-id></element-citation></ref><ref id="bib117"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname> <given-names>W</given-names></name><name><surname>Jia</surname> <given-names>Y</given-names></name><name><surname>Pham</surname> <given-names>DT</given-names></name><name><surname>Palmer</surname> <given-names>LC</given-names></name><name><surname>Jung</surname> <given-names>KM</given-names></name><name><surname>Cox</surname> <given-names>CD</given-names></name><name><surname>Rumbaugh</surname> <given-names>G</given-names></name><name><surname>Piomelli</surname> <given-names>D</given-names></name><name><surname>Gall</surname> <given-names>CM</given-names></name><name><surname>Lynch</surname> <given-names>G</given-names></name></person-group><year iso-8601-date="2018">2018b</year><article-title>Atypical endocannabinoid signaling initiates a new form of Memory-Related plasticity at a cortical input to Hippocampus</article-title><source>Cerebral Cortex</source><volume>28</volume><fpage>2253</fpage><lpage>2266</lpage><pub-id pub-id-type="doi">10.1093/cercor/bhx126</pub-id><pub-id pub-id-type="pmid">28520937</pub-id></element-citation></ref><ref id="bib118"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wong</surname> <given-names>HH</given-names></name><name><surname>Lin</surname> <given-names>JQ</given-names></name><name><surname>Ströhl</surname> <given-names>F</given-names></name><name><surname>Roque</surname> <given-names>CG</given-names></name><name><surname>Cioni</surname> <given-names>JM</given-names></name><name><surname>Cagnetta</surname> <given-names>R</given-names></name><name><surname>Turner-Bridger</surname> <given-names>B</given-names></name><name><surname>Laine</surname> <given-names>RF</given-names></name><name><surname>Harris</surname> <given-names>WA</given-names></name><name><surname>Kaminski</surname> <given-names>CF</given-names></name><name><surname>Holt</surname> <given-names>CE</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>RNA docking and local translation regulate Site-Specific axon remodeling in Vivo</article-title><source>Neuron</source><volume>95</volume><fpage>852</fpage><lpage>868</lpage><pub-id pub-id-type="doi">10.1016/j.neuron.2017.07.016</pub-id><pub-id pub-id-type="pmid">28781168</pub-id></element-citation></ref><ref id="bib119"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname> <given-names>Y</given-names></name><name><surname>Wang</surname> <given-names>XB</given-names></name><name><surname>Frerking</surname> <given-names>M</given-names></name><name><surname>Zhou</surname> <given-names>Q</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Spine expansion and stabilization associated with long-term potentiation</article-title><source>Journal of Neuroscience</source><volume>28</volume><fpage>5740</fpage><lpage>5751</lpage><pub-id pub-id-type="doi">10.1523/JNEUROSCI.3998-07.2008</pub-id><pub-id pub-id-type="pmid">18509035</pub-id></element-citation></ref><ref id="bib120"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname> <given-names>Y</given-names></name><name><surname>Calakos</surname> <given-names>N</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Presynaptic long-term plasticity</article-title><source>Frontiers in Synaptic Neuroscience</source><volume>5</volume><elocation-id>8</elocation-id><pub-id pub-id-type="doi">10.3389/fnsyn.2013.00008</pub-id><pub-id pub-id-type="pmid">24146648</pub-id></element-citation></ref><ref id="bib121"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yao</surname> <given-names>I</given-names></name><name><surname>Takagi</surname> <given-names>H</given-names></name><name><surname>Ageta</surname> <given-names>H</given-names></name><name><surname>Kahyo</surname> <given-names>T</given-names></name><name><surname>Sato</surname> <given-names>S</given-names></name><name><surname>Hatanaka</surname> <given-names>K</given-names></name><name><surname>Fukuda</surname> <given-names>Y</given-names></name><name><surname>Chiba</surname> <given-names>T</given-names></name><name><surname>Morone</surname> <given-names>N</given-names></name><name><surname>Yuasa</surname> <given-names>S</given-names></name><name><surname>Inokuchi</surname> <given-names>K</given-names></name><name><surname>Ohtsuka</surname> <given-names>T</given-names></name><name><surname>Macgregor</surname> <given-names>GR</given-names></name><name><surname>Tanaka</surname> <given-names>K</given-names></name><name><surname>Setou</surname> <given-names>M</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>SCRAPPER-dependent ubiquitination of active zone protein RIM1 regulates synaptic vesicle release</article-title><source>Cell</source><volume>130</volume><fpage>943</fpage><lpage>957</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2007.06.052</pub-id><pub-id pub-id-type="pmid">17803915</pub-id></element-citation></ref><ref id="bib122"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yin</surname> <given-names>HH</given-names></name><name><surname>Davis</surname> <given-names>MI</given-names></name><name><surname>Ronesi</surname> <given-names>JA</given-names></name><name><surname>Lovinger</surname> <given-names>DM</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>The role of protein synthesis in striatal long-term depression</article-title><source>Journal of Neuroscience</source><volume>26</volume><fpage>11811</fpage><lpage>11820</lpage><pub-id pub-id-type="doi">10.1523/JNEUROSCI.3196-06.2006</pub-id><pub-id pub-id-type="pmid">17108154</pub-id></element-citation></ref><ref id="bib123"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Younts</surname> <given-names>TJ</given-names></name><name><surname>Chevaleyre</surname> <given-names>V</given-names></name><name><surname>Castillo</surname> <given-names>PE</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>CA1 pyramidal cell theta-burst firing triggers endocannabinoid-mediated long-term depression at both somatic and dendritic inhibitory synapses</article-title><source>Journal of Neuroscience</source><volume>33</volume><fpage>13743</fpage><lpage>13757</lpage><pub-id pub-id-type="doi">10.1523/JNEUROSCI.0817-13.2013</pub-id><pub-id pub-id-type="pmid">23966696</pub-id></element-citation></ref><ref id="bib124"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Younts</surname> <given-names>TJ</given-names></name><name><surname>Monday</surname> <given-names>HR</given-names></name><name><surname>Dudok</surname> <given-names>B</given-names></name><name><surname>Klein</surname> <given-names>ME</given-names></name><name><surname>Jordan</surname> <given-names>BA</given-names></name><name><surname>Katona</surname> <given-names>I</given-names></name><name><surname>Castillo</surname> <given-names>PE</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Presynaptic protein synthesis is required for Long-Term plasticity of GABA release</article-title><source>Neuron</source><volume>92</volume><fpage>479</fpage><lpage>492</lpage><pub-id pub-id-type="doi">10.1016/j.neuron.2016.09.040</pub-id><pub-id pub-id-type="pmid">27764673</pub-id></element-citation></ref><ref id="bib125"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname> <given-names>G</given-names></name><name><surname>Deinhardt</surname> <given-names>K</given-names></name><name><surname>Chao</surname> <given-names>MV</given-names></name><name><surname>Neubert</surname> <given-names>TA</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Study of neurotrophin-3 signaling in primary cultured neurons using multiplex stable isotope labeling with amino acids in cell culture</article-title><source>Journal of Proteome Research</source><volume>10</volume><fpage>2546</fpage><lpage>2554</lpage><pub-id pub-id-type="doi">10.1021/pr200016n</pub-id><pub-id pub-id-type="pmid">21370927</pub-id></element-citation></ref><ref id="bib126"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname> <given-names>G</given-names></name><name><surname>Neubert</surname> <given-names>TA</given-names></name><name><surname>Jordan</surname> <given-names>BA</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>RNA binding proteins accumulate at the postsynaptic density with synaptic activity</article-title><source>Journal of Neuroscience</source><volume>32</volume><fpage>599</fpage><lpage>609</lpage><pub-id pub-id-type="doi">10.1523/JNEUROSCI.2463-11.2012</pub-id><pub-id pub-id-type="pmid">22238095</pub-id></element-citation></ref><ref id="bib127"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname> <given-names>L</given-names></name><name><surname>Alger</surname> <given-names>BE</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Enhanced endocannabinoid signaling elevates neuronal excitability in fragile X syndrome</article-title><source>Journal of Neuroscience</source><volume>30</volume><fpage>5724</fpage><lpage>5729</lpage><pub-id pub-id-type="doi">10.1523/JNEUROSCI.0795-10.2010</pub-id><pub-id pub-id-type="pmid">20410124</pub-id></element-citation></ref><ref id="bib128"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zlebnik</surname> <given-names>NE</given-names></name><name><surname>Cheer</surname> <given-names>JF</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Drug-Induced alterations of Endocannabinoid-Mediated plasticity in brain reward regions</article-title><source>The Journal of Neuroscience</source><volume>36</volume><fpage>10230</fpage><lpage>10238</lpage><pub-id pub-id-type="doi">10.1523/JNEUROSCI.1712-16.2016</pub-id><pub-id pub-id-type="pmid">27707960</pub-id></element-citation></ref><ref id="bib129"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zou</surname> <given-names>S</given-names></name><name><surname>Kumar</surname> <given-names>U</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Cannabinoid receptors and the endocannabinoid system: signaling and function in the central nervous system</article-title><source>International Journal of Molecular Sciences</source><volume>19</volume><elocation-id>833</elocation-id><pub-id pub-id-type="doi">10.3390/ijms19030833</pub-id></element-citation></ref></ref-list></back><sub-article article-type="decision-letter" id="sa1"><front-stub><article-id pub-id-type="doi">10.7554/eLife.54812.sa1</article-id><title-group><article-title>Decision letter</article-title></title-group><contrib-group><contrib contrib-type="editor"><name><surname>Westbrook</surname><given-names>Gary L</given-names></name><role>Reviewing Editor</role><aff><institution>Oregon Health and Science University</institution><country>United States</country></aff></contrib></contrib-group><contrib-group><contrib contrib-type="reviewer"><name><surname>Schuman</surname><given-names>Erin M</given-names></name><role>Reviewer</role><aff><institution>Max Planck Institute for Brain Research</institution><country>Germany</country></aff></contrib></contrib-group></front-stub><body><boxed-text><p>In the interests of transparency, eLife publishes the most substantive revision requests and the accompanying author responses.</p></boxed-text><p><bold>Acceptance summary:</bold></p><p>This study reveals structural plasticity of presynaptic terminal bouton sizes and underlying molecular mechanisms for endocannabinoid induced long-term depression of inhibitory synapses (iLTD) in the hippocampus. The results establish that the well-described postsynaptic plasticity-related spine growth/shrinkage can also exist in presynaptic compartments in presynaptic forms of plasticity and provide insights into this relatively less understood aspect of synaptic plasticity.</p><p><bold>Decision letter after peer review:</bold></p><p>Thank you for submitting your article &quot;CB<sub>1</sub> receptor-mediated inhibitory LTD triggers presynaptic remodeling via protein synthesis and ubiquitination&quot; for consideration by <italic>eLife</italic>. Your article has been reviewed by three peer reviewers, and the evaluation has been overseen by a Reviewing Editor and Gary Westbrook as the Senior Editor. The following individual involved in review of your submission has agreed to reveal their identity: Erin M Schuman (Reviewer #1).</p><p>The reviewers have discussed the reviews with one another and the Reviewing Editor has drafted this decision to help you prepare a revised submission.</p><p>The reviewers were positive about the manuscript but had a robust discussion of points that they though required additional input. The summary includes the main points that arose in the discussion. The original reviews follow. Please address both the summary and the reviews in your revised manuscript.</p><p>Summary of reviewer discussion:</p><p>1) Immunostaining for the CB<sub>1</sub> receptor was used as a proxy for terminal size. This could be OK, but the bouton volume data should be checked critically. For example, the shrinkage of the terminal as measured by Bassoon is smaller than that measured by CB<sub>1</sub>. The authors use an agonist of CB<sub>1</sub> throughout the paper – this will certainly change the configuration of the receptor (dimerization, clustering, internalization) that could artificially inflate the shrinkage they claim. This point should be discussed.</p><p>2) The MS data needs the tolerance value and stats. The link between the requirement for ubiquitination and protein synthesis is not as strong as it could be. The authors could add experimental data or should at least include a working model in their discussion addressing such questions as: Are both required? Do they operate in parallel or is new synthesis needed for ubiquitination?</p><p>3) Drug alone controls are missing for several conditions, particularly CHX and JSK.</p><p>4) The conclusions RE Rac and Arp need to be modified because the cellular site of action is not established in this study. The manipulations are pharmacological, and although the narrative and proteomics wants us to think about a pre-terminal action, one could imagine postsynaptic effects as these proteins are well-known for postsynaptic roles. The authors need to modify their conclusions or use tools that exist to cell specifically manipulate these proteins and establish the site of action.</p><p><italic>Reviewer #1:</italic></p><p>This manuscript explores a functional role for presynaptic protein synthesis in modulating structural plasticity of inhibitory presynaptic boutons during LTD. The authors provide data for protein synthesis dependent shrinkage of CB<sub>1</sub>+ boutons during endocannabinoid mediated LTD. Using proteomics, they identify 33 upregulated and 27 downregulated proteins during LTD. They narrow in and explore a role for actin remodeling during LTD, focusing on the role of Rac1 and Arp2/3, specifically the downregulation of both, for the manifestation of CB<sub>1</sub>+ boutons shrinkage. Lastly, they argue that while proteasomal degradation is induced during LTD, only the ubiquitination itself is important for the structural and functional manifestation of LTD.</p><p>The data presented on presynaptic structural plasticity are exciting but there are missing key control experiments and validations – as indicated below.</p><p>Figure 1:</p><p>While the detailed description of the analysis of the boutons was appreciated, the data presented in 1C are not convincing in their present state. The authors provide no controls to ensure that it's not endocytosis/remodeling of the CB<sub>1</sub> receptors themselves, which would also result in a decreased CB<sub>1</sub> volume. Additional inhibitory presynaptic markers (such as VGAT) should also be assessed and scored. Given the strict cutoffs the authors use in the analysis (ie sphericity value within the Imaris analysis), it could be that they're simply detecting a subset of smaller CB<sub>1</sub> puncta resulting from local changes in the receptor pool; while the boutons themselves remain largely unchanged. The use of this CB<sub>1</sub> volumetric analysis through the paper is problematic, as in almost all cases the authors do not test the effects of the pharmacological treatment alone (CHX, JSK, CK-666, NSC and ziram). Most if not all of the conclusions could be substantially undercut if these treatments in control conditions show the same change as when paired with WIN treatment. The study of structural plasticity in the postsynapse has largely relied on live cell imaging, so the compartment can be analyzed before, during and post treatment. While challenging, the authors should consider a similar approach, even if only to demonstrate their CB<sub>1</sub> volumetric approach is valid. Using either an inhibitory neuron restricted GFP expression or expression of a tagged inhibitory presynaptic protein to allow live imaging of the bouton volume before and after WIN application, the authors could the perform fixation and staining for CB<sub>1</sub> receptors and analyze how this compartment changed during the course of the treatments. This would bring their approach more in line with the standard in the field and allow for much more current and compelling analysis for structural plasticity to be performed.</p><p>Specific comments:</p><p>– Examples (similar as in 1A) should be provided of CB<sub>1</sub> boutons with WIN/WIN+CHX treatment.</p><p>– CHX treatment alone should be assessed for C.</p><p>– CHX and WIN+CHX should be assessed for D.</p><p>– Did the authors look at what happens to the corresponding inhibitory postsynaptic compartments? Presumably these also may decrease in size as well.</p><p>– For Figure 1—figure supplement 1C, the indicated mean for the WIN group for the graph provided should be checked. Given the large increase in the low volume population seen in the WIN group vs control group; and the similar size of the groups (540 vs 602) it's hard to understand how both means can be right around 1.</p><p>Figure 2:</p><p>The experimental design (multiplexing of fully medium-heavy and heavy labeled cell cultures) is nice, but there are several potential issues regarding data processing and interpretation.</p><p>Protein identification and quantification:</p><p>– The accepted parent mass tolerance of 50 PPM is very high and might lead to false identifications. When acquiring the data with an MS1 resolution of 60k on a well-calibrated Orbitrap LTQ instrument, a MS1 mass tolerance of ~5 PPM should be used.</p><p>– Why are the SILAC labels (Lys4/Arg6 and Lys8/Arg10) specified as variable modifications instead of “SILAC pairs”? Please describe in more detail how the medium-heavy and heavy counterparts were quantified and how the fold-changes were calculated. Were only peptides species considered that were quantified in the medium heavy and heavy form? Why not using software that provide well-established workflows for SILAC quantification (such as the freeware MaxQuant)?</p><p>– From Supplementary file 1, we understand that each ~700 proteins were identified in the forward and the reverse samples. The overlap between the two samples is 391 proteins (main text), indicating that the reproducibility is fairly low between the measurements.</p><p>Statistics:</p><p>– Please perform proper statistics to identify differentially regulated proteins (e.g. t-test and multiple testing correction). A simple fold-change cut-off (as described in Figure 2C) is not state-of-the-art.</p><p>Specific comments:</p><p>– The supplementary data should be improved to enable the reader to understand the proteomics data and inspect all quantified proteins. Please include one table that presents the quantitative results for all proteins in all biological replicates (forward and reverse), so that the reader can get a sense for the biological variability. Please include a column with gene names. In Supplementary file 1, why does the table contain proteins from <italic>rattus norvegicus</italic>, <italic>mus musculus</italic> and human?</p><p>– All mass spec raw data and database search results should be uploaded to the PRIDE repository prior to publication and the PRIDE identifier should be included in the Materials and methods section.</p><p>Data interpretation:</p><p>– Protein up-regulation is often interpreted as increased protein synthesis and protein down-regulation is often interpreted as increased degradation in the manuscript. However, based on the SILAC-MS data one cannot draw these conclusions. Protein up-regulation could result from more synthesis or less degradation and protein down-regulation could result from less synthesis or more degradation. Based on the presented data there is no evidence for one or the other.</p><p>– Based on the proteomics data one cannot distinguish proteins from different subcellular compartment or different cell types. The following statement from the Discussion sections is hence misleading: &quot;[…] why ribosomal proteins would be synthesized locally if ribosomes are exclusively assembled in the nucleolus is unclear.&quot;</p><p>Figure 3:</p><p>The authors refer to JSK as an &quot;actin stabilizing drug&quot;, whereas in fact it's a drug that promotes actin polymerization. This fact complicates the data presented in this figure as essential controls (such as JSK treatment alone for 3A) are missing. If JSK treatment alone increases the bouton size, is this really demonstrating that the structural remodeling requires actin depolymerization?</p><p>Specific comments:</p><p>– 3A, the examples provided with the black background are harder to examine. The authors should use the white background used in Figure 1 and Figure 1—figure supplement 1 examples.</p><p>– 3B, what explanation do the authors have for why the +JSK/WIN treated curve stabilizes around 80%?</p><p>– Additionally, the authors should test the effect of the Arp2/3 inhibitor and Rac inhibitor with and without WIN treatment on the bouton volume.</p><p>Figure 5:</p><p>Specific comments</p><p>– 5D, examples would be better with white backgrounds.</p><p>– Analysis for the effect of ziram alone needs to be done.</p><p><italic>Reviewer #2:</italic></p><p>In this study by Monday and colleagues, the investigators reveal structural plasticity of presynaptic terminal bouton sizes and underlying molecular mechanisms for iLTD, a form of endocannabinoid induced long-term depression of inhibitory synapses. Their discovery establishes that the well-described post-synaptic phenomenon of spine growth/shrinkage with plasticity can also exist in presynaptic compartments in presynaptic forms of plasticity. This finding is demonstrated by volumetric bouton measurements of CB<sub>1</sub>+ terminals in hippocampal slices. The remainder of the study involves a series of elegantly and rigorously designed experiments to provide insights to the molecular mechanisms for this structural plasticity. Insights begin with a proteomic analysis performed on cultured hippocampal neurons, and then use pharmacology and Western analysis to test a main hypothesis that changes in the abundance and activity of actin regulators underlie the structural plasticity. The study continues to reveal that despite their hypothesis that proteasomal degradation could drive those shifts, experiments instead support the idea that ubiquitination, in the absence of degradation (assessed by MG-132) appears to underlie the functional differences required for iLTD.</p><p>Overall, this study provides an important extension to the Castillo lab's recent work demonstrating the requirement for local protein synthesis for this form of plasticity (Younts et al., 2016). Strengths of this study include the mechanistic depth, general rigor in approaches, and novel insights to a relatively less understood aspect of synaptic plasticity.</p><p>I have two major concerns that should be addressed.</p><p>1) Boutons simply should not be considered individual n's for statistics. The authors are welcome to argue for what the independent biological unit is. Please also clarify, for a given condition (such as Veh or WIN), were slices from the same animal used for multiple conditions, or were the slices from one animal used for one condition at a time? If the latter, then an animal is the biological unit, with the possibility of using nested data statistical approaches. Alternatively, the mean value/slice could be considered. Issues such as animal health, temperature fluctuations, buffer osmolarity et cetera could otherwise exist and generate 100s of values per slice that are a little bigger or smaller due to technical variables. This is a foundational observation for the study and needs to be robust. As presented, it looks small and only visible when n's are in the 1000s. Likewise, although it was good to consider involvement of other inhibitory synapses (like PV<sup>+</sup>), a figure showing no significant difference that is potentially grossly underpowered is not so useful (n's of 500).</p><p>2) In general, the bioinformatics approach was rigorously and thoroughly presented. It is also nice that the authors further discuss results from other programs. One item to clarify – since the GO analyses are the major data presented: please review and clarify the extent to which the <italic>same</italic> protein is annotated with multiple functional properties such that it is populating (and driving) multiple terms on those lists.</p><p><italic>Reviewer #3:</italic></p><p>In this manuscript the authors show that CB<sub>1</sub>-LTD involves presynaptic structural plasticity: bouton volumes are reduced, which occurs at least partially via actin reorganization.</p><p>Mass spec data showed results that may have been expected (downregulation of synaptic proteins), but also some unexpected results were found (upregulation of protein synthesis as well as protein degradation system). Finally, the authors show that activation of the ubiquitination system is required for CB<sub>1</sub>-LTD, however not by promoting protein degradation by the proteasome.</p><p>The manuscript contains an interesting data set and the involvement of the ubiquitination system in CB<sub>1</sub>-LTD is highly intriguing. However, after reading the manuscript there are many “lose ends”, and it is still not clear what happens during CB<sub>1</sub>-LTD. Indeed, the authors themselves describe these events as “coordinated engagement of multiple cellular processes”, which does not clarify much. I would like to encourage the authors to try and formulate a more complete hypothesis of the cellular events that underlie CB<sub>1</sub>-LTD.</p><p>I have two major points:</p><p>1) It is not easy to link the proteomics findings to changes in the actin cytoskeleton in presynaptic boutons. For instance, the authors show that WIN slightly reduces Arp2c protein levels, but that inactivating Arp2/3 actually enhances CB<sub>1</sub>-LTD. I am wondering if the explanation given by the authors the most plausible interpretation of the data. Is it known how CB<sub>1</sub>-LTD is expressed (fewer vesicles? reduced release probability?) and is it possible to link this to specific changes in the actin cytoskeleton?</p><p>2) The proteomics data show that multiple processes are activated during CB<sub>1</sub>-LTD. The manuscript does not provide a model or hypothesis for how these processes are linked. For instance, are ubiquitination and protein synthesis independently regulated by CB<sub>1</sub>? What is the link between ubiquitination and presynaptic actin remodeling? Would it be possible to link CB<sub>1</sub>-LTD to a specific E2 or E3 ligase in the presynapse?</p><p>[Editors' note: further revisions were suggested prior to acceptance, as described below.]</p><p>Thank you for submitting your revised article &quot; CB<sub>1</sub> receptor-mediated inhibitory LTD triggers presynaptic remodeling via protein synthesis and ubiquitination&quot; to <italic>eLife</italic>. Your article has been reviewed by three peer reviewers, and the evaluation has been overseen by Gary Westbrook as the Senior Editor. The following individuals involved in review of your submission have agreed to reveal their identity: Erin M Schuman (Reviewer #1).</p><p>The reviewers have discussed the reviews with one another and the Senior Editor. There are some remaining concerns raised by one of the reviewers and by me that we would like you to address as below. These are concerns about the data presentation as embodied in comment 1 of reviewer 2 in the original review. The issue concerns what constitutes &quot;n&quot; in the bouton counts. We suggest a compromise in which supplemental data are shown by slice for full data transparency. Overall, we suspect that artifact is not the basis of the findings, but the data presentation does not allow that assessment and therefore lowers the rigor and potential reproducibility.</p><p>Requested revisions</p><p>1) The authors in their rebuttal argue that standard power calculations are &quot;unreasonable&quot; because n of 145 slices would be required. At the most fundamental level, if this were true, this question and conclusion are not appropriate given the constraints of the methodology and one should focus on powerable questions. However, a statistical analysis by a statistician might indicate other analytical approaches. The authors show how close to being powered they may be with the slice means alone (not including nesting) showing significance. If the authors want to show the data as is in the main figure, the authors could address this concern by creating supplemental figures that show bouton size distributions for each slice and also figures with slice means and exact p values.</p><p>2) Bassoon puncta were to serve as an independent measure of bouton size to support the CB<sub>1</sub> observations. However, the methods describe first making a binary mask of CB<sub>1</sub> signal, then using the &quot;and&quot; function to isolate the bassoon pixels that overlap with CB<sub>1</sub> pixels. As described, it is almost impossible to reach any other conclusion than reproducing the CB<sub>1</sub> measurement results. Please clarify methods substantially to remove this concern.</p><p>3) In working to propose a solution for data presentation, the authors raise an important point, supplemental data should include an analysis that addresses whether the plasticity effects preferentially involve a particular size subset, smaller or large.</p><p>[Editors' note: further revisions were suggested prior to acceptance, as described below.]</p><p>Thank you for submitting your article &quot; CB<sub>1</sub> receptor-mediated inhibitory LTD triggers presynaptic remodeling via protein synthesis and ubiquitination&quot; for consideration by <italic>eLife</italic>. Your article has been reviewed by one peer reviewer, and the evaluation has been overseen by Gary Westbrook as the Senior Editor. Before final acceptance, please edit the text and Materials and methods to indicate your response to the final reviewer comments as below. I would appreciate it if you indicate in the text where the revisions have been made. The final submission will not go back to the reviewers.</p><p>We would like to draw your attention to changes in our revision policy that we have made in response to COVID-19 (https://elifesciences.org/articles/57162). Specifically, we are asking editors to accept without delay manuscripts, like yours, that they judge can stand as <italic>eLife</italic> papers without additional data, even if they feel that they would make the manuscript stronger. Thus the revisions requested below only address clarity and presentation.</p><p>Reviewer #2:</p><p>1) The supplementary figures are highly appreciated and allow critical review of the nature of the experimental data and robustness of the conclusions.</p><p>2) The authors' response indicating that data was removed to balance slice numbers needs to be clarified. One should not have to remove data. If slices were removed from supplementary figure analyses, what guided those decisions? Do the removed slices remain in the main figure data? I would suggest all the data that were believed to be valid in the original submission be included in the main and supplementary figures. (Or was there a situation of grossly unequal n's in the control/win condition and the authors are trying to make statistical comparisons across similarly sized groups post hoc? In principle, a similar number of interleaved controls should exist for each additional test condition.) Please clarify.</p></body></sub-article><sub-article article-type="reply" id="sa2"><front-stub><article-id pub-id-type="doi">10.7554/eLife.54812.sa2</article-id><title-group><article-title>Author response</article-title></title-group></front-stub><body><disp-quote content-type="editor-comment"><p>Summary of reviewer discussion:</p><p>1) Immunostaining for the CB<sub>1</sub> receptor was used as a proxy for terminal size. This could be OK, but the bouton volume data should be checked critically. For example, the shrinkage of the terminal as measured by Bassoon is smaller than that measured by CB<sub>1</sub>. The authors use an agonist of CB<sub>1</sub> throughout the paper – this will certainly change the configuration of the receptor (dimerization, clustering, internalization) that could artificially inflate the shrinkage they claim. This point should be discussed.</p></disp-quote><p>The bouton volume and active zone data has been thoroughly checked. We have addressed the reviewers concerns about using CB<sub>1</sub> as a proxy for bouton volume in the following ways: 1. While CB<sub>1</sub> internalization has been reported, it does not require protein synthesis, so the fact that we see a blockade of the structural change with cycloheximide would suggest we are measuring a change in volume, not internalization of CB<sub>1</sub>. 2. Based on previous work, it seems unlikely that our protocol would cause significant redistribution of CB<sub>1</sub> (Dudok et al., 2015; Thibault et al., 2013). In particular, the very high density of CB<sub>1</sub> on interneuron boutons makes it such that even a partial shift of CB<sub>1</sub> to endosomes would not affect the labeling of the bouton membrane (Thibault et al., 2013). 3. We have quantified the colocalization of CB<sub>1</sub> and endosomal marker, Rab7 (Feng et al., 1995), a way of estimating internalized CB<sub>1</sub> (Howlett et al., 2010), which was not significantly altered by CB<sub>1</sub>-iLTD induction (see <xref ref-type="fig" rid="sa2fig1">Author response image 1</xref> in response to reviewer 1 below) 4. We do not anticipate that clustering or dimerization could artificially inflate the shrinkage because these processes would not necessarily pull receptors towards the bouton centerpoint, but would more likely stochastically change the distribution of CB<sub>1</sub> on the surface of the membrane which, given our 3D analysis, would still provide an accurate measure of the bouton volume. Moreover, dimerization/clustering should not be sensitive to protein synthesis inhibition. 5. Finally, and as suggested by reviewer 1, we have added new data demonstrating that VGAT, an additional CB<sub>1</sub>-independent marker of inhibitory boutons, is also robustly reduced by CB<sub>1</sub> (Figure 1—figure supplement 1E). 6. Lastly, we have now added a thorough discussion of the research that exists on CB<sub>1</sub> internalization.</p><p>In addition, as requested, we have added new data in which we analyzed the Bassoon size following cycloheximide treatment (See Figure 1F). In this dataset, which now includes more “n’s”, the magnitude of the reduction in active zone size following WIN treatment is similar to that measured with CB<sub>1</sub>. However, it is not clear whether all components of the presynaptic bouton shrink proportionately. For example, we see a fairly large change in VGAT volume, consistent with previous reports of short-term CB<sub>1</sub> activation-induced vesicle redistribution and changes in numbers of docked/primed vesicles (Garcia-Morales et al., 2015; Ramirez-Franco et al., 2014).</p><disp-quote content-type="editor-comment"><p>2) The MS data needs the tolerance value and stats. The link between the requirement for ubiquitination and protein synthesis is not as strong as it could be. The authors could add experimental data or should at least include a working model in their discussion addressing such questions as: Are both required? Do they operate in parallel or is new synthesis needed for ubiquitination?</p></disp-quote><p>In response, we now include the tolerance value (added in Materials and methods section) and results of statistical comparison between vehicle and treatment conditions. We have also included our proposed model for the molecular mechanisms underlying CB<sub>1</sub>-iLTD (Figure 5E). Our data demonstrate that CB<sub>1</sub> activation triggers protein synthesis, protein degradation and structural changes. Our SILAC data clearly show an increase in several proteins that are involved in proteasomal function, suggesting that protein synthesis is upstream of protein degradation, and not in parallel.</p><disp-quote content-type="editor-comment"><p>3) Drug alone controls are missing for several conditions, particularly CHX and JSK</p></disp-quote><p>The drug alone controls have now been included for CHX and JSK (Figure 1—figure supplement 1A, Figure 1E, 3A) and also for ziram (Figure 5D).</p><disp-quote content-type="editor-comment"><p>4) The conclusions RE Rac and Arp need to be modified because the cellular site of action is not established in this study. The manipulations are pharmacological, and although the narrative and proteomics wants us to think about a pre-terminal action, one could imagine postsynaptic effects as these proteins are well-known for postsynaptic roles. The authors need to modify their conclusions or use tools that exist to cell specifically manipulate these proteins and establish the site of action.</p></disp-quote><p>The model of the mechanism of action of Rac1 and Arp2/3 has been modified (Figure 3G) to reflect this criticism. We have also modified the Discussion to acknowledge that these drugs may not only be acting presynaptically. While these proteins have been well studied postsynaptically, they also have established roles in presynaptic function (Gokhale et al., 2016; Njoo et al., 2015; Roesler et al., 2019). Given that our induction protocol relies only on presynaptic receptor activation (e.g. CB<sub>1</sub> receptors are expressed at GABAergic terminals but not CA1 pyramidal neurons), which triggers a presynaptic structural change that relies on actin dynamics, a presynaptic target is the most likely explanation for our findings.</p><disp-quote content-type="editor-comment"><p>Reviewer #1:</p><p>[…]</p><p>Figure 1:</p><p>While the detailed description of the analysis of the boutons was appreciated, the data presented in 1C are not convincing in their present state. The authors provide no controls to ensure that it's not endocytosis/remodeling of the CB<sub>1</sub> receptors themselves, which would also result in a decreased CB<sub>1</sub> volume. Additional inhibitory presynaptic markers (such as VGAT) should also be assessed and scored. Given the strict cutoffs the authors use in the analysis (ie sphericity value within the Imaris analysis), it could be that they're simply detecting a subset of smaller CB<sub>1</sub> puncta resulting from local changes in the receptor pool; while the boutons themselves remain largely unchanged. The use of this CB<sub>1</sub> volumetric analysis through the paper is problematic, as in almost all cases the authors do not test the effects of the pharmacological treatment alone (CHX, JSK, CK-666, NSC and ziram). Most if not all of the conclusions could be substantially undercut if these treatments in control conditions show the same change as when paired with WIN treatment. The study of structural plasticity in the postsynapse has largely relied on live cell imaging, so the compartment can be analyzed before, during and post treatment. While challenging, the authors should consider a similar approach, even if only to demonstrate their CB<sub>1</sub> volumetric approach is valid. Using either an inhibitory neuron restricted GFP expression or expression of a tagged inhibitory presynaptic protein to allow live imaging of the bouton volume before and after WIN application, the authors could the perform fixation and staining for CB<sub>1</sub> receptors and analyze how this compartment changed during the course of the treatments. This would bring their approach more in line with the standard in the field and allow for much more current and compelling analysis for structural plasticity to be performed.</p></disp-quote><p>We thank the reviewer for her constructive criticism.</p><p>Protein synthesis inhibition blocks the change in bouton volume, whereas receptor internalization or dimerization is not dependent on protein synthesis. The parameters used in Imaris include a lower size limit which was meant to exclude small CB<sub>1</sub> puncta. Our experiment measuring Bassoon labeling within CB<sub>1</sub>+ boutons was designed as a control that is independent of changes in CB<sub>1</sub>. We have now also added data demonstrating that VGAT labeling is also reduced by CB<sub>1</sub>-iLTD induction (Figure 1—figure supplement 1E).</p><p>In response to concerns about internalization, we have performed an experiment to compare the subpopulation of CB<sub>1</sub> receptors that colocalize with endosomal marker Rab7, following CB<sub>1</sub>-iLTD induction which showed no increase in CB<sub>1</sub> internalization with WIN.</p><fig id="sa2fig1"><label>Author response image 1.</label><caption><title>Left, Airyscan confocal images of Rab7/CB<sub>1</sub> labeling.</title><p>Right, % overlap of CB<sub>1</sub> and Rab7 within CB<sub>1</sub>+ boutons was not significantly altered by 25 min WIN treatment when quantified as average per field of view nor by animal. CTRL: 0.09 ± 0.01 v. WIN : 0.06 ± 0.004, U = 18111; Z = 0.746, n.s. indicates p &gt; 0.05; Mann-Whitney. n = number of fields of view (3 images/ slice, 1 slices/rat, 5 rats/CTRL, 4 rats/WIN). Data are presented as box plots (left) and data points (right) where box represents the 25th and 75th percentile of data range, mean is represented with a square, and median with a line inside the box.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-54812-resp-fig1-v2.tif"/></fig><p>In addition, we have added an in-depth discussion wherein we argue that it is very unlikely that receptor internalization and degradation could account for our findings.</p><p>We performed all drug only controls with JSK, CHX, and ziram alone and found they have no effect on basal bouton volume.</p><p>We attempted using CCK-Cre mice to test the viability of a Cre-dependent viral strategy to label CB<sub>1</sub> interneurons with GFP, but we found this line to be leaky in excitatory neurons and we struggled to resolve boutons clearly given the background in the acute slices with 2-photon laser microscopy. We then attempted live imaging strategies with this interneuron population, by patch-loading CB<sub>1</sub>+ interneurons with morphological dyes as we did previously (Younts et al., 2016). Unfortunately, in our hands, the tiny caliber of the axon restricts dye loading and is difficult to resolve with the 2P to the extent needed to detect small changes in bouton volume.</p><disp-quote content-type="editor-comment"><p>Specific comments:</p><p>– Examples (similar as in 1A) should be provided of CB<sub>1</sub> boutons with WIN/WIN+CHX treatment.</p></disp-quote><p>We have now added representative boutons for WIN and WIN + CHX and additional widefield images in supplemental information to illustrate the boutons selected.</p><disp-quote content-type="editor-comment"><p>– CHX treatment alone should be assessed for C.</p></disp-quote><p>See Figure 1—figure supplement 1A</p><disp-quote content-type="editor-comment"><p>– CHX and WIN+CHX should be assessed for D.</p></disp-quote><p>See new Figure 1F</p><disp-quote content-type="editor-comment"><p>– Did the authors look at what happens to the corresponding inhibitory postsynaptic compartments? Presumably these also may decrease in size as well.</p></disp-quote><p>This is a very interesting question. Given that there are multiple reports of concurrent presynaptic changes resulting from postsynaptically-expressed forms of plasticity, we agree that there may be postsynaptic changes resulting from presynaptic plasticity. Testing this possibility is not straightforward given that inhibitory synapses mainly occur directly on the dendritic shaft, or in this case, on the cell soma, which makes structural analysis very difficult. In any event, we feel this issue is beyond the scope of our paper.</p><disp-quote content-type="editor-comment"><p>– For Figure 1—figure supplement 1C, the indicated mean for the WIN group for the graph provided should be checked. Given the large increase in the low volume population seen in the WIN group vs control group; and the similar size of the groups (540 vs 602) it's hard to understand how both means can be right around 1.</p></disp-quote><p>We have now added an additional technical replicate to this dataset (Figure 1—figure supplement 1C). Even with the addition of more “n”, there is still no significant difference between control and WIN-treated slices. We admit that while it appeared that the distributions were different in the previous dataset, we carefully rechecked the graph, and the means were accurate. We think that the population of larger boutons was also increased in the WIN group, but this was more difficult to detect by eye.</p><disp-quote content-type="editor-comment"><p>Figure 2:</p><p>The experimental design (multiplexing of fully medium-heavy and heavy labeled cell cultures) is nice, but there are several potential issues regarding data processing and interpretation.</p><p>Protein identification and quantification</p><p>– The accepted parent mass tolerance of 50 PPM is very high and might lead to false identifications. When acquiring the data with an MS1 resolution of 60k on a well-calibrated Orbitrap LTQ instrument, a MS1 mass tolerance of ~5 PPM should be used.</p></disp-quote><p>The instrument error during acquisition was ± 15 PPM and was collected prior to calibrating the mass spectrometer. Though the precursor tolerance was ± 50 PPM the false discovery rate was adjusted to below 1% at the protein and peptide levels. The MS/MS of a large sampling of proteins were validated manually as well.</p><disp-quote content-type="editor-comment"><p>– Why are the SILAC labels (Lys4/Arg6 and Lys8/Arg10) specified as variable modifications instead of “SILAC pairs”? Please describe in more detail how the medium-heavy and heavy counterparts were quantified and how the fold-changes were calculated. Were only peptides species considered that were quantified in the medium heavy and heavy form? Why not using software that provide well-established workflows for SILAC quantification (such as the freeware MaxQuant)?</p></disp-quote><p>In Mascot the Quantitation Method (SILAC K+4 K+8 R+6 R+10) was used with each SILAC modification in exclusive mode. The raw data files were first processed using precursor ion quantitation of the Quantitation toolbox of Mascot Distiller (Matrix Science Ltd; version 2.7). Mascot was then used to search the rat databases (SwissProt and NCBI nr along with a decoy database to obtain FDRs) using the following parameters: trypsin; product ion mass tolerance of 0.40 Da; precursor ion tolerance of 50 PPM; carbamidomethyl Cys – fixed modification and variable modifications of: deamidated Asn and Gln; label:2H(4) of Lys; label:13C(6) of Arg; label:13C(6)15N(2) of Lys; label:13C(6)15N(4) of Arg and oxidation of Met. The result files obtained from Distiller and the Mascot searches were then uploaded to Scaffold Q+S (Proteome Software Inc.; version 4.9) using between-subjects, log<sub>2</sub> ratio-based analysis of unique peptides against a reference to obtain the protein’s mean quantitative values and t-test p-values with Benjamini-Hochberg correction.</p><disp-quote content-type="editor-comment"><p>– From Supplementary file 1, we understand that each ~700 proteins were identified in the forward and the reverse samples. The overlap between the two samples is 391 proteins (main text), indicating that the reproducibility is fairly low between the measurements.</p><p>Statistics</p></disp-quote><p>We thank the reviewer for pointing out the inconsistency. After careful re-examination of our results, we identified a misprint in the initial version of the manuscript that has now been corrected. The quantitation software Scaffold gives the Mascot search results showing 68% overlap (see Venn diagram in <xref ref-type="fig" rid="sa2fig2">Author response image 2</xref>) which is quite good for MS/MS: 754 Proteins at 99.0% Minimum, 0.1% Decoy FDR with 2 unique peptides; 84,231 Spectra at 95.0% Minimum and 0.35% Decoy FDR. We have also updated Supplementary file 1 and Figure 2—figure supplement 1C accordingly.</p><fig id="sa2fig2"><label>Author response image 2.</label><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-54812-resp-fig2-v2.tif"/></fig><disp-quote content-type="editor-comment"><p>– Please perform proper statistics to identify differentially regulated proteins (e.g. t-test and multiple testing correction). A simple fold-change cut-off (as described in Figure 2C) is not state-of-the-art.</p></disp-quote><p>We have now performed a new analysis of the dataset using statistical testing and multiple test correction (Benjamini-Hochberg) following the reviewer’s recommendation. We identified a total of 99 differentially expressed proteins (43 upregulated and 56 downregulated). Results of the analysis have been included in a volcano plot in Figure 2D as well as in Supplementary file 1.</p><disp-quote content-type="editor-comment"><p>Specific comments:</p><p>– The supplementary data should be improved to enable the reader to understand the proteomics data and inspect all quantified proteins. Please include one table that presents the quantitative results for all proteins in all biological replicates (forward and reverse), so that the reader can get a sense for the biological variability. Please include a column with gene names. In Supplementary file 1, why does the table contain proteins from <italic>rattus norvegicus</italic>, <italic>mus musculus</italic> and human?</p></disp-quote><p>We have now edited the Supplementary file 1 following the reviewer’s request to include values for all biological replicates, gene name. The initial table had not been properly filtered by species. However, all analysis was conducted on filtered data from exclusively <italic>Rattus norvegicus</italic> proteins, and the table has been updated to reflect this.</p><disp-quote content-type="editor-comment"><p>– All mass spec raw data and database search results should be uploaded to the PRIDE repository prior to publication and the PRIDE identifier should be included in the Materials and methods section.</p></disp-quote><p>The mass spectrometry proteomics data have been deposited to the ProteomeX change with identifier Consortium via the PRIDE [1] partner repository with the dataset identifier PXD020008 and 10.6019/PXD020008.</p><disp-quote content-type="editor-comment"><p>Data interpretation:</p><p>– Protein up-regulation is often interpreted as increased protein synthesis and protein down-regulation is often interpreted as increased degradation in the manuscript. However, based on the SILAC-MS data one cannot draw these conclusions. Protein up-regulation could result from more synthesis or less degradation and protein down-regulation could result from less synthesis or more degradation. Based on the presented data there is no evidence for one or the other.</p></disp-quote><p>The reviewer is correct that changes in protein levels could result from more or less synthesis/degradation and that these cannot be disentangled at the level of the SILAC-MS. We have now edited the manuscript to reflect this point. We do, however, provide evidence that ubiquitin-proteasome system activity and the degradation of ubiquitinated proteins is enhanced by CB<sub>1</sub> activation in hippocampal slices (Figure 5A). Moreover, cycloheximide treatment blocks the reduction in bouton volume suggesting that protein synthesis is required.</p><disp-quote content-type="editor-comment"><p>– Based on the proteomics data one cannot distinguish proteins from different subcellular compartment or different cell types. The following statement from the Discussion sections is hence misleading: &quot;[…] why ribosomal proteins would be synthesized locally if ribosomes are exclusively assembled in the nucleolus is unclear.&quot;</p></disp-quote><p>We have now removed this statement so as not to mislead the reader. We also clearly state in the Discussion that our results reflect protein isolated from whole neurons.</p><disp-quote content-type="editor-comment"><p>Figure 3:</p><p>The authors refer to JSK as an &quot;actin stabilizing drug&quot;, whereas in fact it's a drug that promotes actin polymerization. This fact complicates the data presented in this figure as essential controls (such as JSK treatment alone for 3A) are missing. If JSK treatment alone increases the bouton size, is this really demonstrating that the structural remodeling requires actin depolymerization?</p></disp-quote><p>New results indicate that JSK alone had no effect on the structure of boutons on its own (Figure 3A) suggesting that the blockade of structural change we see with WIN + JSK is due to the drug preventing an <italic>activity-dependent</italic> remodeling process. While some in vitro data supports the notion that JSK promotes actin nucleation, the effect of JSK is highly dependent on the presence of monomeric actin, other actin binding proteins, and the concentration and duration of JSK exposure (Bubb et al., 2000). There is also evidence for a paradoxical decrease in the amount of F-actin with JSK in some parts of the cell wherein actin remodeling was prevented via a sequestration of monomeric actin (Bubb et al., 2000; Spector et al., 1999). Overall, the net effect of JSK may be hard to predict, but all reports agree that it interferes with the normal polymerization of actin. For this reason and since we cannot measure exact F- or G-actin levels at these particular boutons, we have modified our conclusions with JSK accordingly to indicate only that CB<sub>1</sub>-iLTD relies on “actin dynamics” and not polymerization specifically.</p><disp-quote content-type="editor-comment"><p>Specific comments:</p><p>– 3A, the examples provided with the black background are harder to examine. The authors should use the white background used in Figure 1 and Figure 1—figure supplement 1 examples.</p></disp-quote><p>Good suggestion; thank you. We have now made these changes.</p><disp-quote content-type="editor-comment"><p>– 3B, what explanation do the authors have for why the +JSK/WIN treated curve stabilizes around 80%?</p></disp-quote><p>We do not know but can speculate on two possibilities. The most likely explanation is that the mechanism of iLTD may rely only partially on the stabilization of filamentous actin. This is somewhat borne out by the structural data which is also not completely restored to baseline and may be due to the additional requirement of Arp2/3 or other actin binding proteins in iLTD. Alternatively, this could be a result of incomplete stabilization of actin polymers due to the inability of the drug to permeate deep enough into the tissue or other changes associated with JSK treatment such as sequestration of monomeric actin (discussed in more detail above).</p><disp-quote content-type="editor-comment"><p>– Additionally, the authors should test the effect of the Arp2/3 inhibitor and Rac inhibitor with and without WIN treatment on the bouton volume.</p></disp-quote><p>We attempted to perform this experiment but were interrupted by the COVID-19-related shutdown of the lab which resulted in the loss of the samples we had collected. Repeating these experiments involves a significant investment of time that is current magnified by the fact that our animal colonies, facilities, and laboratory access are all still operating at reduced capacity due to COVID-19 precautionary measures. However, given the strong correlation that is observed with all structural and functional manipulations (i.e. CHX, JSK, and ziram), our electrophysiology results with the Rac1 and Arp2/3 inhibitors strongly suggest concomitant structural changes or blockade thereof.</p><disp-quote content-type="editor-comment"><p>Figure 5:</p><p>Specific comments:</p><p>– 5D, examples would be better with white backgrounds.</p></disp-quote><p>We have now changed the representative boutons accordingly.</p><disp-quote content-type="editor-comment"><p>– Analysis for the effect of ziram alone needs to be done.</p></disp-quote><p>Agreed; please, see new Figure 5D.</p><disp-quote content-type="editor-comment"><p>Reviewer #2:</p><p>[…]</p><p>1) Boutons simply should not be considered individual n's for statistics. The authors are welcome to argue for what the independent biological unit is. Please also clarify, for a given condition (such as Veh or WIN), were slices from the same animal used for multiple conditions, or were the slices from one animal used for one condition at a time? If the latter, then an animal is the biological unit, with the possibility of using nested data statistical approaches. Alternatively, the mean value/slice could be considered. Issues such as animal health, temperature fluctuations, buffer osmolarity et cetera could otherwise exist and generate 100s of values per slice that are a little bigger or smaller due to technical variables. This is a foundational observation for the study and needs to be robust. As presented, it looks small and only visible when n's are in the 1000s. Likewise, although it was good to consider involvement of other inhibitory synapses (like PV<sup>+</sup>), a figure showing no significant difference that is potentially grossly underpowered is not so useful (n's of 500).</p></disp-quote><p>In these figures, we have used slices from the same rats for multiple conditions. We absolutely agree that slices are vulnerable to factors such as temperature fluctuations, changes in buffer osmolarity/oxygenation, etc. For this reason, each experiment and all conditions were performed at the same time on the same day with the same buffer using slices from the same animal. In order to further balance the conditions, slices were matched by location in the dorsalventral axis across the conditions. We also image at 3 specific locations in the CA1 pyramidal layer to tile the area between CA2 and subiculum. However, even with all these variables controlled for, it is still highly expected that boutons will not be uniform in size. We feel that the intrinsic variability in volume present in the population of boutons is biologically relevant and should be represented for the reader as has been previously reported (Dudok et al., 2015; Lees et al., 2019; Meyer et al., 2014). Moreover, while we fully acknowledge that the percent change we see in bouton volume is small, it is clear that small changes in the nervous system are no less functionally important. According to our power analysis, in order to achieve 80% power, given the standard deviation of bouton volume per slice was averaged at ~0.45, we would require 142 slices per group for an effect size of 10% (see <xref ref-type="fig" rid="sa2fig3">Author response image 3</xref>). Such a high number would be next to impossible to achieve with any standard animal protocol.</p><fig id="sa2fig3"><label>Author response image 3.</label><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-54812-resp-fig3-v2.tif"/></fig><p>As for the analysis of inhibitory synapses established by PV<sup>+</sup> neurons, we would anticipate a similar “n” is necessary to see a WIN-induced change and therefore n’s of 500 are well-within range. However, to make the power of the PV control experiment more comparable to those performed on CB<sub>1</sub>+ boutons we have now added additional “n” to this experiment. We still see the WIN treatment has no effect on PV bouton volume. We also should note that although all datasets presented in this paper represent multiple technical replicates pooled together, we routinely see the WIN induced shrinkage in each individual technical replicate with much lower ‘n’s and the WIN effect is evident if we average the bouton volume values from Figure 1C per slice (see <xref ref-type="fig" rid="sa2fig4">Author response image 4</xref>).</p><fig id="sa2fig4"><label>Author response image 4.</label><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-54812-resp-fig4-v2.tif"/></fig><disp-quote content-type="editor-comment"><p>2) In general, the bioinformatics approach was rigorously and thoroughly presented. It is also nice that the authors further discuss results from other programs. One item to clarify – since the GO analyses are the major data presented: please review and clarify the extent to which the same protein is annotated with multiple functional properties such that it is populating (and driving) multiple terms on those lists.</p></disp-quote><p>We agree with the reviewer regarding the annotation redundancy in Gene Ontology (GO) analysis. In order to overcome that issue, we have attempted a two-pronged approach: (i) we used several annotation tools (GSEA, IPA and SynGO) and (ii) we performed Enrichment map analysis of GSEA (Figure 2C). Here, each node represents a GO term and edges represent overlap between gene sets. This analysis highlighted 4 dense clusters (e.g. protein synthesis and processing, neuronal projections, energy metabolism and extracellular space). The observation of distinct clusters of enriched GO terms demonstrates the low overlap between gene-sets and confirms that the associated functional properties are populated by distinct gene-sets. Within a given cluster, there is indeed a higher level of similarity as indicated by the proximity between the nodes (see also Supplementary file 2).</p><disp-quote content-type="editor-comment"><p>Reviewer #3:</p><p>[…]</p><p>The manuscript contains an interesting data set and the involvement of the ubiquitination system in CB<sub>1</sub>-LTD is highly intriguing. However, after reading the manuscript there are many “lose ends”, and it is still not clear what happens during CB<sub>1</sub>-LTD. Indeed, the authors themselves describe these events as “coordinated engagement of multiple cellular processes”, which does not clarify much. I would like to encourage the authors to try and formulate a more complete hypothesis of the cellular events that underlie CB<sub>1</sub>-LTD.</p></disp-quote><p>We thank the reviewer for their comments about our study. To clarify our hypothesis of the molecular events that underlie CB<sub>1</sub>-LTD, we have now modified the text and summarized the molecular mechanisms underlying CB<sub>1</sub>-iLTD in a diagram (Figure 5E). Our SILAC data clearly show an increase in several proteins that are involved in proteasomal function, raising the possibility that protein synthesis is upstream of protein degradation, and not in parallel.</p><disp-quote content-type="editor-comment"><p>I have two major points:</p><p>1) It is not easy to link the proteomics findings to changes in the actin cytoskeleton in presynaptic boutons. For instance, the authors show that WIN slightly reduces Arp2c protein levels, but that inactivating Arp2/3 actually enhances CB<sub>1</sub>-LTD. I am wondering if the explanation given by the authors the most plausible interpretation of the data. Is it known how CB<sub>1</sub>-LTD is expressed (fewer vesicles? reduced release probability?) and is it possible to link this to specific changes in the actin cytoskeleton?</p></disp-quote><p>CB<sub>1</sub>-iLTD causes a reduction in neurotransmitter release, i.e. reduced release probability (Chevaleyre and Castillo, 2004; Heifets et al., 2008), however the mechanism(s) driving this phenomenon are, as yet, unknown. We have attempted to address this question here, but more work is still needed to understand the exact molecular pathways involved. Early research suggested the mechanism of CB<sub>1</sub>-iLTD might rely on dephosphorylation of the active zone protein RIM1α (Chevaleyre et al., 2007), but phosphorylation of RIM1α by PKA was later shown not to be involved (Kaeser et al., 2008). CB<sub>1</sub> receptor activation has also been suggested to control release via change in vesicular release mode (Aubrey et al., 2017) or change in the distribution of vesicles around the active zone (Garcia-Morales et al., 2015; Ramirez-Franco et al., 2014), but these studies were performed at different synapses that may not express the same form of CB<sub>1</sub>-iLTD. In general, it is well-established that the size of the presynaptic bouton and active zone is correlated with the postsynaptic response (Bartol et al., 2015; Bourne et al., 2013; Meyer et al., 2014). Here, we suggest that a smaller bouton and active zone in combination with ubiquitination and subsequent degradation of presynaptic release machinery proteins could explain the reduction in GABA release associated with iLTD.</p><p>The finding that Arp2/3 inactivation enhances CB<sub>1</sub>-iLTD may seem a bit counterintuitive but in fact fits well with literature demonstrating that loss of interaction between WASF1/WAVE1 and Arp2/3 causes a loss of functional presynapses (Wegner et al., 2008) and CB<sub>1</sub> activation drives growth cone collapse in a Rac1 dependent manner (Njoo et al., 2015) Our SILAC and WB data show that CB<sub>1</sub>-iLTD triggers loss of ARPC2 and WASF1/WAVE1 which functionally would have the effect of reducing neurotransmitter release (i.e. LTD). Presumably, when we apply CK-666 we are further reducing the pool of Arp2/3 available to participate in the maintenance of actin branches, on top of the Arp2/3 protein that is presumably being degraded, and that is why we see enhanced LTD (i.e. further reduction in neurotransmitter release).</p><disp-quote content-type="editor-comment"><p>2) The proteomics data show that multiple processes are activated during CB<sub>1</sub>-LTD. The manuscript does not provide a model or hypothesis for how these processes are linked. For instance, are ubiquitination and protein synthesis independently regulated by CB<sub>1</sub>? What is the link between ubiquitination and presynaptic actin remodeling? Would it be possible to link CB<sub>1</sub>-LTD to a specific E2 or E3 ligase in the presynapse?</p></disp-quote><p>We have now provided a proposed model in Figure 5E. Based on two pieces of data, the most likely scenario seems to be that protein synthesis triggered by CB<sub>1</sub> activation via mTOR (Younts et al., 2016) is upstream of ubiquitination and structural change. CB<sub>1</sub> activation triggers an upregulation of several proteasomal subunits and E2 ligases (Figure 2, 4), which suggests these components may be synthesized on demand to regulate protein degradation locally. While we cannot exclude that their upregulation comes from a reduction in their degradation, the long half-life of proteasomal subunits makes it unlikely that we could see such a strong increase from reduction in degradation alone in such a short time window (25 min)(Dorrbaum et al., 2018). Structural change requires protein synthesis. Our data suggests that CB<sub>1</sub> activation induces rapid reduction of ARPC2, WASF1/WAVE1 and other components of the WAVE regulatory complex (WRC), and that this pathway is required for iLTD. We propose that ubiquitination of these proteins underlies structural remodeling.</p><p>[Editors' note: further revisions were suggested prior to acceptance, as described below.]</p><disp-quote content-type="editor-comment"><p>Requested revisions:</p><p>1) The authors in their rebuttal argue that standard power calculations are &quot;unreasonable&quot; because n of 145 slices would be required. At the most fundamental level, if this were true, this question and conclusion are not appropriate given the constraints of the methodology and one should focus on powerable questions. However, a statistical analysis by a statistician might indicate other analytical approaches. The authors show how close to being powered they may be with the slice means alone (not including nesting) showing significance. If the authors want to show the data as is in the main figure, the authors could address this concern by creating supplemental figures that show bouton size distributions for each slice and also figures with slice means and exact p values.</p></disp-quote><p>Excellent point. In response, we have created new supplemental figures (Superplots) that show the bouton size distribution color-coded by slice with the slice means plotted on top and the overall mean of slices overlaid with a vertical line representing the 95% confidence interval (CI) to clearly represent the effect size (Lord et al., 2020). For these figures, we reanalyzed the data and balanced the number of slices/animals across conditions and performed one-way ANOVA with post hoc Tukey test for multiple comparisons. Exact p-values and confidence intervals are included in each supplemental figure legend. Importantly, our key observations were reproduced using slice as the independent variable.</p><disp-quote content-type="editor-comment"><p>2) Bassoon puncta were to serve as an independent measure of bouton size to support the CB<sub>1</sub> observations. However, the methods describe first making a binary mask of CB<sub>1</sub> signal, then using the &quot;and&quot; function to isolate the bassoon pixels that overlap with CB<sub>1</sub> pixels. As described, it is almost impossible to reach any other conclusion than reproducing the CB<sub>1</sub> measurement results. Please clarify methods substantially to remove this concern.</p></disp-quote><p>We apologize for the confusion. A dilated CB<sub>1</sub> mask was used to isolate Bassoon in the vicinity of and inside CB<sub>1</sub> boutons, the size of Bassoon is free to vary inside the presynaptic terminal since Bassoon labeling is considerably smaller than the CB<sub>1</sub> terminal volume (Average control volume of bassoon: ~ 0.51 μm<sup>3</sup> v. CB<sub>1</sub>: 1.85 μm<sup>3</sup>). We acknowledge the limitations of our method and have removed mentions of the CB<sub>1</sub>-independent nature of this measurement. Of note, our findings are consistent with a large body of previous work showing the active zone size is highly correlated to the overall presynaptic size (Matz et al., 2010; Maus et al., 2020; Meyer et al., 2014).</p><disp-quote content-type="editor-comment"><p>3) In working to propose a solution for data presentation, the authors raise an important point, supplemental data should include an analysis that addresses whether the plasticity effects preferentially involve a particular size subset, smaller or large.</p></disp-quote><p>We have now included a histogram showing binned bouton distribution per slice to address this question (Figure 1—figure supplement 1C). These data suggest that iLTD results in a reduction in the number of large boutons and an increase in the fraction of small boutons.</p><p>[Editors' note: further revisions were suggested prior to acceptance, as described below.]</p><disp-quote content-type="editor-comment"><p>Reviewer #2:</p><p>1) The supplementary figures are highly appreciated and allow critical review of the nature of the experimental data and robustness of the conclusions.</p><p>2) The authors' response indicating that data was removed to balance slice numbers needs to be clarified. One should not have to remove data. If slices were removed from supplementary figure analyses, what guided those decisions? Do the removed slices remain in the main figure data? I would suggest all the data that were believed to be valid in the original submission be included in the main and supplementary figures. (Or was there a situation of grossly unequal n's in the control/win condition and the authors' are trying to make statistical comparisons across similarly sized groups post hoc? In principle, a similar number of interleaved controls should exist for each additional test condition.) Please clarify.</p></disp-quote><p>We have made the requested clarification points in the manuscript. The reviewers suggested we include <italic>all</italic> slices and use “slice” as our independent variable. Following their advice, we went ahead and included plots showing average bouton volume per slices in the main figures (similar to the plots we included in our response to the reviewers) and kept the superplots in supplementary figures.</p><p><bold>References</bold></p><p>Bubb, M.R., Spector, I., Beyer, B.B., and Fosen, K.M. (2000). Effects of jasplakinolide on the kinetics of actin polymerization. An explanation for certain in vivo observations. J Biol Chem <italic>275</italic>, 5163-5170.</p><p>Dorrbaum, A.R., Kochen, L., Langer, J.D., and Schuman, E.M. (2018). Local and global</p><p>Feng, Y., Press, B., and Wandinger-Ness, A. (1995). Rab 7: an important regulator of late endocytic membrane traffic. J Cell Biol <italic>131</italic>, 1435-1452.</p><p>Gokhale, A., Hartwig, C., Freeman, A.H., Das, R., Zlatic, S.A., Vistein, R., Burch, A., Carrot, G., Lewis, A.F., Nelms, S.<italic>, et al.</italic> (2016). The Proteome of BLOC-1 Genetic Defects Identifies the Arp2/3 Actin Polymerization Complex to Function Downstream of the Schizophrenia Susceptibility Factor Dysbindin at the Synapse. J Neurosci <italic>36</italic>, 12393-12411.</p><p>Howlett, A.C., Blume, L.C., and Dalton, G.D. (2010). CB(1) cannabinoid receptors and their associated proteins. Curr Med Chem <italic>17</italic>, 1382-1393.</p><p>Kaeser, P.S., Kwon, H.B., Blundell, J., Chevaleyre, V., Morishita, W., Malenka, R.C., Powell, C.M., Castillo, P.E., and Sudhof, T.C. (2008). RIM1alpha phosphorylation at serine-413 by protein kinase A is not required for presynaptic long-term plasticity or learning. Proc Natl Acad Sci U S A <italic>105</italic>, 14680-14685.</p><p>Lees, R.M., Johnson, J.D., and Ashby, M.C. (2019). Presynaptic Boutons That Contain Mitochondria Are More Stable. Front Synaptic Neurosci <italic>11</italic>, 37.</p><p>Maus, L., Lee, C., Altas, B., Sertel, S.M., Weyand, K., Rizzoli, S.O., Rhee, J., Brose, N., Imig, C., and Cooper, B.H. (2020). Ultrastructural Correlates of Presynaptic Functional Heterogeneity in Hippocampal Synapses. Cell Rep <italic>30</italic>, 3632-3643 e3638.</p><p>Roesler, M.K., Lombino, F.L., Freitag, S., Schweizer, M., Hermans-Borgmeyer, I., Schwarz, J.R., Kneussel, M., and Wagner, W. (2019). Myosin XVI Regulates Actin Cytoskeleton Dynamics in Dendritic Spines of Purkinje Cells and Affects Presynaptic Organization. Front Cell Neurosci <italic>13</italic>, 330.</p><p>Spector, I., Braet, F., Shochet, N.R., and Bubb, M.R. (1999). New anti-actin drugs in the study of the organization and function of the actin cytoskeleton. Microsc Res Tech <italic>47</italic>, 18-37.</p><p>Wegner, A.M., Nebhan, C.A., Hu, L., Majumdar, D., Meier, K.M., Weaver, A.M., and Webb, D.J. (2008). N-wasp and the arp2/3 complex are critical regulators of actin in the development of dendritic spines and synapses. J Biol Chem <italic>283</italic>, 15912-15920.</p></body></sub-article></article>